Compositions and methods of cellular rejuvenation and treating age-related degeneration

By increasing expression of specific proteins in eye cells using polynucleotides and vectors, the treatment effectively addresses the limitations of current AMD therapies by enhancing cell survival and reducing oxidative stress in retinal pigment epithelium cells.

WO2026236711A1PCT designated stage Publication Date: 2026-11-12WHITEHEAD INST FOR BIOMEDICAL RES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027452
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for dry age-related macular degeneration (AMD) are limited, and there is a need for therapeutic agents and methods to address this condition.

Method used

The use of polynucleotides encoding proteins such as NKX2-5, LTBR, C4BPA, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB_1, and FosB_2, combined with eye cell-specific promoters, delivered via lipid nanoparticles or adeno-associated virus vectors, to increase expression of these proteins in eye cells and enhance oxidative resistance and rejuvenation.

Benefits of technology

Enhances the survival and rejuvenation of retinal pigment epithelium cells, providing protection against oxidative stress and reducing the progression of AMD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000040_0001_TABLE
    Figure IMGF000040_0001_TABLE
  • Figure IMGF000086_0001_TABLE
    Figure IMGF000086_0001_TABLE
  • Figure IMGF000086_0002_TABLE
    Figure IMGF000086_0002_TABLE
Patent Text Reader

Abstract

The disclosure provides, in various embodiments, methods of treating age- and / or oxidative stress-related disease or condition, rejuvenating a cell, and / or enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, C11orf1, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB_1, and FosB_2 in the subject. The disclosure also provides, in various embodiments, methods of treating AMD, rejuvenating a retinal pigment epithelium (RPE) cell, and / or treating damage to RPE cells in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 or a variant thereof (e.g., NKX2-5∆HD) in the subject.
Need to check novelty before this filing date? Find Prior Art

Description

0399.2077001Compositions and Methods of Cellular Rejuvenation and Treating Age-related DegenerationRELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 803,067, filed on May 9, 2025. The entire teachings of the above application are incorporated herein by reference.INCORPORATION BY REFERENCE OF MATERIAL IN XML

[0002] This application incorporates by reference the Sequence Listing contained in the following extensible Markup Language (XML) file being submitted concurrently herewith: a) File name: 03992077-001_SL.xml; created May 8, 2026, 16,175 Bytes in size.GOVERNMENT SUPPORT

[0003] This invention was made with government support under EY037340 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND

[0004] Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in those over the age of sixty -five. There are over 200 million patients in the world suffering from AMD, and even more are at high risk of developing AMD, for example, with sensitive allele of Complement Factor H (CFH). Between eighty and ninety percent of AMD is dry AMD, characterized by atrophic degeneration of the macula and gradual visual loss.Currently, treatment option for dry AMD is very limited.SUMMARY

[0005] There is a critical need for therapeutic agents and methods for treating age-related macular degeneration (AMD) (e.g., dry AMD). The disclosure provides such agents and methods.

[0006] In one aspect, the disclosure provides a polynucleotide comprising:a) a nucleic acid sequence encoding a protein or a variant thereof, wherein the protein is selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1- 1 - 5099429. vl0399.2077001(NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, and FosB_2, homologs; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter.

[0007] In some embodiments, a nucleic acid sequence encodes a NKX2-5 variant comprising a mutation within the homeodomain, optionally wherein the mutation comprises a substitution of at least one amino acid, a deletion of at least one amino acid, or both.

[0008] In some embodiments, a mutation within NKX2-5 homeodomain comprises:a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12); orb) a deletion of 2 to 60 amino acids (e.g., a deletion of at least 10, 20, 30, 40, or 50 amino acids) within the homeodomain.

[0009] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NOs: 1-14. In some embodiments, a NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO:8.

[0010] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in:a) SEQ ID NO:2 and SEQ IDNO:6;b) SEQ ID NO:2 and SEQ IDNO:3;c) SEQ ID NO:8;d) SEQ ID NO: 9;e) SEQ ID NO: 10;f) SEQ ID NO: 11;g) SEQ ID NO: 13; orh) SEQ ID NO: 14.

[0011] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, 11, or 13. In some embodiments, aNKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, or 11. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

[0012] In some embodiments, a promoter:a) is a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, or a human Synapsin 1 (hSyn) promoter;- 2 - 5099429. vl0399.2077001b) comprises an inducer-responsive element, optionally, wherein the inducer- responsive element comprises a Tet response element (TRE),or both a) and b).

[0013] In another aspect, the disclosure provides a polynucleotide comprising a nucleic acid sequence encoding a protein or a variant thereof, wherein the protein is selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cllorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, and FosB_2, homologs, and wherein:a) the polynucleotide is a messenger ribonucleic acid (mRNA) encapsulated in lipid nanoparticles (LNPs); orb) the polynucleotide is an adeno-associated virus (AAV) vector

[0014] In some embodiments, an AAV vector is an AAV2 or AAV9 vector, or a variant thereof.

[0015] In another aspect, the disclosure provides a cell comprising a polynucleotide or composition (e.g., pharmaceutical composition) disclosed herein.

[0016] In some embodiments:a) a cell is an eye cell, an epithelial cell, a bone cell, a brain cell, a liver cell, a lung cell, a mesenchymal cell, a muscle cell, or a nerve cell, optionally wherein the cell is a retinal pigment epithelium (RPE) cell; orb) a cell is an induced pluripotent stem cell (iPSC).

[0017] In another aspect, the disclosure provides a method of treating an age-related disease or condition in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting ofNKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)).

[0018] In some embodiments, a subject is suspected of having, or at risk, for developing an age-related disease or condition. In some embodiments, a subject is diagnosed with an age-related disease or condition.

[0019] In some embodiments:- 3 - 5099429. vl0399.2077001a) an age-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof;b) an age-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof;c) an age-related disease or condition comprises:i. an age-related macular degeneration (AMD);ii. osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;iii. osteoarthritis, intervertebral disc degeneration, or both;iv. osteoporosis, osteonecrosis, or both;v. fibrosis, systemic sclerosis, skin aging, or a combination thereof;vi. type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof;vii. sarcopenia, muscle degeneration, or both;viii. microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; orix. tendinopathy, rotator cuff injury, or both;d) an age-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof;e) an age-related disease or condition comprises an AMD, optionally wherein the AMD is dry AMD,or any combination of the foregoing.

[0020] In another aspect, the disclosure provides a method of rejuvenating a cell in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In- 4 - 5099429. vl0399.2077001some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)).

[0021] In another aspect, the disclosure provides a method of treating an oxidative stress-related disease or condition in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting ofNKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)).

[0022] In some embodiments, a subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition. In some embodiments, a subject is diagnosed with an oxidative stress-related disease or condition.

[0023] In some embodiments:a) an oxidative stress-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof;b) an oxidative stress-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof;c) an oxidative stress-related disease or condition comprises:i. an AMD;ii. osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;iii. osteoarthritis, intervertebral disc degeneration, or both;iv. osteoporosis, osteonecrosis, or both;v. fibrosis, systemic sclerosis, skin aging, or a combination thereof;vi. type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof;vii. sarcopenia, muscle degeneration, or both;- 5 - 5099429. vl0399.2077001viii. microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; orix. tendinopathy, rotator cuff injury, or both;d) an oxidative stress-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof;e) an oxidative stress-related disease or condition comprises an AMD, optionally wherein the AMD is dry AMD,or any combination of the foregoing.

[0024] In another aspect, the disclosure provides a method of enhancing oxidative resistance of a cell in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, orI184P)).

[0025] In some embodiments, a NKX2-5 variant comprises a mutation within the homeodomain. In some embodiments, a mutation comprises a substitution of at least one amino acid or a deletion of at least one amino acid within a homeodomain.

[0026] In some embodiments, a mutation within the homeodomain comprises:a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12); orb) a deletion of 2 to 60 amino acids (e.g., a deletion of at least 10, 20, 30, 40, or 50 amino acids) within the homeodomain.

[0027] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NOs: 1-14. In some embodiments, a NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8, 10, 11, or 13. In some embodiments, a NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8.

[0028] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in:a) SEQ ID NO:2 and SEQ IDNO:6;b) SEQ ID NO:2 and SEQ IDNO:3;c) SEQ ID NO:8;d) SEQ ID NO: 9;- 6 - 5099429. vl0399.2077001e) SEQ ID NO: 10;f) SEQ ID NO: 11;g) SEQ ID N0:13; orh) SEQ ID NO: 14.

[0029] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

[0030] In some embodiments, a method comprises increasing expression of C2CD2L.

[0031] In another aspect, the disclosure provides a method of rejuvenating a retinal pigment epithelium (RPE) cell in a subject in need thereof, comprising increasing expression of a NKX2-5 variant in the RPE cell, wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ IDNO:10, SEQ IDNO:11, SEQ ID NO:13, or SEQ ID NO: 14, optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, 11, or 13. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, or 11. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

[0032] In another aspect, the disclosure provides a method of treating damage to RPE cells in a subject in need thereof, comprising increasing expression of a NKX2-5 variant in the RPE cell, wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO: 14, optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, 11, or 13. In some embodiments, aNKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, 10, or 11. In some embodiments, aNKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 8.

[0033] In some embodiments, a subject is suspected of having, or at risk for developing AMD. In some embodiments, a subject is diagnosed with AMD. In some embodiments, an AMD is dry AMD.

[0034] In some embodiments, a subject is a human.

[0035] In some embodiments, a method comprises administering a polynucleotide comprising a nucleic acid sequence encoding a protein or variant thereof (e.g., a NKX2-5 variant comprising an amino acid sequence set forth in SEQ ID NO:8, 10, 11, or 13) to a subject.- 7 - 5099429. vl0399.2077001

[0036] In some embodiments, a polynucleotide comprises a nucleic acid sequence operably linked to a promoter.

[0037] In some embodiments, a method comprises administering a vector comprising a polynucleotide to a subject.

[0038] In some embodiments, a polynucleotide or vector is locally administered to an organ or tissue in need of such treating or rejuvenation.

[0039] In another aspect, the disclosure provides a polynucleotide, comprising:a) a nucleic acid sequence encoding at least one target protein selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2- like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, FosB_2, homologs, and variants thereof; andb) a promoter operably linked to the nucleic acid sequence, optionally, the promoter is mesenchymal cell-specific.

[0040] In some embodiments, a nucleic acid sequence encodes NKX2-5.

[0041] In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least 80% sequence identity to at least one of SEQ ID NOs: 1-5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, or 5.

[0042] In some embodiments, a promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter.

[0043] In some embodiments, a promoter is a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, or a human Synapsin 1 (hSyn) promoter.

[0044] In some embodiments, a promoter comprises an inducer-responsive element. In some embodiments, an inducer-responsive element comprises a Tet response element (TRE).

[0045] In some embodiments, a polynucleotide is a deoxyribonucleic acid (DNA). In some embodiments, a polynucleotide is an mRNA.

[0046] In some embodiments, a polynucleotide is encapsulated in at least one nanoparticle.- 8 - 5099429. vl0399.2077001

[0047] In another aspect, the disclosure provides a vector comprising a polynucleotide disclosed herein.

[0048] In some embodiments, a vector comprises:a) a nucleic acid sequence encoding NKX2-5 or a variant thereof; andb) a promoter selected from a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, and a human Synapsin 1 (hSyn) promoter, wherein the promoter is operably linked to the nucleic acid sequence.

[0049] In some embodiments, a vector is a virus vector.

[0050] In some embodiments, a vector is an AAV vector. In some embodiments, an AAV vector is an AAV2 or AAV9 vector, or a variant thereof.

[0051] In another aspect, the disclosure provides a composition comprising a polynucleotide or vector disclosed herein.

[0052] In some embodiments, a composition comprises two polynucleotides disclosed herein, wherein the two polynucleotides encode different target proteins.

[0053] In another aspect, the disclosure provides a gene delivery system comprising a polynucleotide, vector, or composition (e.g., pharmaceutical composition) disclosed herein.

[0054] In another aspect, the disclosure provides a kit comprising a container and optionally an instruction for use, wherein the container comprises a polynucleotide, vector, composition (e.g., pharmaceutical composition), or gene delivery system disclosed herein.

[0055] In another aspect, the disclosure provides a cell comprising a polynucleotide, vector, composition (e.g., pharmaceutical composition), or gene delivery system disclosed herein.

[0056] In another aspect, the disclosure provides a progeny cell derived from a cell disclosed herein.

[0057] In another aspect, the disclosure provides a method of treating an age-related disease or condition in a subject in need thereof, comprising increasing expression and / or an activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0058] In another aspect, the disclosure provides a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or an activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.- 9 - 5099429. vl0399.2077001

[0059] In another aspect, the disclosure provides a method of treating an oxidative stress-related disease or condition in a subject in need thereof, comprising increasing expression and / or an activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0060] In another aspect, the disclosure provides a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or an activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0061] In another aspect, the disclosure provides a method of rejuvenating a retinal pigment epithelium (RPE) cell in a subject in need thereof, comprising increasing expression and / or an activity of NKX2-5 in the RPE cell.

[0062] In another aspect, the disclosure provides a method of treating damage to RPE cells in a subject in need thereof, comprising increasing expression and / or an activity of NKX2-5 in the RPE cells.

[0063] In another aspect, the disclosure provides a method of treating AMD in a subject in need thereof, comprising increasing expression and / or an activity of NKX2-5 in the subject.BRIEF DESCRIPTION OF THE DRAWINGS

[0064] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0065] The foregoing will be apparent from the following more particular description of example embodiments, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments.

[0066] FIGs. 1A-1E. Oxidative stress (ROS) increases retinal pigment epithelium (RPE) aging and sodium iodate (NalOsj-induced injury. FIG. 1A. Experimental pipeline for quantifying ROS in young and aged RPE through flat mount imaging and flow cytometry.FIGs. 1B-1C. Flat mount display and quantification of ROS in young or aged RPEs.FIG. ID. Relative ROS intensity of RPEs. FIG. IE. Histogram showing intensity of ROS of neuroretina and RPE cells from young mice, young mice treated with NalOs, or old mice.

[0067] FIGs. 2A-2E. A genome wide open reading frame (ORF) screen identified genes that promote the survival of RPE to NalOs-induced oxidative stress. FIG. 2A. The ORF library and- 10 - 5099429. vl0399.2077001screening pipeline. FIGs. 2B-2C. Volcano plots depicting the significance and log fold change of individual ORF (live / dead or live / undamaged). FIG. 2D. Barcodes representation for validated ORFs. FIGs. 2E-2F. Validating the candidate genes using lactate dehydrogenase (LDH) and post-NalOs cell replating survival assays.

[0068] FIGs. 3A-3G. Analysis of gene expression, pathways, and transcriptomic age in RPE cells with protective ORF overexpression. FIG. 3A. RPE expression profiles of selected genes (FOSB, LTBR, Cllorfl, C2CD2L, M0CS2, NKX2-5, NKX2-1, and C4RPA) across different age groups and disease states (control, age-related macular degeneration (AMD)) in human ocular scRNA-seq database Spectacle (7). Log expression values were plotted for RPE cells, with subdivisions for adult and aged samples and disease state comparisons. FIG. 3B. Tissue-specific expression heatmap of candidate genes, indicating normalized transcripts per kilobase million (TPM) values across various tissues, highlighting cardiac-specific expression of NKX2-5.FIG. 3C. Correlation matrix with Pearson correlation coefficients visualized between TNFa, LTBR, FOSB, NKX2-5, Nrf2, and others, suggesting two distinct groups of antioxidative genes.FIG. 3D. Mortality transcriptomic age (tAge) residual from tissues of healthy people and AMD patients. FIG. 3E. Chronological tAge from young or old RPE collected in house.FIG. 3F. Effects of ORF overexpression measured by tAge, #,p<0.000L FIG. 3G. Functional pathway enrichment analysis linking selected genes to major biological processes, including oxidative phosphorylation, immune signaling, and chromatin modifications. Color gradients represent normalized differences in aging-associated transcriptional activity, purple indicates the direction of rejuvenation.

[0069] FIGs. 4A-4E. Candidate ORFs represented by LTBR, a TNF superfamily receptor. FIG. 4A. LTBR induction provided oxidative protection but induced EMT alterations.FIG. 4B. Transcriptomic analysis showing that LTBR activates NF-KB, RelA / RelB, and SOD2.FIG. 4C. Ligands of the TNFa superfamily conferred protective effects against oxidative stress, with TNFa showing the strongest effect. FIG. 4D. CRISPRcut of RelA / RelB and SOD2 blocks the protection effect of TNFa. Intact (TNFa): TNFa treatment to cells without NalOs damage; gNT: non-targeting guide. FIG. 4E. Illustration of identified pathway: LTBR belongs to the TNFa superfamily receptor, both activates NF-KB / SOD2 axis to offer protection.

[0070] FIGs. 5A-5F. Candidates represented by NKX2-5 provide fast-acting and long-lasting protection from NalCh. FIG. 5A. NKX2-5 distribution. FIG. 5B. Arising retinal pigment epithelia (ARPE)-19 cells with stable lentiviral integration of inducible NKX2-5 were matured in nicotinamide containing 1% FBS medium for three weeks (2), then doxycycline- 11 - 5099429. vl0399.2077001(DOX) was added to turn on NKX2-5 before or during 18 hours of NalOs treatment. FIG. 5C.Cell survival in each regimen shown in FIG. 5B. Survival posts of replated cells show that NKX2-5 conferred fast-acting and long-lasting protection against NalOs. FIG. 5D. NKX2-5 induction conferred oxidative protection without morphological alterations.FIG. 5E. Transcriptomic changes induced by NKX2-5; top significant genes highlighted in red.FIG. 5F. NKX2-5 overexpression conferred DNA methylation age reduction.

[0071] FIGs. 6A-6D. The role and response of mitochondria with NKX2-5.FIG. 6A. Examination of NKX2-5-mediated survival post NalCh with intact or toxin-impaired mitochondrial electron transport chain. FIG. 6B. Cell ROS level and mitochondria surface area with or without NKX2-5. FIGs. 6C-6D. Oxygen consumption rate (OCR) measured using seahorse Mito Stress Test with GFP or NKX2-5 induction in the presence or absence of NalOs.

[0072] FIGs. 7A-7J. NKX2-5 domain architecture, AlphaFold structure, assays for dissecting functional unit, and in vivo effects of NKX2-5 AHD. FIG. 7A. Schematic representation of indicated NKX2-5 protein domains, including the Tinman (TN) region, Homeodomain (HD), NK-2 specific domain (NK-2 SD), and YRD. FIG. 7B. AlphaFold structures show N terminal structure conservation between NKX2-5 and its homeodomain deletion mutant (AHD). FIG. 7C. Quantification of replating survival in cells expressing wildtype (WT) NKX2-5 or a functional variant (I184M, I184P, or AHD). FIG. 7D. Cellular localization of wild-type (WT) NKX2-5 or a functional variant (I184M, I184P, or AHD).FIG. 7E. Mitochondrial surface area for NKX2-5 or NKX2-5 AHD with or without NalCh. FIG. 7F. Transcriptomic changes induced by NKX2-5 and NKX2-5 AHD with top significant genes labelled. FIG. 7G. Cellular localization of wild-type (WT) NKX2-5 or a functional variant having an impaired YRD domain (A YRD or YRD-Y-A). FIG. 7H. Quantification of cell survival in cells expressing wild-type (WT) NKX2-5 or a functional variant having an impaired YRD domain (A YRD or YRD-Y-A). FIG. 71. Experimental timeline for evaluating effects of AAV-mediated NKX2-5 AHD expression in aged mice. FIG. 7J. OMR tracking until 8wks post AAV-GFP or AAV-NKX2-5 AHD subretinal injection.

[0073] FIGs. 8A-8F. AAV-NKX2-5 protects RPE in vivo. FIG. 8A. Outline of a NaIO3-induced RPE injury model with AAV injection in adults. FIG. 8B. Quantification of RPE atrophy area between eyes treated with AAV-expressing GFP, LTBR, NKX2-1, or NKX2-5. FIG. 8C. F-actin staining showing (i) uninfected area, (ii) NalOs-induced RPE atrophy (yellow circle), and (iii) NKX2-5 -infected area (white square within the injection ring), where RPE cell shape and nucleus were preserved. FIG. 8D. En face images, heatmaps and optical coherence- 12 - 5099429. vl0399.2077001tomography (OCT) cross-sectional images showing total retinal thickness and outer nuclear layer (ONL) thickness in different groups. ONL thickness is highlighted with red lines in OCT images.FIG. 8E. Quantified results of total retinal and ONL thickness at AAV injection region. V, ventral; D, dorsal; N, nasal; T, temporal. FIG. 8F. Design of a second-generation DOX inducible AAV vector and experimental outline: with AAV injection at birth and gene expression turned on at adulthood, specifically in RPE cells through the Bestl promoter.

[0074] FIGs. 9A-9H. Examination and toxicology of AAV-NKX2-5 in aged mice.FIG. 9A. Experimental timeline for evaluating effects of AAV-mediated NKX2-5 expression in aged mice. FIG. 9B. Optomoter (OMR) vision test set up. FIGs. 9C-9D. OMR readout at baseline, 2, 4, 6, or 8 weeks post AAV-GFP or AAV-NKX2-5 subretinal injection.FIG. 9E. Retinal thickness revealed by OCT at 5 weeks post AAV-NKX2-5. FIGs. 9F-9G. Toluidine-blue image of a 23-month-old retina at AAV-NKX2-5 injected or non-injected site, and quantification of pigmented RPE area. FIG. 9H. Transmission electron microscopy (TEM) images of RPE ultrastructure of a 23-month-old mouse, with evident intracellular lipid deposit (LD), lipoprotein-rich basal deposits (BD), and cytoplasmic vacuolization (CV) in untreated (WT) area, but not in AAV-NKX2-5-treated area. A TEM image of RPE ultrastructure of a 4-month-old mouse was provided for comparison.

[0075] FIGs. 10A-10E. Broad oxidative protection with ORF combinations. FIGs. 10A-10C. Damage dose curve testing of smoking extract, tert-Butyl hydroperoxide, or complement.FIG. 10D. Protection effects of controls or gene candidates from the screen against five AMD-related stressors, suggesting a combination of ORFs may provide synergistic, broad protections.FIG. 10E. A CFH-H / H mouse model of AMD will be used to examine protective effects of combining NKX2-5 with another ORF (upper panel) (3). RPE dysmorphia in aged CFH mice may be measured by the percentage of multinucleate RPE cells (see, e.g., lower panel, n > 3 nuclei, yellow arrows).

[0076] FIGs. 11A-11C. Long-term safety of NKX2-5AHD and the toxicity cause of HD domain. FIG. HA. Experimental timeline for evaluating long-term toxicity effects of AAV-NKX2-5AHD on retinal thickness until 32wks. Mice received subretinal AAV-GFP or AAV-NKX2-5 or AAV-NKX2-5AHD injection at 3 months of age. Retinal structure was monitored every 4wks longitudinally by OCT over the subsequent 32wks. FIG. 11B. Longitudinal measurements of retinal thickness at injection site months after AAV-GFP or AAV-NKX2-5 or AAV-NKX2-5AHD injection. FIG. 11C. Co-IP-mass spectrometry identified binding partners of NKX2-5 and NKX2-5AHD, revealing CARDIO as a strong HD-domain-associated interactor.- 13 - 5099429. vl0399.2077001

[0077] FIGs. 12A-12I. Functional benefits and transcriptomic rejuvenation by AAV-NKX2-5AHD in aged mice. FIG. 12A. Experimental timeline for evaluating effects of AAV-NKX2-5 AHD on visual acuity of aged mice until lOwks post AAV. FIG. 12B. OMR tracking until lOwks post AAV-GFP or AAV-NKX2-5 AHD subretinal injection, with supplemental animal batch included. FIG. 12C. Experimental timeline for evaluating effects of AAV-mediated NKX2-5 AHD expression in aged mice until 25wks post AAV. FIG. 12D. OMR tracking until 25wks post AAV-GFP or AAV-NKX2-5 AHD subretinal injection for a subgroup of animal. FIGs. 12E-12G. Electroretinogram (ERG) results showing responses from 18-month-old mice at 10 weeks post AAV-GFP or AAV-NKX2-5AHD injection in a wave (FIG. 12E), b wave (FIG. 12F) and c wave (FIG. 12G). Young, n = 12; Untreated Old, n = 12; Old (GFP), n = 12; Old (NKX2-5 AHD), n = 11. FIG. 12H. Transcriptomic age (tAge) of (17 mo.) mouse RPE cells, treated with AAV-GFP or AAV-NKX2-5AHD, as predicted by multi-tissue transcriptomic clock of chronological age. FIG. 121. Standardized chronological tAge differences induced by AAV-NKX2-5AHD treatment in old mouse RPE cells, according to module-specific multi-tissue chronological clocks. Red and blue bars denote pro-aging and anti-aging transcriptomic changes, respectively.DETAILED DESCRIPTION

[0078] A description of example embodiments follows.

[0079] Oxidative stress is a key risk factor for the development of AMD. Using NalOs-induced retinal degeneration to study cell death in AMD, it was discovered that wild-type (WT) mature arising retinal pigment epithelia (ARPE) cells do not survive or proliferate after treated with 5 mM NalOs for 18 hours. Based on this discovery, a genome-wide open reading frame (ORF) overexpression screen was designed and performed to identify genes that modulate resistance to oxidative stress. Among candidate genes identified from the screen, two transcription factors, NKX2.1 and NKX2.5, were robustly enriched in the surviving cells.NKX2.1, also known as thyroid transcription factor 1 (TTF-1), plays a crucial role in the development and function of lung and thyroid gland. NKX2.5 is important for the specification, differentiation, and proliferation of cardiac progenitor cells. Lung and heart are known to be exposed to the highest levels of oxidative stress in the body. Overexpression of NKX2.1 or NKX2.5 robustly protected RPE cells against oxidative stress-induced cell death and enhanced the survival rate. It is hypothesized that expression of NKX2.1 and / or NKX2.5 confers RPE cells the ability to defend oxidative stress, similar to lung and heart.- 14 - 5099429. vl0399.2077001Definitions

[0080] Certain terms used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0081] As used herein, the term “a,” “an,” or “the” should be understood to include plural reference unless the context clearly indicates otherwise.

[0082] As used herein, unless the context requires otherwise, the term “comprise,” and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of, e.g., a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step. As used herein, the term “comprising” can be substituted with the term “containing” or “including.”

[0083] As used herein, “consisting of’ excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of’ does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any of the terms “comprising,” “containing,” “including,” and “having,” whenever used herein in the context of an aspect or embodiment of the disclosure, can in some embodiments, be replaced with the term “consisting of,” or “consisting essentially of’ to vary scopes of the disclosure.

[0084] As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and / or.”

[0085] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list, and every combination of that list, is a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.”

[0086] Unless otherwise indicated or otherwise evident from the context and / or understanding of one of ordinary skill in the art, values herein that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments- 15 - 5099429. vl0399.2077001disclosed herein, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0087] As used herein, the term “about” means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art. Typically, an acceptable error range for a particular value depends, at least in part, on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. It is to be understood that the term “about” can precede any particular value specified herein, except for particular values used in the Exemplification. When “about” precedes a range, as in “1-20”, the term “about” should be read as applying to both given values of the range, such that “about 1-20” means about 1 to about 20.

[0088] It should be understood that for all numerical bounds describing some parameter in this application, such as “about,” “at least,” “less than,” “fewer than,” and “more than,” the description also necessarily encompasses any range bounded by the recited values. Accordingly, for example, the description “at least 1, 2, 3, 4, or 5” also describes, inter alia, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, etcetera.

[0089] Whenever the term “no more than,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0090] As used herein, the term “sequence identity” refers to the extent to which two nucleotide sequences, or two amino acid sequences, have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which test sequences are compared. The sequence identity between reference and test sequences is expressed as the percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity. As an example, two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide or amino acid residue at 70% of the same positions over the entire length of the reference sequence.- 16 - 5099429. vl0399.2077001

[0091] Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, the alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), and visual inspection (see generally Ausubel el al., Current Protocols in Molecular Biology).

[0092] When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. A commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990).

[0093] In some embodiments, an amino acid substitution is a conservative substitution. The term “conservative amino acid substitution(s)” or “conservative substitution(s)” refers to an amino acid substitution having a value of 0 or greater in BLOSUM62.

[0094] In some embodiments, an amino acid substitution is a highly conservative substitution. The term “highly conservative amino acid substitution(s)” or “highly conservative substitution(s)” refers to an amino acid substitution having a value of at least 1 (e.g., at least 2) in BLOSUM62.

[0095] In some embodiments, an amino acid substitution (e.g., a substitution of a NKX2-5 homeodomain (HD) residue such as 1184 of human HD) is a non-conservative substitution.

[0096] The term “polynucleotide” refers to a biopolymer comprising naturally occurring deoxyribonucleotide monomers, non-naturally occurring deoxyribonucleotide monomers (e.g., 7-deazaguanosine, inosine, or a methylated nucleotide such as 5-methyl dCTP or 5 -hydroxymethyl cytosine), naturally occurring ribonucleotide monomers, or non-naturally occurring ribonucleotide monomers (e.g., a locked nucleic acid (LNA)), or a combination thereof. A polynucleotide described herein can be single stranded (ss) or double stranded (ds). In some- 17 - 5099429. vl0399.2077001embodiments, a polynucleotide described herein is a DNA molecule. In some embodiments, a polynucleotide described herein is an RNA molecule (e.g, a linear or a circular RNA molecule).

[0097] The term “encoding” refers to specific sequences of nucleotides in a polynucleotide, such as a DNA (e.g, a cDNA) or an RNA (e.g., an mRNA), that serve as a template for synthesis of a protein having a defined sequence of amino acids. Unless otherwise specified, a polynucleotide encoding an amino acid sequence can have any one nucleic acid sequence of all nucleic acid sequences that are degenerate versions of each other and that encode the amino acid sequence.

[0098] The term “vector” refers to a nucleic acid molecule which may be employed to introduce a nucleic acid sequence or gene into a cell, either in vitro, ex vivo, or in vivo.

[0099] The term “ex vivo” refers to methods conducted within or on cells or tissue in an artificial environment outside an organism with minimum alteration of natural conditions.

[0100] The term “zzz vivo” refers to a method that is conducted within living organisms in their normal, intact state.

[0101] The term “zzz vitro” method is conducted using components of an organism that have been isolated from its usual biological context.

[0102] The term “expression vector” refers to a replicable nucleic acid from which one or more proteins can be expressed when the expression vector is transformed into a suitable expression host cell.

[0103] The term “host” cell refers to a cell into which a polynucleotide has been introduced by molecular biology techniques. All techniques by which a polynucleotide can be introduced into a host cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration are contemplated herein.

[0104] The term “promoter” refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene.

[0105] The term “operably linked” means that the nucleic acid is positioned in the recombinant polynucleotide, e.g., vector, in such a way that enables expression of the nucleic acid under control of the element (e.g., promoter) to which it is linked.

[0106] The term “selectable marker element” is an element that confers a trait suitable for artificial selection. Selectable marker elements can be negative or positive selection markers.

[0107] The term “pharmaceutically acceptable” means that the substance or composition the phrase modifies is, within the scope of sound medical judgment, suitable for use in contact with- 18 - 5099429. vl0399.2077001the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio.

[0108] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge etal., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, the relevant teachings of which are incorporated herein by reference in their entirety. Pharmaceutically acceptable salts of the compounds described herein include salts derived from suitable inorganic and organic acids, and suitable inorganic and organic bases.

[0109] Examples of salts derived from suitable acids include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts derived from suitable acids include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cinnamate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutarate, glycolate, hemisulfate, heptanoate, hexanoate, hydroiodide, hydroxybenzoate, 2-hydroxy-ethanesulfonate, hydroxymaleate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 2-phenoxybenzoate, phenylacetate, 3 -phenylpropionate, phosphate, pivalate, propionate, pyruvate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0110] Either the mono-, di- or tri-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form.

[0111] Salts derived from appropriate bases include salts derived from inorganic bases, such as alkali metal, alkaline earth metal, and ammonium bases, and salts derived from aliphatic, alicyclic or aromatic organic amines, such as methylamine, trimethylamine and picoline, or N+((Ci-C4)alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, barium and the like. Further pharmaceutically- 19 - 5099429. vl0399.2077001acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.

[0112] The term “subject” or “patient” refers to a mammal (e.g., a human). In some embodiments, a subject is a mammal selected from a dog, a cat, a mouse, a rat, a hamster, a guinea pig, a horse, a pig, a sheep, a cow, a chimpanzee, a macaque, a cynomolgus, and a human. In some embodiments, a subject is a primate. In some embodiments, a subject is a human.

[0113] The term “a therapeutically effective amount,” “an effective amount” or “an effective dosage” is an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition, etc.). The full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount may vary according to factors such as disease state, age, sex, and weight of a mammal, mode of administration and the ability of a therapeutic, or combination of therapeutics, to elicit a desired response in an individual.

[0114] An effective amount of an agent to be administered can be determined by a clinician of ordinary skill using the guidance provided herein and other methods known in the art.Relevant factors include the given agent, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject (e.g., age, sex, weight) or host being treated, and the like. For example, suitable dosages can be from about 0.001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 10 mg / kg, from about 0.01 mg / kg to about 1 mg / kg body weight per treatment. Determining a dosage for a particular agent, subject and disease is well within the abilities of one of skill in the art. Preferably, a dosage does not cause or produces minimal adverse side effects.

[0115] Desired response or desired results include effects at the cellular level, tissue level, or clinical results. As such, “a therapeutically effective amount” or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments, it is an amount of a composition sufficient to achieve a treatment response as compared to the response obtained without administration of the composition. In other embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of a composition may be readily determined by one of ordinary- 20 - 5099429. vl0399.2077001skill by routine methods known in the art. Dosage regimen and route of administration may be adjusted to provide an optimum therapeutic response.

[0116] As used herein, the term “treating,” or its equivalents (e.g., “treatment” or “treat”), refers to the medical management of a subject with the intent to improve, ameliorate, stabilize ( / .< ., not worsen), prevent or cure a disease, pathological condition, or disorder — such as the particular indications exemplified herein. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of a disease or condition (e.g., age-related disease or condition such as age-related macular degeneration (AMD)); preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0117] The term “ameliorating” or “palliating” a disease or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.

[0118] As used herein, the term “treating,” or its equivalents (e.g., “treatment” or “treat”), refers to the medical management of a subject with the intent to improve, ameliorate, stabilize ( / .< ., not worsen), prevent or cure a disease, pathological condition, or disorder — such as the particular indications exemplified herein. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of a disease or- 21 - 5099429. vl0399.2077001condition (e.g., an age-related disease such as age-related macular degeneration or an aging-associated impairment); preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0119] The term “ameliorating” or “palliating” a disease or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.

[0120] In some embodiments, an age-related disease or an aging-associated impairment affects a cell and / or a tissue of the blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth (e.g., gum, roots of teeth), muscle (e.g., cardiac muscle), nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof. In some embodiments, an age-related disease or an aging-associated impairment affects a cell and / or a tissue of the blood vessel, breast, bone, brain, ear, eye, hair, heart, intestine, kidney, liver, lung, mouth (e.g., gum, roots of teeth), muscle (e.g., cardiac muscle), nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, or a combination thereof.

[0121] Non-limiting examples of ocular diseases (eye diseases) include blepharochalasis, blepharitis, chalazion, ectropion, eyelid dermatitis, lagophthalmos, ptosis, stye, xanthelasma, demodex eye infection, acanthamoeba keratitis, herpetic keratitis, impetigo of the eye, keratomy cosis, leishmaniasis, leprosy, loiasis, molluscum contagiosum, ocular syphilis, ocular toxoplasmosis, ocular tuberculosis, onchocerciasis, phthiriasis, ocular zoster, conjunctivitis, corneal abrasion, corneal dystrophy, corneal fibrosis, corneal inflammation, corneal ulcer, dacryoadenitis, Harada’s disease, keratitis, scleritis, sympathetic ophthalmia, corneal neovascularization, Fuchs’ dystrophy, keratoconus, keratoconjunctivitis sicca, iritis, uveitis, aniridia, cataract(s), nuclear sclerosis, hypermetropia, angioid streaks, central serous retinopathy, chorioretinal inflammation, chorioretinal scars, chorioretinitis, choroid of the eye, choroidal hemorrhage, choroiditis, diabetic retinopathy, disseminated chorioretinal inflammation, exudative retinopathy, focal chorioretinal inflammation, hereditary retinal dystrophy, hypertensive retinopathy, peripheral retinal degeneration, retinal detachment, retinal hemorrhage,- 22 - 5099429. vl0399.2077001retinitis, retinitis pigmentosa, retinochoroiditis, retinopathy, retinopathy of prematurity, retinoschisis, solar retinopathy, posterior cyclitis, pars planitis, age-related macular degeneration, bull’s eye maculopathy, gyrate atrophy, macular scars, macular degeneration, macular edema, choroidal degeneration, choroidal detachment, choroidal dystrophy, choroideremia, Leber’s hereditary optic neuropathy, optic disc drusen, optic neuropathy (e.g., anterior ischemic optic neuropathy (AION), non-arteritic anterior ischemic optic neuropathy (NAION)), glaucoma, angle-closure glaucoma, normal tension glaucoma, open-angle glaucoma, eye accommodation, ophthalmoparesis, ophthalmoplegia, progressive external ophthalmoplegia, Argyll Robertson pupil, anisocoria, anisometropia, anopsia, astigmatism, blindness, blurry vision, burning eyes, color blindness, diabetic eye disease, disorders of refraction, distorted vision, dry eye, epiphora, esotropia, exophthalmos, eye floaters, myopia, nyctalopia, ocular hypertension, pinguecula, presbyopia, pterygium, riverblindness, scotoma, snowblindness, strabismus, Thygeson’s superficial punctate keratopathy, xerophthalmia, and ocular cancer (e.g., lymphoma of the eye, melanoma of the eye, medulloepithelioma, retinoblastoma, squamous cell cancer of the conjunctiva).

[0122] In some embodiments, an ocular disease affects the eyelid, lacrimal system and / or orbit. In some embodiments, an ocular disease is a disorder of the conjunctiva. In some embodiments, an ocular disease is a disorder of sclera, cornea, iris, and / or ciliary body. In some embodiments, an ocular disease is a disorder of the lens. In some embodiments, an ocular disease is a disorder of choroid and / or retina. In some embodiments, an ocular disease is glaucoma. In some embodiments, an ocular disease is a disorder of vitreous body and / or globe. In some embodiments, an ocular disease is a disorder of optic nerve and / or visual pathways. In some embodiments, an ocular disease is a disorder of ocular muscles, binocular movement, accommodation, and / or refraction. In some embodiments, an ocular disease is a visual disturbance and / or blindness. In some embodiments, an ocular disease is associated with aging, for example, vision loss associated with aging, decline in visual acuity associated with aging, and / or decline in retinal function. In some embodiments, an ocular disease is a retinal disease (e.g, macular degeneration).

[0123] Non-limiting examples of liver diseases include ascites, alcoholic liver diseases (e.g, fatty liver, hepatitis, cirrhosis), angiomyolipoma, angiosarcoma, bile stones, calcified liver metastases, carcinoid, carcinosarcoma, cholangiocarcinoma, cholestasis, cystadenocarcinoma, cystic liver metastases, epithelial tumors (e.g., bile duct hamartoma, bile duct adenoma), erythrohepatic porphyria, fatty liver (e.g., alcoholic fatty liver, Reye’s syndrome), fibrolamellar- 23 - 5099429. vl0399.2077001hepatocarcinoma, fibrosarcoma, focal nodular hyperplasia, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic cysts (e.g., Simple cysts, Polycystic liver disease, hepatobiliary cystadenoma, choledochal cyst), hepatic encephalopathy, hepatic porphyria (e.g., acute intermittent porphyria, porphyria cutanea tarda), hepatic vein thrombosis, hepatitis (e.g., alcoholic hepatitis, animal hepatitis, chronic hepatitis (e.g., autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced chronic hepatitis), toxic hepatitis, viral human hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), granulomatous hepatitis), hepatocellular adenoma, hepatolenticular degeneration (Wilson’s disease), hepatoma, hepatomegaly, hepatoblastoma, hepatocellular carcinoma, intrahepatic cholestasis (e.g., alagille syndrome, biliary liver cirrhosis), jaundice (e.g., hemolytic, hepatocellular, cholestatic jaundice), Kaposi’s sarcoma, leiomyosarcoma, liver abscess (e.g., amebic liver abscess), liver cirrhosis (e.g., alcoholic, biliary, and experimental liver cirrhosis), liver enlargement, liver failure (e.g., hepatic encephalopathy, acute liver failure), mesenchymal tumors (mesenchymal hamartoma, infantile hemangioendothelioma, hemangioma, peliosis hepatis, lipomas, inflammatory pseudotumor), nodular regenerative hyperplasia, parasitic liver disease (e.g., hepatic echinococcosis, fascioliasis, amebic liver abscess), peliosis hepatis, portal hypertension, primary biliary cirrhosis, primary lymphoma, primary sclerosing cholangitis, rhabdomyosarcoma, secondary biliary cirrhosis, squamous carcinoma, teratoma, tumors of blood vessels, varices, and Zellweger syndrome.

[0124] Non-limiting examples of lung diseases include acute respiratory distress syndrome (ARDS), asbestosis, aspergilloma, aspergillosis, asthma (e.g., intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma), bronchiectasis, bronchitis, bronchopulmonary dysplasia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, emphysema, interstitial lung disease, lung cancer (e.g., nonsmall-cell lung carcinoma (e.g., adenocarcinoma, squamous-cell lung carcinoma, large-cell lung carcinoma), small-cell lung carcinoma), occupational lung disease, pneumonia (e.g., lobar pneumonia, multilobar pneumonia, bronchial pneumonia, interstitial pneumonia), pulmonary embolism, pulmonary fibrosis, pulmonary tuberculosis, rheumatoid lung disease, sarcoidosis, and severe acute respiratory syndrome (SARS).

[0125] Musculoskeletal diseases (MSDs) affect the bones, connective tissues (e.g., cartilage), joints, and muscles.

[0126] Non-limiting examples of MSDs affecting the bones include achondroplasia, acromegaly, Apert syndrome, Bloom syndrome, bone callus, bone demineralization, bone- 24 - 5099429. vl0399.2077001fracture, bone marrow disease, bone marrow neoplasm, bone neoplasm, brachydactyly, Camurati-Engelmann syndrome, Cockayne syndrome, craniosynostosis, Crouzon craniofacial dysostosis, dwarfism, dyskeratosis congenita, Ellis-van Creveld syndrome, Ewing sarcoma, Gorham-Stout syndrome, hyperostosis, Kashin-Beck disease, Klippel-Trenaunay-Weber syndrome, Leri -Weill dyschondrosteosis, leukemia (e.g., hairy cell leukemia, lymphocytic leukemia, myeloid leukemia, Philadelphia chromosome-positive leukemia, plasma cell leukemia, stem cell leukemia), Marfan syndrome, McCune-Albright syndrome, Meckel syndrome, multiple myeloma, myelodysplastic syndromes, myeloid sarcoma, myeloproliferative disorders, osteitis, osteoarthritis, osteochondritis, osteochondrodysplasia, osteochondroma, osteochondrosis, osteoclastoma, osteodystrophy, osteogenesis imperfecta, osteolysis, osteomalacia, osteomyelitis, osteonecrosis, osteopenia, osteopetrosis, osteophyte, osteoporosis, osteosarcoma, osteosclerosis, otospondylomegaepiphyseal dysplasia, pachydermoperiostosis, Paget disease of bone, paroxysmal nocturnal hemoglobinuria, Pearson marrow-pancreas syndrome, polycythemia vera, polydactyly, rickets, Rothmund-Thomson syndrome, Seckel syndrome, Sotos syndrome, spondyloepiphyseal dysplasia, spondyloepiphyseal dysplasia congenita, syndactyly, syndactyly type II, systemic mastocytosis, and Werner syndrome.

[0127] Non-limiting examples of MSDs affecting the cartilages include cartilage neoplasm, Leri-Weill dyschondrosteosis, Kashin-Beck disease, osteochondritis, and osteochondrodysplasia.

[0128] Non-limiting examples of MSDs affecting the joints include arthralgia, arthritis (e.g., gout (e.g., Kelley-Seegmiller syndrome, Lesch-Nyhan syndrome)), Blau syndrome, Felty syndrome, Lyme disease, nail-patella syndrome, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatoid arthritis, spondyloarthropathy, Stickler syndrome, synovial membrane disease, and synovitis.

[0129] Non-limiting examples of MSDs affecting the muscles include Barth syndrome, congenital myasthenic syndrome, dermatomyositis, fibromyalgia, Kearns-Sayre syndrome, Kearns-Sayre syndrome, Lambert-Eaton myasthenic syndrome, MELAS syndrome, MERRF syndrome, mitochondrial encephalomyopathy, mitochondrial myopathy, MNGIE syndrome, muscular dystrophy, myalgia, myasthenia, myasthenia gravis, myoma, myositis, myotonia, myotonia congenita, neuromuscular disease, ophthalmoplegia, polymyalgia rheumatica, rhabdomyolysis, spinal muscular atrophy, and tetany.

[0130] In some embodiments, an MSD is a rheumatic disease, non-limiting examples include arthritis (e.g., gout (e.g., Kelley-Seegmiller syndrome, Lesch-Nyhan disease)), Blau syndrome, Felty syndrome, gout (e.g., Kelley-Seegmiller syndrome, Lesch-Nyhan syndrome), osteoarthritis,- 25 - 5099429. vl0399.2077001polymyalgia rheumatica, psoriatic arthritis, reactive arthritis, rheumatic fever, rheumatic heart disease, rheumatoid arthritis, Sjogren’s syndrome, and synovitis.

[0131] In some embodiments, an MSD is a skeleton disease, non-limiting examples include ankylosing spondylitis, intervertebral disk hernia, Leri-Weill dyschondrosteosis, Melnick-Needles syndrome, pachydermoperiostosis, reactive arthritis, Rieger syndrome, scoliosis, skeleton malformations, spina bifida, spinal column disease, spondylitis, spondyloarthropathy, spondyloepiphyseal dysplasia, spondyloepiphyseal dysplasia congenita, and spondylosis.

[0132] In some embodiments, an MSD comprises a hernia (e.g., an intervertebral disk hernia), Langer-Giedion syndrome, Proteus syndrome, Schwartz-Jampel syndrome, or a combination thereof.

[0133] Non-limiting examples of spleen diseases include asplenia, Felty’s syndrome, Hodgkin’s disease, idiopathic purpura, spleen cancer, spleen trauma, splenomegaly, and immune-mediated destruction of the spleen.

[0134] Non-limiting examples of age-related diseases include autoimmune diseases, cancers, cardiovascular diseases (e.g., arrhythmias, coronary heart disease (CHD), chronic diseases, genetic diseases, heart failure, peripheral artery disease (PAD), and stroke), hematological diseases, infectious diseases, inflammatory diseases, metabolic disorders, neurological diseases (e.g., neurodegenerative diseases), noncancerous blood disorders, painful conditions, proliferative diseases, psychiatric disorders, and genetic diseases.

[0135] Non-limiting examples of autoimmune diseases include ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic poly angiitis), ankylosing spondylitis, antiphospholipid antibody syndrome, cardiomyopathy, Crohn’s disease, dermatomyositis / polymyositis, glomerulonephritis, Goodpasture’s syndrome, Guillain-Barre syndrome, Hashimoto’s thyroiditis, necrotizing vasculitis, Lyme disease, lymphadenitis, pemphigus vulgaris, peri-arteritis nodosa, psoriasis, psoriatic arthritis, Reiter’s syndrome, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Sjogren’s syndrome, systemic sclerosis, ulcerative colitis, and uveitis.

[0136] In some embodiments, a cancer is a solid tumor (e.g., a tumor of the breast, lung, prostate, colon, bladder, ovary, kidney, stomach, colon, rectum, testes, head and / or neck, pancreas, brain, skin). Accordingly, in some embodiments, a cancer is a solid tumor. Nonlimiting examples of solid tumors include breast cancer, lung cancer, prostate cancer, colon cancer, bladder cancer, ovarian cancer, renal cancer, gastric cancer, rectal cancer, colorectal cancer, testicular cancer, head and neck cancer, pancreatic cancer, brain cancer and skin cancer.- 26 - 5099429. vl0399.2077001In some embodiments, a cancer is a hematologic cancer (e.g., leukemia, lymphoma, myeloma). Non-limiting examples of hematologic cancers include leukemias (e.g., acute leukemias, chronic leukemias), lymphomas (e.g., B-cell lymphoma, T-cell lymphoma) and multiple myeloma.

[0137] Non-limiting examples of cancers include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, childhood, aids-related cancer (e.g., Kaposi sarcoma, AIDS-related lymphoma, primary CNS lymphoma), anal cancer, appendix cancer, astrocytomas, childhood, atypical teratoid / rhabdoid tumor, childhood, central nervous system, basal cell carcinoma of the skin, bile duct cancer, bladder cancer, bladder cancer, childhood, bone cancer (including Ewing sarcoma, osteosarcoma, and malignant fibrous histiocytoma), brain tumors / cancer, breast cancer, Burkitt lymphoma, carcinoid tumor (gastrointestinal), carcinoid tumor, childhood, cardiac (heart) tumors, childhood, embryonal tumors, childhood, germ cell tumor, childhood, primary CNS lymphoma, cervical cancer, childhood cervical cancer, cholangiocarcinoma, chordoma, childhood, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, childhood colorectal cancer, craniopharyngioma, childhood, cutaneous T-cell lymphoma (e.g., mycosis fungoides and Sezary syndrome), ductal carcinoma in situ (DCIS), embryonal tumors, central nervous system, childhood, endometrial cancer (uterine cancer), ependymoma, childhood, esophageal cancer, childhood esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, extracranial germ cell tumor, childhood, extragonadal germ cell tumor, eye (ocular) cancer, childhood intraocular melanoma, intraocular melanoma, retinoblastoma, fallopian tube cancer, fibrous histiocytoma of bone, malignant, and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, childhood gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), childhood gastrointestinal stromal tumors, germ cell tumors, childhood central nervous system germ cell tumors (e.g., childhood extracranial germ cell tumors, extragonadal germ cell tumors, ovarian germ cell tumors, testicular cancer), gestational trophoblastic disease, hairy cell leukemia, head and neck cancer, heart tumors, childhood, hepatocellular (liver) cancer, histiocytosis, Langerhans cell, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, childhood intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, Kaposi sarcoma, kidney (renal cell) cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lung cancer (non-small cell and small cell), childhood lung cancer, lymphoma, male breast cancer, malignant fibrous histiocytoma of bone and osteosarcoma, melanoma, childhood melanoma, melanoma, intraocular (eye), childhood intraocular melanoma, Merkel cell- 27 - 5099429. vl0399.2077001carcinoma, mesothelioma, malignant, childhood mesothelioma, metastatic cancer, metastatic squamous neck cancer with occult primary, midline tract carcinoma with Nut gene changes, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndromes, myelodysplastic / myeloproliferative neoplasms, myelogenous leukemia, chronic (CML), myeloid leukemia, acute (AML), myeloproliferative neoplasms, chronic, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, lip and oral cavity cancer and oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer, childhood ovarian cancer, pancreatic cancer, childhood pancreatic cancer, pancreatic neuroendocrine tumors, papillomatosis (childhood laryngeal), paraganglioma, childhood paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, childhood pheochromocytoma, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system (CNS) lymphoma, primary peritoneal cancer, prostate cancer, rectal cancer, recurrent cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, childhood, salivary gland cancer, sarcoma (e.g., childhood rhabdomyosarcoma, childhood vascular tumors, Ewing sarcoma, Kaposi sarcoma, osteosarcoma (bone cancer), soft tissue sarcoma, uterine sarcoma), Sezary syndrome, skin cancer, childhood skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma of the skin, squamous neck cancer with occult primary, metastatic, stomach (gastric) cancer, childhood stomach (gastric) cancer, T-cell lymphoma, cutaneous (e.g, mycosis fungoides and Sezary syndrome), testicular cancer, childhood testicular cancer, throat cancer (e.g, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer), thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, ureter and renal pelvis, transitional cell cancer, urethral cancer, uterine cancer, endometrial, uterine sarcoma, vaginal cancer, childhood vaginal cancer, vascular tumors, vulvar cancer, and Wilms tumor and other childhood kidney tumors.

[0138] Non-limiting examples of hematological diseases include diseases resulting from bone marrow irradiation or chemotherapy treatments for cancer, polycythemia, infectious mononucleosis (EBV), acute lymphocytic leukemia (ALL), acute non-lymphocytic leukemia (ANLL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AMMoL), chronic lymphocytic leukemia, polycythemia vera, lymphoma, Wilms’ tumor, retinoblastoma, hemophilia, disorders associated with an increased- 28 - 5099429. vl0399.2077001risk of thrombosis, herpes, thalassemia, antibody-mediated disorders (e.g., transfusion reactions and erythroblastosis), mechanical trauma to red blood cells (e.g., micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation), infections by parasites (e.g., Plasmodium), chemical injuries (e.g., from lead poisoning), and hypersplenism.

[0139] Non-limiting examples of metabolic disorders include diabetes (e.g., Type I diabetes, Type II diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity.

[0140] Non-limiting examples of noncancerous blood disorders include blood clotting disorders, bleeding disorders, and anemias (e.g., acquired anemias, inherited anemias, hemolytic anemia, sideroblastic anemia, and microcytic anemia).

[0141] Non-limiting examples of blood clotting disorders include prothrombin gene mutation, antiphospholipid syndrome, protein S deficiency, protein C deficiency, antithrombin deficiency, paroxysmal nocturnal hemoglobinuria, and disseminated intravascular coagulation (DIC).

[0142] Non-limiting examples of bleeding disorders include Von Willebrand disease, inherited hemophilia, thrombocytopenia, and fibrinogen deficiency conditions.

[0143] Non-limiting examples of acquired anemias include pernicious anemia, iron-deficiency anemia, megaloblastic anemia, aplastic anemia, autoimmune hemolytic anemia, macrocytic anemia, and normocytic anemia.

[0144] Non-limiting examples of inherited anemias include Sickle cell anemia, Fanconi anemia, Diamond-Blackfan anemia, and thalassemia.

[0145] Non-limiting examples of inflammatory diseases include acute anaphylaxis, adult respiratory distress syndrome (ARDS), allergies, allograft rejection, angitis, ankylosing spondylitis, appendicitis, arteritis, arthrosteitis, asbestosis, asthma, atherosclerosis, arteriosclerosis, autoimmune disorders, berylliosis, blepharitis, bronchiectasis, bronchiolitis, bronchitis, bursitis, cellular interstitial pneumonia, cellulitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, chronic bronchitis, chronic cholecystitis, Crohn’s disease, cystic fibrosis, cystitis, dacryoadenitis, degenerative arthritis, delayed-type hypersensitivity reactions (e.g., poison ivy dermatitis), dermatomyositis, desquamative interstitial pneumonia, diabetes (e.g., Type I diabetes), encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, extrinsic allergic alveolitis, fasciitis, fibrositis, gastritis, gastroenteritis, giant cell arteritis, giant cell interstitial pneumonia, gingivitis,5099429. vl0399.2077001glomerulonephritis, Goodpasture’s disease, gouty arthritis, Graves’ disease, Hashimoto’s thyroiditis, hayfever, hepatitis, host-versus-graft rejection, immediate hypersensitivity reactions, ileitis, inflammatory arthritis, inflammatory bowel disease, inflammatory dermatoses, iritis, ischemia (ischemic injury), laryngitis, lymphoid interstitial pneumonia, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, myelitis, myocarditis, necrotizing enterocolitis, necrotizing fasciitis, nephritis, ocular inflammatory disease (e.g., post-surgical inflammation), omphalitis, oophoritis, optic neuritis, orchitis, osteitis, osteomyelitis, otitis, pancreatitis, parotitis, pemphigoid, pemphigus, pericarditis, pernicious anemia, pharyngitis, phlebitis, pleuritis, pneumoconiosis, pneumonitis, pneumonia, polymyalgia rheumatica (PMR), polymyositis, proctitis, progressive systemic sclerosis (scleroderma), prostatitis, psoriasis, reperfusion injury, respiratory tract inflammation, rheumatoid arthritis, rheumatic fever, rhinitis, pyelonephritis, salpingitis, sarcoidosis, sclerosing cholangitis, silicosis, sinusitis, Sjogren’s syndrome, stomatitis, synovitis, systemic lupus erythematosus, talcosis, temporal arteritis, tendonitis, testitis, tonsillitis, transverse myelitis, ulcerative colitis, urethritis, urocystitis, usual interstitial pneumonitis (UIP), uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, and Wegener’s granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa). In some embodiments, an inflammatory disease is inflammaging (inflammation that is a side effect of aging).

[0146] Non-limiting examples of neurological disorders include, amyloidosis, Angelman syndrome, behavioral disorders, bulbar palsy, cancers (e.g., a CD20-positive cancer with brain metastases, a Her2-positive cancer with brain metastases), central nervous system (CNS) inflammation, coma, cystic fibrosis, demyelinating diseases, eye diseases / disorders, Friedreich’s ataxia, frontotemporal lobar degeneration, hepatolenticular degeneration, Huntington’s disease, infections, ischemia, Jakob disease, Kennedy disease, Lafora disease, Lesch-Nyhan syndrome, Liddle syndrome, lysosomal storage diseases, stroke, Menkes syndrome, microbial diseases, motor neuron diseases, multiple sclerosis, multiple system atrophy, muscular dystrophy, spinal muscular atrophy, neurodegenerative diseases (e.g., Alexander’s disease, Alper's disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), ataxia telangiectasia, Batten disease, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease (e.g., dementia with Lewy bodies (LBD), frontotemporal dementia, HIV-related dementia, mixed dementia, vascular dementia), movement disorders, neoplasms, neuronal ceroid lipofuscinosis, neuro-ophthalmology, neuropathic disorders, Parkinson’s disease, Paget’s disease, Pick’s disease, primary lateral sclerosis, prion diseases (e.g., bovine spongiform encephalopathy, scrapie, kuru, Gerstmann-Straussler-Scheinker disease, chronic wasting disease, and fatal- 30 - 5099429. vl0399.2077001familial insomnia), progressive supranuclear palsy, Refsum’s disease, Rett syndrome, seizure, sleep disorders, spinal cord disorders, spinal muscular atrophy, spinocerebellar ataxias (SCAs), stupor, tauopathies (e.g., episodic age-related tauopathy), Tourette’s syndrome, transverse myelitis), trauma, traumatic brain injuries, Unverricht-Lundborg syndrome, viral diseases, and disorders of peripheral nerves, muscle and neuromuscular junctions.

[0147] Further non-limiting examples of neurological diseases include acquired epileptiform aphasia, acute disseminated encephalomyelitis, adrenoleukodystrophy, agenesis of the corpus callosum, agnosia, Aicardi syndrome, alternating hemiplegia, anencephaly, angiomatosis, anoxia, aphasia, apraxia, arachnoid cysts, arachnoiditis, Arnold-Chiari malformation, arteriovenous malformation, Asperger syndrome, attention deficit hyperactivity disorder, autism, autonomic dysfunction, back pain, Behcet’s disease, Bell’s palsy, benign essential blepharospasm, benign focal, amyotrophy, benign intracranial hypertension, Binswanger’s disease, blepharospasm, Bloch Sulzberger syndrome, brachial plexus injury, brain abscess, brain injury, brain tumors (including glioblastoma multiforme), Brown-Sequard syndrome, carpal tunnel syndrome (CTS), causalgia, central pain syndrome, central pontine myelinolysis, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, Charcot-Marie-Tooth disease, chemotherapy-induced neuropathy and neuropathic pain, Chiari malformation, chorea, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, chronic regional pain syndrome, Coffin Lowry syndrome, coma, including persistent vegetative state, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorders, Cushing’s syndrome, cytomegalic inclusion body disease (CIBD), cytomegalovirus infection, dancing eyes-dancing feet syndrome, Dandy -Walker syndrome, Dawson disease, De Morsier’s syndrome, Dejerine-Klumpke palsy, dementia, dermatomyositis, diabetic neuropathy, diffuse sclerosis, dysautonomia, dysgraphia, dyslexia, dystonias, early infantile epileptic encephalopathy, empty sella syndrome, encephalitis, encephaloceles, encephalotrigeminal angiomatosis, epilepsy, Erb’s palsy, essential tremor, Fabry’s disease, Fahr’s syndrome, fainting, familial spastic paralysis, febrile seizures, Fisher syndrome, Friedreich’s ataxia, frontotemporal dementia and other “tauopathies”, Gaucher’s disease, Gerstmann’s syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, Guillain-Barre syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, head injury, headache, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, HIV-associated dementia and neuropathy (see also neurological manifestations of- 31 - 5099429. vl0399.2077001AIDS), holoprosencephaly, Huntington’s disease and other polyglutamine repeat diseases, hydranencephaly, hydrocephalus, hypercorti soli sm, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile, phytanic acid storage disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg- Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, learning disabilities, Leigh’s disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig’s disease (aka motor neuron disease or amyotrophic lateral sclerosis), lumbar disc disease, Lyme disease-neurological sequelae, Machado- Joseph disease, macroencephaly, megalencephaly, Melkersson-Rosenthal syndrome, Meniere’s disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, migraine, Miller Fisher syndrome, ministrokes, mitochondrial myopathies, Mobius syndrome, monomelic amyotrophy, motor neurone disease, moyamoya disease, mucopolysaccharidoses, multi infarct dementia, multifocal motor neuropathy, multiple sclerosis and other demyelinating disorders, multiple system atrophy with postural hypotension, muscular dystrophy, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic encephalopathy of infants, myoclonus, myopathy, myotonia congenita, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, neurological manifestations of AIDS, neurological sequelae of lupus, neuromyotonia, neuronal ceroid lipofuscinosis, neuronal migration disorders, Niemann-Pick disease, O’Sullivan-McFeod syndrome, occipital neuralgia, occult spinal dysraphism sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus, optic neuritis, orthostatic hypotension, overuse syndrome, paresthesia, paramyotonia congenita, paraneoplastic diseases, paroxysmal attacks, Parry Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, painful neuropathy and neuropathic pain, persistent vegetative state, pervasive developmental disorders, photic sneeze reflex, phytanic acid storage disease, pinched nerve, pituitary tumors, polymyositis, porencephaly, Post-Polio syndrome, postherpetic neuralgia (PHN), postinfectious encephalomyelitis, postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive, hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive sclerosing poliodystrophy, pseudotumor cerebri, Ramsay-Hunt syndrome (Type I and Type II), Rasmussen’s Encephalitis, reflex sympathetic dystrophy syndrome, repetitive motion disorders, repetitive stress injuries, restless legs syndrome, retrovirus-associated- 32 - 5099429. vl0399.2077001myelopathy, Reye’s syndrome, Saint Vitus Dance, Sandhoff disease, Schilder’s disease, schizencephaly, septo-optic dysplasia, shaken baby syndrome, shingles, Shy -Drager syndrome, Sjogren’s syndrome, sleep apnea, Soto’s syndrome, spasticity, spina bifida, spinal cord injury, spinal cord tumors, stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subarachnoid hemorrhage, subcortical arteriosclerotic encephalopathy, sydenham chorea, syncope, syringomyelia, tardive dyskinesia, Tay-Sachs disease, temporal arteritis, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd’s paralysis, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, tuberous sclerosis, vascular dementia (multi-infarct dementia), vasculitis including temporal arteritis, Von Hippel -Lindau Disease (VHL), Wallenberg’s syndrome, Werdnig-Hoffman disease, West syndrome, whiplash, Williams syndrome, Wilson’s disease, and Zellweger syndrome.

[0148] Non-limiting examples of painful conditions include acute pain (e.g., phantom and transient acute pain), arthritic pain (e.g, pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis or Reiter’s arthritis), bum pain, central pain, chronic pain (e.g, chronic nociceptive pain, and other forms of chronic pain such as post-operative pain, e.g., pain arising after hip, knee, or other replacement surgery), deafferentiation pain, dental / maxillofacial pain, headache, inflammatory pain, joint pain, lower back pain, lumbosacral pain, migraine, muscle ache, musculo-skeletal pain, neck pain, neuropathic pain (e.g., peripheral neuropathic pain), noninflammatory pain, painful bladder syndrome, postoperative pain, pre-operative pain, stimulus of nociceptive receptors (nociceptive pain), toothache, visceral pain, wound pain, and pain associated with cancer, medical procedures, premenstrual dysphoric disorder, premenstrual syndrome, chronic fatigue syndrome, pre-term labor, and / or withdrawal symptoms from drug addiction, and / or pruritus.

[0149] In some embodiments, a proliferative disease is associated with (i) pathological proliferation of normally quiescent cells, (ii) pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells), (iii) pathological expression of proteolytic enzymes (e.g., matrix metalloproteinases such as collagenases, gelatinases, or elastases), (iv) pathological angiogenesis (e.g., proliferative retinopathy or tumor metastasis). Non-limiting examples of proliferative disorders include angiogenesis, autoimmune diseases, benign neoplasms, and cancers.

[0150] The terms “neoplasm” and “tumor” are used interchangeably herein.- 33 - 5099429. vl0399.2077001

[0151] In some embodiments, a neoplasm or tumor is a benign neoplasm. Non-limiting examples of benign neoplasms include acrochordon, adenomas, chondroma, lentigos, lipoma, sebaceous hyperplasias, seborrheic keratoses, and senile angiomas.

[0152] In some embodiments, a neoplasm or tumor is a pre-malignant neoplasm. A nonlimiting example of pre-malignant neoplasm is teratoma.

[0153] In some embodiments, a neoplasm or tumor is a malignant neoplasm.

[0154] Non-limiting examples of cancers include acoustic neuroma, adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangio sarcoma, lymphangioendotheliosarcoma, hemangiosarcoma), appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma), breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast), bronchus cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), chordoma, choriocarcinoma, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), connective tissue cancer, craniopharyngioma, endometrial cancer (e.g., uterine cancer, uterine sarcoma), endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma), ependymoma, epithelial carcinoma, esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma), Ewing’s sarcoma, familial hypereosinophilia, gall bladder cancer, gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), germ cell cancer, head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)), hemangioblastoma, hypopharynx cancer, immunocytic amyloidosis, inflammatory myofibroblastic tumors, intraepithelial neoplasms, hematopoietic cancers (e.g., leukemia, lymphoma, multiple myeloma (MM), and heavy chain disease), kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma), leiomyosarcoma (LMS), liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung), mastocytosis (e.g., systemic mastocytosis), mesothelioma, muscle cancer, myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)),- 34 - 5099429. vl0399.2077001neuroblastoma, neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis), ocular cancer e.g., intraocular melanoma, retinoblastoma), osteosarcoma e.g., bone cancer), ovarian cancer e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), pancreatic cancer e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors), papillary adenocarcinoma, paraneoplastic syndromes, penile cancer e.g., Paget’s disease of the penis and scrotum), pinealoma, plasma cell neoplasia, primitive neuroectodermal tumor (PNET), prostate cancer e.g., prostate adenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary gland cancer, sebaceous gland carcinoma, skin cancer e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)), small bowel cancer e.g., appendix cancer), small intestine cancer, soft tissue sarcoma e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sweat gland carcinoma, synovioma, testicular cancer e.g., seminoma, testicular embryonal carcinoma), thyroid cancer e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer), urethral cancer, vaginal cancer, and vulvar cancer e.g., Paget’s disease of the vulva).

[0155] Non-limiting examples of leukemias include acute lymphocytic leukemia (ALL, e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML, e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML, e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL, e.g., B-cell CLL, T-cell CLL).

[0156] Non-limiting examples of lymphomas include Hodgkin lymphoma (HL, e.g., B-cell HL, T-cell HL), non-Hodgkin lymphoma (NHL, e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL, e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma, T-cell NHL (such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL, e.g., cutaneous T-cell lymphoma (CTCL, e.g., mycosis fungoides, Sezary syndrome)), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma,- 35 - 5099429. vl0399.2077001enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma).

[0157] Non-limiting examples of heavy chain diseases include alpha chain disease, gamma chain disease, and mu chain disease.

[0158] Non-limiting examples of psychiatric disorders include addiction and mental illness, adjustment disorder, anxiety disorders (e.g., acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia), autism, childhood disorders (e.g., attention-deficit / hyperactivity disorder, conduct disorder, and oppositional defiant disorder), delirium, dementia, eating disorders (e.g., anorexia nervosa and bulimia nervosa), learning and memory disorders (e.g., age-related memory loss and amnesia), mood disorders (e.g., depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), multi-infarct dementia, personality disorders (e.g., antisocial personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, and schizotypal personality disorder), psychotic disorders (e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder, and shared psychotic disorder), substance-related disorders (e.g., alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, and sedative dependence), and Tourette’s disorder.

[0159] Non-limiting examples of genetic diseases include a progeroid syndrome (e.g., Hutchinson-Gilford progeria syndrome), Aarskog-Scott syndrome, Aase syndrome, ablepharon-macrostomia syndrome, achondroplasia, acrodysostosis, addiction, adreno-leukodystrophy, alagille syndrome, albinism, alkaptonuria, alpha-1 antitrypsin deficiency, Alport’s syndrome, Alzheimer’s disease, androgen insensitivity syndrome, Angelman syndrome, asthma, ataxia, ataxia telangiectasia, atherosclerosis, attention deficit hyperactivity disorder (ADHD), autism, autoimmune polyglandular syndrome, baldness, Batten disease, Beckwith-Wiedemann syndrome, Best disease, bipolar disorder, brachydactyly, breast cancer, Burkitt lymphoma, Charcot-Marie-Tooth disease, chronic myeloid leukemia, cleft lip, Cockayne syndrome, Coffin Lowry syndrome, colon cancer, congenital adrenal hyperplasia, Cornelia de Lange syndrome, Costello syndrome, Cowden syndrome, craniofrontonasal dysplasia, Creutzfeldt- Jakob disease,- 36 - 5099429. vl0399.2077001Crigler-Najjar syndrome, Crohn’s disease, cystic fibrosis, deafness, depression, diabetes, diastrophic dysplasia, DiGeorge syndrome, Down’s syndrome, Dubowitz syndrome, Duchenne muscular dystrophy, dyslexia, ectodermal dysplasia, Ellis-van Creveld syndrome, Ehlers-Danlos, epidermolysis bullosa, epilepsy, essential tremor, familial hypercholesterolemia, familial Mediterranean fever, fragile X syndrome, Friedreich’s ataxia, Gaucher disease, glaucoma, glucose galactose malabsorption, glutaricaciduria, Goldberg Shprintzen syndrome (velocardiofacial syndrome), Gorlin syndrome, gyrate atrophy, Hailey-Hailey disease, hemihypertrophy, hemochromatosis, hemophilia, hereditary motor and sensory neuropathy (HMSN), hereditary nonpolyposis colorectal cancer (HNPCC), Huntington’s disease, immunodeficiency with hyper-IgM, juvenile onset diabetes, Kabuki syndrome, Klinefelter’s syndrome, Leigh’s disease, long QT syndrome, lung cancer, malignant melanoma, manic depression, Marfan syndrome, Menkes syndrome, miscarriage, mucopolysaccharide disease, multiple endocrine neoplasia, multiple sclerosis, muscular dystrophy, myotonic dystrophy, myotrophic lateral sclerosis, neurofibromatosis, Niemann-Pick disease, Noonan syndrome, obesity, ovarian cancer, pancreatic cancer, Parkinson’s disease, paroxysmal nocturnal hemoglobinuria, Pendred syndrome, peroneal muscular atrophy, phenylketonuria (PKU), polycystic kidney disease, Prader-Willi syndrome, primary biliary cirrhosis, prostate cancer, REAR syndrome, Refsum disease, retinitis pigmentosa, retinoblastoma, Rett syndrome, Sanfilippo syndrome, schizophrenia, severe combined immunodeficiency, sickle cell anemia, spina bifida, spinal muscular atrophy, spinocerebellar atrophy, sudden adult death syndrome, Tangier disease, Tay-Sachs disease, thrombocytopenia absent radius syndrome, Townes-Brocks syndrome, tuberous sclerosis, Turner syndrome, Usher syndrome, von Hippel-Lindau syndrome, Waardenburg syndrome, Weaver syndrome, Werner syndrome, Williams syndrome, Wilson’s disease, xeroderma pigmentosum, and Zellweger syndrome.

[0160] In some embodiments, an age-related disease is a mitochondrial disease. Non-limiting examples of mitochondrial diseases include Alpers disease, and mitochondrial DNA depletion. Cellular dysfunction may include mitochondrial dysfunction, Barth syndrome, beta-oxidation defects, carnitine deficiency, CPT I deficiency, DNA replication dysfunction, Friedreich’s ataxia, protein folding dysfunction, RNA replication dysfunction, and translation dysfunction.

[0161] In some embodiments, an age-related disease is an infectious disease. Non-limiting examples of infectious diseases include cholera, dengue fever, hepatitis C, HIV / AIDS, influenza, Lyme disease, malaria, measles, meningitis, plague, poliomyelitis, rabies, tuberculosis, typhoid fever, and whooping cough.- 37 - 5099429. vl0399.2077001

[0162] Non-limiting examples of age-related diseases and / or conditions include heart failure, stroke, heart disease, atherosclerosis, neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease), cognitive decline, memory loss, diabetes, osteoporosis, arthritis, muscle loss, hearing loss (partial or total), eye-related conditions (e.g., poor eyesight or retinal disease), glaucoma, a progeroid syndrome (e.g., Hutchinson-Gilford progeria syndrome), and cancer.

[0163] In some embodiments, an age-related condition is senescence (e.g., senescence of glial cells). In some embodiments, an age-related condition is nerve damage. In some embodiments, an age-related condition is damage in the central nervous system (CNS). In some embodiments, a nerve damage is peripheral nerve damage. In some embodiments, a nerve damage is neurapraxia, axonotmesis, or neurotmesis.Polynucleotides (Nucleic Acid Sequences, Promoters)

[0164] Provided herein, among other things, is a polynucleotide.

[0165] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding a protein or a variant thereof, wherein the protein is selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, and FosB_2, homologs; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter.

[0166] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding NKX2-5 or a variant thereof (e.g., AHD, I184M, orI184P); andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter, optionally wherein a promoter comprises (or consists of) a Synapsin promoter (e.g., a human Synapsin 1 (hSyn) promoter), a rhodopsin (Rho) promoter, a Bestrophin-1 (Bestl) promoter, a retinaldehyde -binding protein 1 (RLBP1) promoter, a GFAP promotor, a HKamac promotor, a GNAT2 promotor, a CD68 promoter, a Krt 12 promoter, an ABCB5 promotor, a Keratocan promotor, a POU6F2- 38 - 5099429. vl0399.2077001promotor, a RedO promoter, a cone arrestin (CAR) promoter, or a human rhodopsin kinase (hRK) promoter.

[0167] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding a protein or a variant thereof, wherein:a) the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, andFosB_2; b) the polynucleotide is a messenger ribonucleic acid (mRNA); andc) the polynucleotide is encapsulated in lipid nanoparticles (LNPs).

[0168] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding NKX2-5 or a variant thereof, wherein the polynucleotide is a mRNA and the polynucleotide is encapsulated in LNPs.

[0169] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding a protein or a variant thereof, wherein:a) the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, andFosB_2; andb) the polynucleotide is an adeno-associated virus (AAV) vector, optionally wherein the AAV vector is an AAV2 or AAV9 vector, or a variant thereof.

[0170] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding NKX2-5 or a variant thereof, wherein the polynucleotide is an AAV vector (e.g., an AAV2 or AAV9 vector, or a variant thereof).

[0171] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding a target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, FosB_2, and variants (e.g., functional variants such as fragments) thereof.

[0172] In some embodiments, a polynucleotide comprises a nucleic acid sequence encoding a target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, C2CD2L, NKX2-1, SEMA4G, FosB_l, FosB_2, and variants (e.g., functional variants such as fragments) thereof.

[0173] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding a target protein selected from the group consisting ofNKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L,- 39 - 5099429. vl0399.2077001NKX2-1, SEMA4G, FosB_l, FosB_2, and variants (e.g., functional variants such as fragments) thereof; andb) a promoter operably linked to the nucleic acid sequence, optionally, the promoter is mesenchymal cell-specific.

[0174] In some embodiments, a polynucleotide further comprises a translation initiation sequence, a post-transcriptional regulatory element, a poly(A) signal, a nucleic acid sequence encoding a selectable marker, or any combination thereof.

[0175] In some embodiments, a polynucleotide further comprises an origin of replication, an enhancer, a nucleic acid sequence encoding a marker (e.g., a selectable marker), a nucleic acid sequence encoding a linker, an internal ribosome entry site (IRES), a post-transcriptional response element e.g., woodchuck hepatitis virus posttranscriptional regulatory element (WPRE)), a terminator, multiple cloning site(s), or any combination thereof.Nucleic Acid Sequences

[0176] In some embodiments, a nucleic acid sequence encodes NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, FosB_2, or a variant e.g., a functional variant such as a fragment) thereof.Gene Symbol Gene Name NCBI Gene ID NKX2-5 NK2 homeobox 5 1482LTBR Lymphotoxin beta receptor 4055C4BPA Complement component 4 binding protein alpha 722Cllorfl Chromosome 11 open reading frame 1 79012MOCS2 Molybdenum cofactor synthesis 2 4338MED1 molybdenum cofactor synthesis 2 5469C2CD2L C2 domain-containing protein 2-like 84254NKX2-1 NK2 homeobox 1 7080SEMA4G Semaphorin 4G 387119FOSB FBJ murine osteosarcoma viral oncogene homolog B 2354

[0177] In some embodiments, a nucleic acid sequence encodes NKX2-5, NKX2-1, or LTBR, or a variant thereof. In some embodiments, a nucleic acid sequence encodes NKX2-5, NKX2-1, or LTBR.

[0178] In some embodiments, a nucleic acid sequence encodes LTBR or a variant thereof. In some embodiments, a nucleic acid sequence encodes LTBR.

[0179] In some embodiments, a nucleic acid sequence encodes C4BPA or a variant thereof. In some embodiments, a nucleic acid sequence encodes C4BPA.- 40 - 5099429. vl0399.2077001

[0180] In some embodiments, a nucleic acid sequence encodes Cl lorfl or a variant thereof. In some embodiments, a nucleic acid sequence encodes Cl lorfl.

[0181] In some embodiments, a nucleic acid sequence encodes MOCS2 or a variant thereof. In some embodiments, a nucleic acid sequence encodes MOCS2.

[0182] In some embodiments, a nucleic acid sequence encodes MED1 or a variant thereof. In some embodiments, a nucleic acid sequence encodes MED1.

[0183] In some embodiments, a nucleic acid sequence encodes C2CD2L or a variant thereof. In some embodiments, a nucleic acid sequence encodes C2CD2L.

[0184] In some embodiments, a nucleic acid sequence encodes NKX2-1 or a variant thereof. In some embodiments, a nucleic acid sequence encodes NKX2-1.

[0185] In some embodiments, a nucleic acid sequence encodes SEMA4G or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEMA4G.

[0186] In some embodiments, a nucleic acid sequence encodes FosB l or a variant thereof. In some embodiments, a nucleic acid sequence encodes FosB l.

[0187] In some embodiments, a nucleic acid sequence encodes FosB_2 or a variant thereof. In some embodiments, a nucleic acid sequence encodes FosB_2.

[0188] In some embodiments, a nucleic acid sequence encodes NKX2-5 or a variant (e.g., a functional variant such as a fragment) thereof. In some embodiments, a nucleic acid sequence encodes NKX2-5. In some embodiments, a nucleic acid sequence encodes a fragment of NKX2-5 (e.g, that maintains its oxidative resistance function). In some embodiments, a nucleic acid sequence encodes a fragment of NKX2-5 that comprises the YRD domain. In some embodiments, a variant of NKX2-5 comprises at least one amino acid substitution (e.g, within homeodomain (HD), such as I184M, I184P), deletion (partial or complete deletion of HD), and / or addition. In some embodiments, at least one amino acid substitution, deletion, and / or addition in the homeodomain reduces DNA-binding and / or transcription regulation mediated by the homeodomain of NKX2-5 (e.g., by at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or by about 100%).

[0189] In some embodiments, a nucleic acid sequence encodes a NKX2-5 variant comprising a mutation within its (NKX2-5’s) homeodomain. In some embodiments, a mutation impairs DNA-binding and / or transcription regulation mediated by the NKX2-5 homeodomain. Nonlimiting examples of mutations impairing DNA-binding and / or transcription regulation of NKX2-5 homeodomain including AHD, I184M, I184P, and “Group 2” mutations (e.g., T178M, N188K, R189G, Y191C) described in H. Kasahara et al., Loss of function and inhibitory effects- 41 - 5099429. vl0399.2077001of human CSX / NKX2.5 homeoprotein mutations associated with congenital heart disease, J Clin Invest. 106(2):299-308 (2000), the relevant teachings of which are incorporated herein by reference in their entirety.

[0190] In some embodiments, aNKX2-5 variant comprises:a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12) (e.g., All 84, 1184M or I184P); b) a substitution or a deletion of a threonine (T) corresponding to T 178 of SEQ ID NO:1 (e.g, T178M);c) a substitution or a deletion of an asparagine (N) corresponding to N188 of SEQ ID NO:1 (e.g., N188K);d) a substitution or a deletion of an arginine (R) corresponding to R189 of SEQ ID NO:1 (e.g., R189G);e) a substitution or a deletion of a tyrosine (Y) corresponding to Y191 of SEQ ID NO:1 (e.g, Y191C); and / orf) a deletion of 1 to 60 amino acids (e.g., a deletion of 2 to 60 amino acids) within its homeodomain.

[0191] In some embodiments, aNKX2-5 variant comprises:a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12); and / orb) a deletion of 1 to 60 amino acids (e.g., a deletion of 2 to 60 amino acids) within its homeodomain.

[0192] In some embodiments, a NKX2-5 variant comprises:a) a substitution (e.g., a non-conservative substitution) of at least one amino acid (e.g, 1184 of SEQ ID NO:1 or 1183 of SEQ ID NO: 12) within its homeodomain; b) a deletion of at least one amino acid (e.g., 1184 of SEQ ID NO: 1 or 1183 of SEQ ID NO: 12) within its homeodomain,or both a) and b).

[0193] In some embodiments, a NKX2-5 variant comprises a substitution (e.g., a nonconservative substitution) of at least one amino acid (e.g., 1184 of SEQ ID NO: 1 or 1183 of SEQ ID NO: 12) within its homeodomain. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 11.- 42 - 5099429. vl0399.2077001

[0194] In some embodiments, a NKX2-5 variant comprises a deletion of at least one amino acid (e.g., 1184 of SEQ ID NO: 1 or 1183 of SEQ ID NO: 12) within its homeodomain. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 13 or SEQ ID NO: 14. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, aNKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 14.

[0195] In some embodiments, a NKX2-5 variant comprises a deletion of 1 to 60 amino acids within its homeodomain, for example, a deletion of 2-60, 2-55, 2-50, 2-45, 2-40, 2-35, 2-30, 2-25, 2-20, 2-15, 2-10, 2-5, 3-60, 3-55, 3-50, 3-45, 3-40, 3-35, 3-30, 3-25, 3-20, 3-15, 3-10, 3-5, 4-60, 4-55, 4-50, 4-45, 4-40, 4-35, 4-30, 4-25, 4-20, 4-15, 4-10, 5-60, 5-55, 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-10, 10-60, 10-55, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 15-60, 15-55, 15-50, 15-45, 15-40, 15-35, 15-30, 15-25, 15-20, 20-60, 20-55, 20-50, 20-45, 20-40, 20-35, 20-30, 20-25, 25-60, 25-55, 25-50, 25-45, 25-40, 25-35, 25-30, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 40-60, 40-55, 40-50, 40-45, 50-60, or 50-55 amino acids within its homeodomain. In some embodiments, a deletion of 1 to 60 amino acids within a homeodomain comprises a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1.

[0196] In some embodiments, a NKX2-5 variant comprises a deletion of at least 1 amino acid within its homeodomain, for example, a deletion of at least: 2, 3, 4, 5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 amino acids within its homeodomain. In some embodiments, a deletion of at least 1 amino acid within its homeodomain comprises a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1.

[0197] In some embodiments, a NKX2-5 variant comprises a deletion of at least 5 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 10 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 15 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 20 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 25 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 30 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 35 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 40 amino acids within its homeodomain. In some- 43 - 5099429. vl0399.2077001embodiments, a NKX2-5 variant comprises a deletion of at least 45 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 50 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of at least 55 amino acids within its homeodomain. In some embodiments, a NKX2-5 variant comprises a deletion of the entire homeodomain. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:9.

[0198] NKX2.5

[0199] NCBI Reference Sequence: NP_004378.1 (e.g., encoded by NM_004387.4)

[0200] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQ LASVLKLTSTQVKIWFQNRRYKCKRQRQDQTLELVGLPPPPPPPARRIAVPVLVRDGKP CLGD S AP YAP AYGVGLNP YGYNAYP AYPGYGGAAC SPGYSCTAAYP AGPSP AQP AT AA ANNNFVNFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO:1)

[0201] NCBI Reference Sequence: NP_032726.1

[0202] MFPSPALTPTPFSVKDILNLEQQQRSLASGDLSARLEATLAPASCMLAAFKPE AYSGPEAAASGLAELRAEMGPAPSPPKCSPAFPAAPTFYPGAYGDPDPAKDPRADKKEL CALQKAVELDKAETDGAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQL ASVLKLTSTQVKIWFQNRRYKCKRQRQDQTLELLGPPPPPARRIAVPVLVRDGKPCLGD PAAYAPAYGVGLNAYGYNAYPYPSYGGAACSPGYSCAAYPAAPPAAQPPAASANSNF VNFGVGDLNTVQSPGMPQGNSGVSTLHGIRAW (SEQ ID NO: 12)

[0203] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRAR (SEQ ID NO:2)

[0204] TLEL VGLPPPPPPP ARRIA VP VL VRDGKPCLGD SAP YAP AYGVGLNP YGYN A YPAYPGYGGAACSPGYSCTAAYP AGPSP AQP ATAAANNNFVNFGVGDLNAVQSPGIPQ SNSGVSTLHGIRAW (SEQ ID NO:3)- 44 - 5099429. vl0399.2077001

[0205] NCBI Reference Sequence: NP_001159648.1 (e.g., encoded by NM_001166176.2)

[0206] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKG CELPRGQRPPVLFSSALSQPDFLQMLSETCRWLPVHLAE (SEQ ID NO:4)

[0207] NCBI Reference Sequence: NP_001159647.1 (e.g., encoded by NM_001166175.2)

[0208] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKA(SEQ ID NO: 5)

[0209] YRD domain

[0210] YAPAYGVGLNPYGYNAYPAYPGYGGAACSPGYSCTAAY (SEQ ID NO:6)

[0211] YRD-Y-A

[0212] AAPAAGVGLNPAGANAAPAAPGAGGAACSPGASCTAAA (SEQ ID NO:7)

[0213] Non-limiting examples of HD Deletion Mutations

[0214] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARRQDQTLELVGLPPPPPPPARRIAVPVLVRDGKPCL GDSAPYAPAYGVGLNPYGYNAYPAYPGYGGAACSPGYSCTAAYPAGPSPAQPATAAA NNNFVNFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO:8)

[0215] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARTLELVGLPPPPPPPARRIAVPVLVRDGKPCLGDSAP YAPAYGVGLNPYGYNAYPAYPGYGGAACSPGYSCTAAYPAGPSPAQPATAAANNNFV NFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO:9)

[0216] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQ LASVLKLTSTQVKWFQNRRYKCKRQRQDQTLELVGLPPPPPPPARRIAVPVLVRDGKPC LGDSAPYAPAYGVGLNPYGYNAYPAYPGYGGAACSPGYSCTAAYPAGPSPAQPATAA ANNNFVNFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO: 13)

[0217] MFPSPALTPTPFSVKDILNLEQQQRSLASGDLSARLEATLAPASCMLAAFKPE AYSGPEAAASGLAELRAEMGPAPSPPKCSPAFPAAPTFYPGAYGDPDPAKDPRADKKEL CALQKAVELDKAETDGAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQL ASVLKLTSTQVKWFQNRRYKCKRQRQDQTLELLGPPPPPARRIAVPVLVRDGKPCLGDP- 45 - 5099429. vl0399.2077001 AAYAPAYGVGLNAYGYNAYPYPSYGGAACSPGYSCAAYPAAPPAAQPPAASANSNFV NFGVGDLNTVQSPGMPQGNSGVSTLHGIRAW (SEQ ID NO: 14)

[0218] Non-limiting examples of HD Substitution Mutations

[0219] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQ LASVLKLTSTQVKMWFQNRRYKCKRQRQDQTLELVGLPPPPPPPARRIAVPVLVRDGK PCLGDSAPYAPAYGVGLNPYGYNAYPAYPGYGGAACSPGYSCTAAYPAGPSPAQPATA AANNNFVNFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO: 10) I184M

[0220] MFPSPALTPTPFSVKDILNLEQQQRSLAAAGELSARLEATLAPSSCMLAAFKP EAYAGPEAAAPGLPELRAELGRAPSPAKCASAFPAAPAFYPRAYSDPDPAKDPRAEKKE LCALQKAVELEKTEADNAERPRARRRRKPRVLFSQAQVYELERRFKQQRYLSAPERDQ LASVLKLTSTQVKPWFQNRRYKCKRQRQDQTLELVGLPPPPPPPARRIAVPVLVRDGKP CLGD S AP YAP AYGVGLNP YGYNAYP AYPGYGGAAC SPGYSCTAAYP AGPSP AQP AT AA ANNNFVNFGVGDLNAVQSPGIPQSNSGVSTLHGIRAW (SEQ ID NO: 11) I184P

[0221] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to at least one sequence set forth in SEQ ID NOs:l-14, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to at least one sequence set forth in SEQ ID NOs:l-14. In some embodiments, aNKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs: 1-14. In some embodiments, a NKX2-5 variant has 100% sequence identity to a sequence set forth in SEQ ID NOs:l-14.

[0222] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to at least one sequence set forth in SEQ ID NOs:8-l 1, 13, and 14, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to at least one sequence set forth in SEQ ID NOs:8-l 1, 13, and 14. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs:8-ll, 13, and 14. In some embodiments, aNKX2-5 variant has 100% sequence identity to a sequence set forth in SEQ ID NOs:8-l 1, 13, and 14.- 46 - 5099429. vl0399.2077001

[0223] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to at least one sequence set forth in SEQ ID NOs:8, 10, 11, 13, and 14, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to at least one sequence set forth in SEQ ID NOs:8, 10, 11, 13, and 14. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs:8, 10, 11, 13, and 14. In some embodiments, a NKX2-5 variant has 100% sequence identity to a sequence set forth in SEQ ID NOs:8, 10, 11, 13, and 14.

[0224] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO:8, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to SEQ ID NO:8. In some embodiments, aNKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO:8. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO: 8.

[0225] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO:9, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to SEQ ID NO:9. In some embodiments, aNKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO:9. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO:9.

[0226] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO: 10, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to SEQ ID NO: 10. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO: 10. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO: 10.

[0227] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO: 11, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%- 47 - 5099429. vl0399.2077001sequence identity to SEQ ID NO: 11. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO: 11. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO: 11.

[0228] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO: 13, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to SEQ ID NO: 13. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO: 13. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO: 13.

[0229] In some embodiments, a NKX2-5 variant has at least 80% sequence identity to SEQ ID NO: 14, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to SEQ ID NO: 14. In some embodiments, a NKX2-5 variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO: 14. In some embodiments, a NKX2-5 variant has 100% sequence identity to SEQ ID NO: 14.

[0230] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in:a) SEQ ID NO:2 and SEQ IDNO:6;b) SEQ ID NO:2 and SEQ IDNO:3;c) SEQ ID NO:8;d) SEQ ID NO: 9;e) SEQ ID NO: 10;f) SEQ ID NO: 11,g) SEQ ID NO: 13, orh) SEQ ID NO: 14,optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

[0231] In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:2 and SEQ ID NO:6. In some embodiments, aNKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:2 and SEQ ID NO:3. In some embodiments, a- 48 - 5099429. vl0399.2077001NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:9. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 11. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, a NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO: 14.

[0232] In some embodiments, a nucleic acid sequence encodes any one of SEQ ID NOs:l-6 or a variant (e.g., a functional variant such as a fragment) thereof. In some embodiments, a nucleic acid sequence encodes any one of SEQ ID NOs:l-6. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to at least one sequence set forth in SEQ ID NOs:l-6, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to at least one sequence set forth in SEQ ID NOs:l-6. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs:l-6. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to a sequence set forth in SEQ ID NOs:l-6.

[0233] In some embodiments, a nucleic acid sequence encodes any one of SEQ ID NOs:l-5 or a variant (e.g., a functional variant such as a fragment) thereof. In some embodiments, a nucleic acid sequence encodes any one of SEQ ID NOs:l-5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to at least one sequence set forth in SEQ ID NOs:l-5, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to at least one sequence set forth in SEQ ID NOs:l-5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs:l-5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to a sequence set forth in SEQ ID NOs:l-5.

[0234] In some embodiments, a nucleic acid sequence encodes SEQ ID NO:1 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO:1. In some- 49 - 5099429. vl0399.2077001embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:1. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO:1. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO: 1.

[0235] In some embodiments, a nucleic acid sequence encodes SEQ ID NO:2 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO:2. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:2, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:2. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO:2. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO:2.

[0236] In some embodiments, a nucleic acid sequence encodes SEQ ID NO: 3 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO:3. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:3, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:3. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO:3. In some embodiments, a nucleic acid5099429. vl0399.2077001sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO:3.

[0237] In some embodiments, a nucleic acid sequence encodes SEQ ID NO:4 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO:4. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:4, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:4. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO:4. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO:4.

[0238] In some embodiments, a nucleic acid sequence encodes SEQ ID NO: 5 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO: 5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:5, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO: 5. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO: 5.

[0239] In some embodiments, a nucleic acid sequence encodes SEQ ID NO: 6 or a variant thereof. In some embodiments, a nucleic acid sequence encodes SEQ ID NO:6. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 6, for example, having at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence set forth in SEQ ID NO:6. In some embodiments, a nucleic acid sequence encodes an- 51 - 5099429. vl0399.2077001amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to the sequence set forth in SEQ ID NO:6. In some embodiments, a nucleic acid sequence encodes an amino acid sequence having 100% sequence identity to the sequence set forth in SEQ ID NO:6.

[0240] In some embodiments, a nucleic acid sequence encodes two or more target proteins selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2, homologs, and variants (e.g., functional variants such as fragments) thereof. In some embodiments, a nucleic acid sequence encodes: (a) NKX2-5 or a variant (e.g., a fragment) thereof, and (b) C2CD2L or a variant (e.g., a fragment) thereof.

[0241] In some embodiments, a nucleic acid sequence is codon-optimized (e.g., for a chosen cell type or species (e.g., human)), for example, to modulate (e.g., improve) protein synthesis and / or limit mRNA destabilization by rare codons (see, e.g., Presnyak et al., Codon optimality is a major determinant of mRNA stability, Cell 160(6): 1111-24 (2015) and Thess et al., Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals, Mol Ther. 23(9): 1456-64 (2015)). Codon optimization is known to those of ordinary skill the art, see, e.g., Patent Cooperation Treaty (PCT) Application Publication Nos. WO1999041397 and W02001079518, the entire contents of which are incorporated herein by reference.Promoters

[0242] In some embodiments, a polynucleotide further comprises a promoter.

[0243] In some embodiments, a polynucleotide comprises a promoter useful for expressing a target protein (e.g., NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)) for rejuvenating retinal ganglion cells (e.g., Synapsin promotor), photoreceptor cells (e.g., Rhodopsin promotor), retinal pigment epithelial cells (e.g., Bestrophin-1 (Bestl) promotor), Muller glial cells (e.g., RLBP1 promotor), astrocytes (e.g., GFAP promotor), amacrine cells (e.g., HKamac promotor (GNAT2 promotor and IRBP enhancer)), glial cells (e.g., GFAP promotor), monocytes (e.g., CD68 promotor), microglia cells of the optic nerve head (e.g., CD68 promotor), corneal epithelial cells (e.g., Krt 12 promotor), limbal stem cells (e.g., ABCB5 promotor), corneal stromal keratocytes (e.g., Keratocan promotor), and / or corneal endothelial cells (e.g., POU6F2 promotor).

[0244] In some embodiments, a polynucleotide comprises a promoter useful for selectively (e.g., specifically) expressing a target protein (e.g., NKX2-5 or a variant thereof (e.g., AHD,- 52 - 5099429. vl0399.2077001I184M, or I184P)) in retinal ganglion cells (e.g., Synapsin promotor), photoreceptor cells (e.g., Rhodopsin promotor), retinal pigment epithelial cells (e.g., Bestrophin-1 (Bestl) promotor), Muller glial cells e.g., RLBP1 promotor), astrocytes e.g., GFAP promotor), amacrine cells e.g., HKamac promotor (GNAT2 promotor and IRBP enhancer)), glial cells e.g., GFAP promotor), monocytes e.g., CD68 promotor), microglia cells of the optic nerve head e.g., CD68 promotor), corneal epithelial cells e.g., Krt 12 promotor), limbal stem cells e.g., ABCB5 promotor), corneal stromal keratocytes e.g., Keratocan promotor), and / or corneal endothelial cells e.g., POU6F2 promotor).

[0245] In some embodiments, a promoter comprises (or consists of) a Synapsin promoter e.g., a human Synapsin 1 (hSyn) promoter), a rhodopsin (Rho) promoter, a Bestrophin-1 (Bestl) promoter, a retinaldehyde-binding protein 1 (RLBP1) promoter, a GFAP promotor, a HKamac promotor, a GNAT2 promotor, a CD68 promoter, a Krt 12 promoter, an ABCB5 promotor, a Keratocan promotor, a POU6F2 promotor. In some embodiments, a promoter comprises a Synapsin promoter. In some embodiments, a promoter comprises a human Synapsin 1 (hSyn) promoter. In some embodiments, a promoter comprises a rhodopsin (Rho) promoter. In some embodiments, a promoter comprises a Bestrophin-1 (Bestl) promoter. In some embodiments, a promoter comprises a retinaldehyde-binding protein 1 (RLBP1) promoter. In some embodiments, a promoter comprises a GFAP promotor. In some embodiments, a promoter comprises a HKamac promotor. In some embodiments, a promoter comprises a GNAT2 promotor. In some embodiments, a promoter comprises a CD68 promoter. In some embodiments, a promoter comprises a Krt 12 promoter. In some embodiments, a promoter comprises an ABCB5 promotor. In some embodiments, a promoter comprises a Keratocan promotor. In some embodiments, a promoter comprises a POU6F2 promotor.

[0246] In some embodiments, a promoter drives transcription in the eye, bone, brain, heart, intestine, liver, lung, muscle, skin, or a combination thereof. In some embodiments, a promoter drives transcription in the eye, bone, brain, heart, intestine, liver, lung, muscle, or skin. In some embodiments, a promoter drives transcription in the eye. In some embodiments, a promoter drives transcription in the bone. In some embodiments, a promoter drives transcription in the brain. In some embodiments, a promoter drives transcription in the heart. In some embodiments, a promoter drives transcription in the intestine. In some embodiments, a promoter drives transcription in the liver. In some embodiments, a promoter drives transcription in the lung. In some embodiments, a promoter drives transcription in the muscle. In some embodiments, a promoter drives transcription in the skin.- 53 - 5099429. vl0399.2077001

[0247] In some embodiments, a promoter is eye-, bone-, brain-, heart-, intestine-, liver-, lung-, muscle-, or skin-specific. In some embodiments, a promoter is eye-specific. In some embodiments, a promoter is bone-specific. In some embodiments, a promoter is brain-specific. In some embodiments, a promoter is heart-specific. In some embodiments, a promoter is intestine-specific. In some embodiments, a promoter is liver-specific. In some embodiments, a promoter is lung-specific. In some embodiments, a promoter is muscle-specific. In some embodiments, a promoter is skin-specific.

[0248] In some embodiments, a promoter is eye-specific. Non-limiting examples of eyespecific promoters include rhodopsin kinase (GRK1, e.g., human GRK1) promoter, cone-rod homeobox transcription factor (CRX, e.g., human CRX) promoter, and neural retina leucine zipper (NRL, e.g., human NRL) promoter. See, e.g., PCT / US2019 / 053545 (WO 2020 / 069373), the entire contents of which are incorporated herein by reference.

[0249] In some embodiments, a promoter drives transcription in an eye cell, an epithelial cell, a heart cell, a nerve cell, or a combination thereof. In some embodiments, a promoter drives transcription in an eye cell, an epithelial cell, a heart cell, or a nerve cell. In some embodiments, a promoter drives transcription in an eye cell. In some embodiments, a promoter drives transcription in an epithelial cell. In some embodiments, a promoter drives transcription in a heart cell. In some embodiments, a promoter does not drive transcription in a heart cell. In some embodiments, a promoter drives transcription in a nerve cell.

[0250] In some embodiments, a promoter is eye cell-, epithelial cell-, mesenchymal cell-, or nerve cell-specific. In some embodiments, a promoter is eye cell-specific. In some embodiments, a promoter is epithelial cell-specific. In some embodiments, a promoter is nerve cell-specific (e.g, sensory neuron-specific, motor neuron-specific, or interneuron-specific). In some embodiments, a promoter is glia cell-specific.

[0251] In some embodiments, a promoter is mesenchymal cell-specific. In some embodiments, a promoter is mesenchymal stem cell-specific. In some embodiments, a promoter is chondrocyte-specific. In some embodiments, a promoter is osteoblast-specific. In some embodiments, a promoter is fibroblast-specific. In some embodiments, a promoter is skin fibroblast-specific. In some embodiments, a promoter is adipocyte-specific. In some embodiments, a promoter is myocyte-specific. In some embodiments, a promoter is pericytespecific. In some embodiments, a promoter is tenocyte-specific.

[0252] In some embodiments, a promoter drives transcription in a retinal pigment epithelium (RPE) cell (e.g., the Bestl promoter), a rod photoreceptor cell (e.g., the RedO, Rho, or human- 54 - 5099429. vl0399.2077001rhodopsin kinase (hRK) promoter), a cone photoreceptor (e.g., the CAR cone arrestin promoter), a retinal ganglion cell (e.g., the hSyn promoter) or a neuronal cell e.g., the hSyn promoter). In some embodiments, a promoter drives transcription in a RPE cell.

[0253] In some embodiments, a promoter is age- or senescence- specific. In some embodiments, a promoter drives transcription in a senescent cell. In some embodiments, a promoter is senescent cell-specific. In some embodiments, a promoter is a cyclin dependent kinase inhibitor 2 A (Cdkn2a, also known as pl 6) promoter.

[0254] In some embodiments, a promoter is a constitutive promoter. Non-limiting examples of constitutive promoters include chicken beta-actin (CAG) promoter, the immediate / early promoter enhancer of cytomegalovirus (CMV promoter), eukaryotic translation elongation factor 1 alpha (EF-la) promoter, human beta actin gene promoter, phosphoglycerate kinase 1 (PGK1) promoter, simian virus 40 (SV40) promoter, upstream activation sequence (UAS) promoter, and ubiquitin C (UBC) promoter.

[0255] In some embodiments, a promoter is an inducible promoter. In some embodiments, a promoter is a chemically (e.g., biochemically) regulated promoter. In some embodiments, a promoter is a physically regulated promoter.

[0256] Non-limiting examples of inducible promoters include those regulated by alcohol, caffeine, xylose, tetracycline and derivatives thereof (e.g., doxycycline), salicylic acid, ethylene, benzothiadi azole (BTH), steroid (e.g., glucocorticoid, estrogen, ecdysone, retinoid, abscisic acid, and thyroid), 4-hydroxytamoxifen, mifepristone, metal (e.g., metallothionein), temperature (e.g., heat), pH, and light. See, e.g., Kallunki et al., How to Choose the Right Inducible Gene Expression System for Mammalian Studies? Cells 8(8):796 (2019); Wang et al., Spatiotemporal control of gene expression by a light-switchable transgene system, Nat Methods 9(3):266-9 (2012); Zhao et al., A coumermycin / novobiocin-regulated gene expression system, Hum Gene Ther. 14(17): 1619-29 (2003), the entire contents of which are incorporated herein by reference.

[0257] In some embodiments, an inducible promoter comprises a bacterial operator, or a functional variant thereof. Non-limiting examples of bacterial operators include LacO, TetO, or CuO and operators regulated / induced by AlcR / Acetaldehyde, ArgR / L-Arginine, BirA / Biotinyl-AMP, EthR / 2 -Phenylethyl butyrate, HdnoR / 6-Hydroxy nicotine, HucR / Uric acid, MphR(A) / Macrolides, PIP / Streptogramins, Rex / NADH, RheA / Heat, ScbR / SCBl, TraR / 3-oxo-C8-HSL, and TtgR / Phloretin.

[0258] In some embodiments, a promoter is suitable for use in a vector described herein e.g., an AAV vector).- 55 - 5099429. vl0399.2077001Enhancers

[0259] In some embodiments, a polynucleotide further comprises an enhancer. In some embodiments, an enhancer is suitable for gene therapy (e.g., AAV-mediated RPE gene therapy). Non-limiting examples of enhancers include CAG, CMV, EFla, VMD2 (Bestl), RPE65, cellular retinaldehyde-binding protein (CRALBP, also known as retinaldehyde-binding protein 1 (RLBP1)), interphotoreceptor retinoid binding protein (IRBP), rhodopsin (RHO), red opsin, and green opsin enhancers and synthetic variants thereof (e.g., designed for small AAV vectors).

[0260] In some embodiments, an enhancer drives RPE expression (e.g., RPE-specific expression). In some embodiments, an enhancer (e.g., RPE-specific enhancer) drives strong and / or sustained RPE expression in rodents (e.g., mice) and / or primates (e.g., humans). In some embodiments, an enhancer is selected from the group consisting of VMD2 (Bestl), RPE65, and CRALBP enhancers, and synthetic variants thereof. In some embodiments, an enhancer comprises a VMD2 (Bestl) enhancer. In some embodiments, an enhancer comprises a synthetic variant of a VMD2 (Bestl) enhancer. In some embodiments, an enhancer comprises a RPE65 enhancer. In some embodiments, an enhancer comprises a synthetic variant of a RPE65 enhancer. In some embodiments, an enhancer comprises a CRALBP enhancer. In some embodiments, an enhancer comprises a synthetic variant of a CRALBP enhancer.

[0261] In some embodiments, an enhancer drives photoreceptor expression (e.g., photoreceptor-specific expression). In some embodiments, an enhancer is selected from the group consisting of IRBP, RHO, red opsin, and green opsin enhancers, and synthetic variants thereof. In some embodiments, an enhancer comprises an IRBP enhancer. In some embodiments, an enhancer drives rod photoreceptor expression (e.g., rod photoreceptor-specific expression). In some embodiments, an enhancer comprises a RHO enhancer. In some embodiments, an enhancer drives cone photoreceptor expression (e.g., cone photoreceptor-specific expression). In some embodiments, an enhancer comprises a red opsin enhancer and / or a green opsin enhancer. In some embodiments, an enhancer comprises a red opsin enhancer. In some embodiments, an enhancer comprises a green opsin enhancer.Markers

[0262] In some embodiments, a polynucleotide further comprises a nucleic acid sequence encoding a marker, e.g., for detection and / or selection of a cell comprising the polynucleotide.

[0263] In some embodiments, a marker increase resistance to an antibiotic. Non-limiting examples of markers (selectable markers) include actinomycin D-resistance, ampicillin-resistance, blasticidin-resistance, carbenicillin-resistance, chloramphenicol-resistance, geneticin-- 56 - 5099429. vl0399.2077001resistance, hygromycin B-resistance, kanamycin-resi stance, neomycin-resistance, puromycin-resistance, tetracycline-resistance, and zeocin-resistance.

[0264] In some embodiments, expression of a marker is detectable. Non-limiting example of detectable markers include enzymes (e.g., P-galactosidase such as senescence-associated P-galactosidase, luciferase, and alkaline phosphatase), fluorescent proteins (e.g., green fluorescent protein (GFP), CFP, RFP, YFP, mCherry, DsRed2FP, mKate), tags (e.g, biotin, FLAG-tag, HA-tag, His-tag, Myc-tag, and V5-tag).Posttranscriptional Response Element

[0265] In some embodiments, a polynucleotide further comprises a posttranscriptional regulatory element. In some embodiments, a posttranscriptional regulatory element is Woodchuck hepatitis virus (WHV) posttranscriptional regulatory element (WPRE).Linkers

[0266] In some embodiments, a polynucleotide comprise a nucleic acid sequence encoding a linker.

[0267] In some embodiments, a linker increases flexibility, is proteolysis resistant, or is selfcleaving, or any combination thereof. In some embodiments, a linker is proteolysis resistant.

[0268] In some embodiments, a linker increases flexibility. In some embodiments, a linker is a glycine-serine linker or a variant thereof, for example, (GGGGS)n, wherein n is 1, 2, 3, 4, 5, 6 or 7 or more, or a variant thereof.

[0269] In some embodiments, a linker is a self-cleaving linker. In some embodiments, a linker is a P2A self-cleaving linker. In some embodiments, a linker is a T2A self-cleaving linker. In some embodiments, a linker is a E2A self-cleaving linker. In some embodiments, a linker is a F2A self-cleaving linker.Polynucleotides

[0270] In some embodiments, a polynucleotide is less than or equal to about 6.2 kilobases (kb) in length, for example, less than or equal to about: 6.1, 6.0, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8 or 1.7 kb in length. In some embodiments, a polynucleotide is about: 1.7-6.2 kb in length, for example, about: 1.8-6.2 kb, 1.8-6.1 kb, 2.0-6.1 kb, 2.0-6.0 kb, 2.2-6.0 kb, 2.2-5.9 kb, 2.4-5.9 kb, 2.4-5.8 kb, 2.6-5.8 kb, 2.6-5.7 kb, 2.8-5.7 kb, 2.8-5.6 kb, 3.0-5.6 kb, 3.0-5.5 kb, 3.2-5.5 kb, 3.2-5.4 kb, 3.4-5.4 kb, 3.4-5.3 kb, 3.6-5.3 kb, 3.6-5.2 kb, 3.8-5.2 kb, 3.8-5.1 kb, 4.0-5.1 kb, 4.0-5.0 kb, 4.2-5.0 kb, 4.2-4.9 kb,- 57 - 5099429. vl0399.20770014.4-4.9 kb, 4.4-4.8 kb, 4.6-4.8 kb, or 4.6-4.7 kb. In some embodiments, a polynucleotide is less than or equal to about 4.7 kb in length.

[0271] In some embodiments, a polynucleotide is single stranded (ss).

[0272] In some embodiments, a polynucleotide is double stranded (ds). In some embodiments, a double-stranded polynucleotide comprises an overhang sequence (e.g., unpaired, overhanging nucleotides which are not directly involved in the formation of the double helical structure by the core sequences). In some embodiments, a polynucleotide comprises a 3’ overhang, a 5’ overhang, or both. In some embodiments, a polynucleotide comprises a 3’ overhang. In some embodiments, a polynucleotide comprises a 5’ overhang. In some embodiments, a polynucleotide comprises a 3’ overhang and a 5’ overhang. In some embodiments, an overhang is about 1-5 nucleotides. In some embodiments, an overhang comprises a modified ribonucleotide or deoxynucleotide, e.g., a thiophosphate, phosphorothioate or deoxynucleotide inverted (3’ to 3’ linked) nucleotide.

[0273] In some embodiments, a polynucleotide is an isolated polynucleotide.

[0274] In some embodiments, a polynucleotide is in a cell. In some embodiments, a polynucleotide is extrachromosomal in a cell. In some embodiments, a polynucleotide is integrated into a cell’s genome.

[0275] In some embodiments, a polynucleotide is a DNA molecule (e.g., a linear or a circular DNA molecule).

[0276] In some embodiments, a polynucleotide is an unprocessed RNA transcript (e.g., a pre-mRNA). In some embodiments, a polynucleotide is an mRNA molecule (e.g., a linear or a circular RNA molecule). In some embodiments, a polynucleotide comprising RNA is chemically synthesized. In some embodiments, a polynucleotide comprising RNA is expressed recombinantly. In some embodiments, an RNA is transcribed in vitro. The making and using of RNA therapeutics are known in the art. See, for example, RNA Therapeutics: Function, Design, and Delivery (Mouldy Sioud eds., 2010) and Kaczmarek etal., Advances in the delivery of RNA therapeutics: from concept to clinical reality, Genome Medicine 9:60 (2017), the entire contents of which are incorporated herein by reference.

[0277] A polynucleotide may be produced by any means available to those of skill in the art. In some embodiments, a polynucleotide is cloned by a standard technique. In some embodiments, a polynucleotide (e.g., a DNA polynucleotide) is produced recombinantly. In some embodiments, a polynucleotide is produced using a polymerase chain reaction (PCR) cloning technique. In some embodiments, a polynucleotide is produced synthetically. In some- 58 - 5099429. vl0399.2077001embodiments, an mRNA is in vitro transcribed (e.g., using a kit such as the MEGAscript™ T7 Transcription Kit (Invitrogen™AM1334)) from a DNA template. In some embodiments, an in vitro transcribed mRNA is modified to increase stability and / or to reduce immunogenicity, for example, by adding a 5’ cap or an analogue, and / or substituting one or more nucleotides (e.g., substituting a UTP solution with Nl-Methylpseudouridine-5’ -Triphosphate). For additional information on in vitro transcription and mRNA production, see, e.g., Neugebauer et al., Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity, Nat Biotechnol. 41(5):673-85 (2023), the entire contents of which are incorporated herein by reference.

[0278] In some embodiments, a polynucleotide comprises: (i) at least one non-naturally occurring deoxyribonucleotide monomer (e.g., 7-deazaguanosine, inosine, methylated nucleotides (such as 5-methyl dCTP and 5 -hydroxymethyl cytosine), (ii) at least one non-naturally occurring ribonucleotide monomer (e.g, a locked nucleic acid (LNA)), or both.

[0279] In some embodiments, a polynucleotide comprises at least one a modified nucleotide. A nucleotide may be modified at any position, for example, to alter certain chemical properties of the nucleotide yet retain the ability to perform its intended function. Non-limiting examples of positions of the nucleotide which may be derivatized include the 5 position, e.g., 5-(2-amino)propyl uridine, 5-bromo uridine, 5-propynyl uridine, and 5-propenyl uridine; the 6 position, e.g., 6-(2-amino)propyl uridine; the 8-position for adenosine and / or guanosines, e.g., 8-bromo guanosine, 8-chloro guanosine, and 8-fluoroguanosine. Nucleotide analogs also include deaza nucleotides, e.g., 7-deaza-adenosine; O- and N-modified (e.g., alkylated orN6-methyl adenosine) nucleotides. In some embodiments, a nucleotide comprises a modification to the sugar portion of the nucleotide. For example, the 2’ OH — group may be replaced by a group selected from H, OR, R, F, Cl, Br, I, SH, SR, NH2, NHR, NR2, COOR, or OR, wherein R is substituted or unsubstituted Ci-Ce alkyl, alkenyl, alkynyl or aryl.

[0280] Non-limiting examples of modified nucleotides include 2’-fluoro, 2’-o-methyl, 2’-deoxy, unlocked nucleic acid, 2’-hydroxy, phosphorothioate, 2’ -thiouridine, 4’ -thiouridine and 2 ’-deoxyuridine. In some embodiments, at least one modified nucleotide increases nuclease resistance, increases serum stability, and / or decrease immunogenicity.

[0281] In some embodiments, a polynucleotide is a modified mRNA. See, e.g., Warren etal., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell 7(5):618-30 (2010), the entire contents of which are incorporated herein by reference. Without being bound by a particular theory, modified RNA- 59 - 5099429. vl0399.2077001(e.g., mRNA) may confer reduced innate immune responses and limited cytotoxicity, thereby enabling robust and sustained protein expression. In some embodiments, an RNA (e.g., mRNA) comprises complete substitution of Cytidine e.g., with 5-methylcytidine (5mC)) or Uridine e.g., with pseudouridine (psi)).

[0282] In some embodiments, an mRNA molecule (linear or circular) is formulated into nanoparticles.

[0283] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding NKX2-5, a homolog, or a variant e.g., functional variant such as a fragment) thereof; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter does not drive expression in the heart or is not heart-specific.

[0284] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding any one of SEQ ID NOs: 1-5 or a variant e.g., a functional variant such as a fragment) thereof; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter drives transcription in a RPE cell e.g., the Bestl promoter), a rod photoreceptor cell e.g., the RedO, Rho, or hRK promoter), a cone photoreceptor e.g., the CAR cone arrestin promoter), a retinal ganglion cell e.g., the hSyn promoter) or a neuronal cell e.g., the hSyn promoter).

[0285] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding NKX2-5 or a variant thereof e.g., a fragment thereof); andb) a promoter selected from a Bestl promoter, a RedO promoter, a Rho promoter, a hRK promoter, a CAR promoter, and a hSyn promoter, wherein the promoter is operably linked to the nucleic acid sequence.

[0286] In some embodiments, a polynucleotide comprises:a) a nucleic acid sequence encoding any one of SEQ ID NOs: 1-5 or a fragment thereof; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter drives transcription in a RPE cell e.g., the Bestl promoter).Vectors

[0287] Also provided herein, among other things, is a vector comprising a polynucleotide disclosed herein.- 60 - 5099429. vl0399.2077001

[0288] In some embodiments, a vector is an expression vector. Expression vectors comprising necessary elements for expression are commercially available and known to one of ordinary skill in the art (see, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press, 2012).

[0289] In some embodiments, a vector is at least 1 kb in length, for example, at least: 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or 100 kb in length. In some embodiments, a vector is less than 10 kb in length, for example, less than: 9, 8, 7, 6, 5, 4, 3, 2, or 1 kb in length.

[0290] Viral Vectors

[0291] In some embodiments, a vector is a viral vector. In some embodiments, a viral vector is an adeno-associated viral vector (AAV vector), an adenoviral vector, a herpes simplex viral vector, or a retroviral vector.

[0292] In some embodiments, a viral vector is an AAV vector.

[0293] An AAV may be any AAV (serotype) (e.g., human AAV serotype), for example, AAV serotype 1 (AAV1), AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, a variant thereof, or a shuffled variant thereof e.g, a chimeric variant thereof). In some embodiments, an AAV vector is an AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, or AAV10 virus vector, or a variant thereof. In some embodiments, an AAV vector is an AAV2 or AAV9 vector, or a variant thereof.

[0294] In some embodiments, a vector is useful for delivering a nucleic acid sequence encoding a target protein (e.g, NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)) for rejuvenating retinal ganglion cells (e.g., AAV2), photoreceptor cells (e.g., AAV2 / 5 or AAV2 / 8), retinal pigment epithelial cells (e.g., AAV2), Muller glial cells (e.g., AAV variant ShHIOY), astrocytes (e.g., AAV5), amacrine cells (e.g., AAV8), glial cells (e.g., AAV variant ALAVPFR), monocytes (e.g., AAV variant ALAVPFR), microglia cells of the optic nerve head (e.g., AAV variant ALAVPFR), corneal epithelial cells (e.g., AAV8), limbal stem cells (e.g., AAV6), corneal stromal keratocytes (e.g., AAV8 / 9), and / or corneal endothelial cells (e.g., AAV2 / 5).

[0295] In some embodiments, a vector is useful for selectively (e.g., specifically) delivering a nucleic acid sequence encoding a target protein (e.g., NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)) to retinal ganglion cells (e.g., AAV2), photoreceptor cells (e.g., AAV2 / 5 or AAV2 / 8), retinal pigment epithelial cells (e.g., AAV2), Muller glial cells (e.g., AAV variant ShHIOY), astrocytes (e.g., AAV5), amacrine cells (e.g., AAV8), glial cells (e.g., AAV variant ALAVPFR), monocytes (e.g., AAV variant ALAVPFR), microglia cells of the optic nerve head (e.g., AAV variant ALAVPFR), corneal epithelial cells (e.g., AAV8), limbal stem cells (e.g.,- 61 - 5099429. vl0399.2077001AAV6), comeal stromal keratocytes (e.g., AAV8 / 9), and / or corneal endothelial cells e.g., AAV2 / 5).

[0296] In some embodiments, an AAV vector is AAV2, AAV5, AAV6, AAV8, AAV2 / 5, AAV2 / 8, AAV8 / 9, AAV variant ShHIOY, or AAV variant ALAVPFR. In some embodiments, an AAV vector is AAV2. In some embodiments, an AAV vector is AAV5. In some embodiments, an AAV vector is AAV6. In some embodiments, an AAV vector is AAV8. In some embodiments, an AAV vector is AAV2 / 5 or AAV2 / 8. In some embodiments, an AAV vector is AAV2 / 5. In some embodiments, an AAV vector is AAV2 / 8. In some embodiments, an AAV vector is AAV8 / 9. In some embodiments, an AAV vector is AAV variant ShHIOY. In some embodiments, an AAV vector is AAV variant ALAVPFR.

[0297] In some embodiments, an AAV vector is a wild-type AAV vector.

[0298] In some embodiments, an AAV vector is a variant of an AAV vector.

[0299] In some embodiments, an AAV variant has at least about 80% sequence identity to a wild-type AAV, for example, has at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wild-type AAV. In some embodiments, an AAVn variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to a wild-type AAV.

[0300] In some embodiments, an AAVn variant (n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) has at least about 80% sequence identity to a wild-type AAVn, for example, has at least about: 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wild-type AAVn. In some embodiments, an AAVn variant has about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to a wild-type AAVn.

[0301] In some embodiments, an AAV vector is an AAV chimera, for example, one or more regions of at least two different AAV serotype viruses are shuffled and reassembled. For example, a chimeric AAV can comprise inverted terminal repeats (ITRs) that are of a heterologous serotype compared to the serotype of the capsid. The resulting chimeric AAV virus can have a different antigenic reactivity or recognition, compared to its parental serotypes. In some embodiments, a chimeric variant of an AAV includes amino acid sequences from 2, 3, 4, 5, or more different AAV serotypes.- 62 - 5099429. vl0399.2077001

[0302] In some embodiments, an AAV vector comprises two inverted terminal repeats (ITRs), and the number of base pairs between the two ITRs is less than 5 kb, for example, less than: 4.9, 4.8, 4.7, 4.64.5, 4.4, 4.3, 4.2, 4.1, 4, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1, 3, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1, 0.9, 0.8, 0.7, 0.6, or 0.5 kb. In some embodiments, the number of base pairs between the two ITRs is less than 4.7 kb.

[0303] In certain embodiments, an AAV vector is capable of being packaged into virus at a titer of at least 0.5xl010particle forming units per ml (pfu / ml), for example, at least: IxlO10, 2xlO10, 5xl010, 8xl010, IxlO11, 2xlOn, 5xl0n, 8xl0n, IxlO12, 2xl012, 5xl012, 8xl012, or IxlO13pfu / ml.

[0304] AAV vectors are known to those of ordinary skill the art. See, e.g., Weitzman & Linden, Chapter 1-Adeno- Associated Virus Biology in Adeno- Associated Virus: Methods and Protocols Methods in Molecular Biology, vol.807; Snyder & Moullier, eds., Springer, 2011; Potter etal., Molecular Therapy — Methods & Clinical Development, 2014, 1, 14034; Bartel et al., Gene Therapy, 2012, 19, 694-700; Ward & Walsh, Virology, 2009, 386(2):237-248; Li etal., Mol Ther, 2008, 16(7): 1252-1260; and U.S. Patent Application Publication No. 2018 / 0155789, the entire contents of which are incorporated herein by reference.

[0305] A polynucleotide disclosed herein can be introduced into a target cell by transducing an AAV virion (e.g., a viral vector or viral particle) into the cell. Packaging a polynucleotide into an AAV viral vector can be performed according to any method known to those skilled in the art, for example, as described in McClure etal., J Vis Exp, 2001, 57:3378, the entire contents of which are incorporated herein by reference.

[0306] In some embodiments, a viral vector is a retroviral vector. Retroviruses are a common tool for gene delivery (Miller, 2000, Nature 357: 455-60). Non-limiting examples of retroviruses include Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus. Non-limiting examples of lentiviruses include human immunodeficiency virus (e.g., HIV type 1 and HIV type 2), visna-maedi virus (VMV), caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immune deficiency virus (BIV), and simian immunodeficiency virus (SIV). In some embodiments, a retroviral vector is a lentiviral vector or a gammaretroviral vector. In some embodiments, a retroviral vector is a gammaretroviral vector. In some embodiments, a retroviral vector is a lentiviral vector.5099429. vl0399.2077001

[0307] In some embodiments, a viral vector is an adeno viral vector. In some embodiments, an adeno viral vector is AD 100.

[0308] In some embodiments, a viral vector is a herpes simplex viral vector. In some embodiments, a herpes simplex viral vector is HSV-2.

[0309] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding a target protein (e.g., NKX2-5), a homolog, or a variant (e.g., a functional variant such as a fragment) thereof, andb) an inducible promoter (e.g., a DOX-inducible promoter) operably linked to the nucleic acid sequence.

[0310] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding any one of SEQ ID NOs: 1-5, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.

[0311] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding SEQ ID NO: 1, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.

[0312] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding SEQ ID NO:2, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.

[0313] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding SEQ ID NO:3, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.

[0314] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding SEQ ID NO:4, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.

[0315] In some embodiments, a vector (e.g., an AAV vector or a lentiviral vector) comprises:a) a nucleic acid sequence encoding SEQ ID NO:5, andb) a DOX-inducible promoter operably linked to the nucleic acid sequence.Non-Viral Vectors

[0316] In some embodiments, a vector is a non-viral vector.

[0317] In some embodiments, a non-viral vector is a transposon vector.

[0318] In some embodiments, a non-viral vector is a plasmid.

[0319] In some embodiments, a non-viral vector is a vector suitable for a gene delivery system comprising nanoparticles. Non-limiting examples include NANOPLASMID® vectors- 64 - 5099429. vl0399.2077001(may be less immunogenic and thus more suitable for longer term expression), Nature Technology Corporation (NTC) 8 series mammalian expression vectors (generally cleared by cells within weeks and thus may be more suitable for shorter term expression), NTC9385R, and NTC8685.

[0320] In some embodiments, nanoparticles are organic (e.g., lipid and / or polymer). In some embodiments, nanoparticles are inorganic. Nanoparticles are well known in the art. Any suitable nanoparticle design can be used to deliver a polynucleotide or vector disclosed herein into a cell or subject. In some embodiments, a gene delivery system comprises lipid nanoparticles. In some embodiments, a gene delivery system comprises polymer nanoparticles.Compositions, Pharmaceutical Compositions & Kits

[0321] Also provided herein, among other things, is a composition comprising any one or more of the polynucleotides and / or vectors disclosed herein.

[0322] In some embodiments, a composition comprises:a) a first polynucleotide comprising:i. a first nucleic acid sequence encoding a first target protein, and ii. a first promoter operably linked to the first nucleic acid sequence, and b) a second polynucleotide comprising:i. a second nucleic acid sequence encoding a second target protein, and ii. a second promoter operably linked to the second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence encode different target proteins.

[0323] In some embodiments:a) a first nucleic acid sequence encodes NKX2-5 or a variant (e.g., a functional variant such as a fragment) thereof, andb) a second nucleic acid sequence encodes C2CD2L or a variant (e.g., a functional variant such as a fragment) thereof.

[0324] In some embodiments, a composition is a pharmaceutical composition.

[0325] In some embodiments, a composition (e.g., pharmaceutical composition) comprises one or more pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed. Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate,- 65 - 5099429. vl0399.2077001histidine), antioxidants e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt-forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICS™ and polyethylene glycol (PEG).

[0326] In some embodiments, a composition (e.g., pharmaceutical composition) is formulated for a suitable administration schedule and route. Non-limiting examples of administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous and topical, etc. In some embodiments, the composition (e.g., pharmaceutical composition) disclosed herein is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized).

[0327] In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to for treating an ocular disease, for example, via AAV-mediated gene therapy. In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by subretinal (SR) injection, intravitreal (IVT) injection, suprachoroidal injection, intracameral injection, subconjunctival injection, or topical drop. In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by SR or IVT injection. In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by SR injection. In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by IVT injection. For additional information on routes of ocular delivery of pharmaceutical composition (e.g., AAV), see He etal., AAV for Gene Therapy in Ocular Diseases: Progress and Prospects. Research (Wash D C) 6:0291 (2023) and Patel etal., Ocular drug delivery systems: An overview. World J Pharmacol. 2(2):47-64 (2013), the entire contents of which are incorporated herein by reference.

[0328] In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by intrathecal administration.

[0329] In some embodiments, a composition (e.g., pharmaceutical composition) is formulated to be administered by bilateral intracerebroventricular injection.

[0330] In some embodiments, a composition is formulated to be administered by infusion (e.g., intravenous infusion). In some embodiments, a composition (e.g., pharmaceutical composition) comprises pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington’s Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the- 66 - 5099429. vl0399.2077001dosages and concentrations employed. Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate, histidine), antioxidants (e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt-forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICS™ and polyethylene glycol (PEG).

[0331] In some embodiments, a composition (e.g., pharmaceutical composition) is formulated for a suitable administration schedule and route. Non-limiting examples of administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous and topical, etc. In some embodiments, the composition (e.g., pharmaceutical composition) disclosed herein is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized).

[0332] In some embodiments, a composition is formulated to be administered by infusion (e.g., intravenous infusion).

[0333] Also provided herein, among other things, is a kit comprising a container and, optionally, an instruction for use, wherein the container comprises any one or more of the polynucleotides, vectors, or compositions (e.g., pharmaceutical compositions) disclosed herein, or any combination of the foregoing.Gene Delivery Systems

[0334] Also provided herein, among other things, is a gene delivery system comprising a polynucleotide, vector, or composition (e.g., pharmaceutical composition) disclosed herein. Lipid-Based Gene Delivery Systems

[0335] In some embodiments, a lipid-based gene delivery system comprises a liposome. In some embodiments, a lipid-based gene delivery system comprises a solid lipid nanoparticle. In some embodiments, a lipid-based gene delivery system comprises a nanostructured lipid carrier. In some embodiments, a lipid-based gene delivery system comprises a lipid nanoparticle (LNP).

[0336] Suitable LNPs, methods of formulation, and methods of delivering payloads to cells or tissues in vitro, ex vivo, and in vivo will be apparent to the skilled artisan in view of the present disclosure and knowledge in the art. In some embodiments, an LNP comprises at least one lipid, for example, at least: two, three, or four lipids. In some embodiments, an LNP comprises two lipids. In some embodiments, the LNP comprises three lipids. In some- 67 - 5099429. vl0399.2077001embodiments, the LNP comprises four lipids. In some embodiments, the LNP comprises more than four lipids.

[0337] In some embodiments, an LNP comprises a cationic lipid, a non-cationic lipid, and a conjugated lipid.

[0338] In some embodiments, an LNP comprises an ionizable cationic lipid. In some embodiments, an LNP comprises a cationic lipid-nucleic acid complex.

[0339] In some embodiments, an LNP comprises a non-cationic lipid. In some embodiments, a non-cationic lipid comprises: (i) a phospholipid, (ii) cholesterol or a cholesterol derivative, or both (i) and (ii). In some embodiments, a non-cationic lipid comprises a phospholipid. In some embodiments, a non-cationic lipid comprises a steroid. Non-limiting examples of steroids include cholestanes (e.g., cholesterol), cholanes (e.g., cholic acid), pregnanes (e.g., progesterone), androstanes, e.g., testosterone, and estranes (e.g., estradiol).

[0340] In some embodiments, an LNP comprises a conjugated lipid. In some embodiments, a conjugated lipid is a polymer-conjugated lipid. In some embodiments, a conjugated lipid is a PEG-conjugated (PEGylated) lipid. In some embodiments, an LNP further comprises a steroid. In some embodiments, an LNP comprises an amino lipid. In some embodiments, an LNP comprises an amino lipid. In some embodiments, an LNP comprises or is conjugated to an N-acetylgalactosamine (GalNAC) moiety.Cationic & Ionizable Lipids

[0341] Non-limiting examples of cationic lipids include DLin-DMA (l,2-dilinoleyloxy-3 -dimethylaminopropane), DLin-MC3-DMA (dilinoleylmethyl-4-dimethylaminobutyrate), DLin-KC2-DMA (2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[l,3]-dioxolane), DODMA (1,2-dioleyloxy-N,N-dimethyl-3-aminopropane), DOTAP (l,2-dioleoyl-3-trimethylammonium-propane), DOTMA (l,2-di-O-octadecenyl-3-trimethylammonium propane), GUADACA (guanidino-dialkyl acid), MPDACA (methylpyridiyl-dialkyl acid), PONA (palmitoyl-oleoyl-nor-arginine), SS18 / 4PE13 (Bis{2-[4-(cis,cis-9,12-octadecadienoateethyl)-l-piperidinyl] ethyl} disulfide), SS18 / 4PE16 (Bis{2-[4-(cis-9-octadecenoateethyl)-l-piperidinyl] ethyl} disulfide), SS-33 / 3 AP05 (Bis{2-[N-methyl-N-(a-D-tocopherolhemisuccinatepropyl)amino]ethyl} disulfide), SS33 / 4PE15 (Bis{2-[4-(a-D-tocopherolhemisuccinateethyl)piperidyl] ethyl} disulfide), SS-OP (Bis[2-(4-{2-[4-(cis-9 octadecenoyloxy) phenylacetoxy]ethyl}piperidinyl)ethyl] disulfide), 98N12-5 (Nl,N16-didodecyl-4,7,13-tris[3-(dodecylamino)-3-oxopropyl]-4,7,10,13-tetraazahexadecanediamide), C12-200 (l,l'-[[2-[4-[2-[[2-[Z>z (2-hydroxydodecyl)amino]ethyl](2-- 68 - 5099429. vl0399.2077001hydroxydodecyl)amino]ethyl]-l-piperazinyl]ethyl]imino]Z»A-2-dodecanol), and derivatives thereof.Cholesterols

[0342] In some embodiments, an LNP comprises cholesterol, cholesterol sulfate, desmosterol-d6, cholesterol-d7, lathosterol-d7, desmosterol, stigmasterol, lanosterol, dehydrocholesterol, dihydrolanosterol, zymosterol, lathosterol, zymosterol-d5, 14-demethyl-lanosterol, 14-demethyl-lanosterol-d6, 8(9)- dehydrocholesterol, 8(14)-dehydrocholesterol, diosgenin, DHEA sulfate, DHEA, lanosterol- d6, dihydrolanosterol-d7, campesterol-d6, sitosterol, lanosterol-95, Dihydro FF-MAS-d6, zymostenol-d7, zymostenol, sitostanol, campestanol, campesterol, 7-dehydrodesmosterol, pregnenolone, sitosterol-d7, Dihydro T-MAS, Delta 5-avenasterol, Brassicasterol, Dihydro FF-MAS, 24-methylene cholesterol, a cholic acid derivative, a cholesteryl ester, a glycosylated sterol, a derivative thereof, or a combination thereof. In some embodiments, a lipid nanoparticle comprises cholesterol.PEG-Lipids

[0343] In some embodiments, an LNP comprises a PEG-conjugated (PEGylated) lipid. In some embodiments, an LNP comprises two or more PEGylated lipids. In some embodiments, an LNP comprises a PEGylated phosphatidylethanolamine, a PEGylated phosphatidic acid, a PEGylated ceramide, a PEGylated dialkylamine, a PEGylated diacylglycerol, a PEGylated dialkyl glycerol, or a combination thereof. Non-limiting examples of PEG-lipids include PEGylated phosphatidylethanolamines (PEGylated PEs, e.g., DSPE-PEG, DPPE-PEG, DOPEPEG, DMPTE-PEG), mPEGylated glycerides (e.g., DMG-PEG, DSG-PEG, DPG-PEG; mPEGylated PEs, e.g, DSPE-mPEG, DPPE-mPEG, DMPE-mPEG), amino-mPEGs (e.g, ALC-0159), and Cholesterol -PEGs (e.g, chole sterol -mPEG, cholesterol -PG).

[0344] In some embodiments, a PEGylated lipid comprises a linear or branched polyethylene glycol or poly-ethylene oxide polymer, or any combination thereof. In some embodiments, a PEGylated lipid comprises a PEG moiety that is substituted, e.g, by at least one alkyl, alKOXly, acyl, hydroxy, or aryl group, or a combination thereof. In some embodiments, a PEGylated lipid comprises a PEG copolymer. In some embodiments, a PEG-copolymer is PEG-polyurethane or PEG-polypropylene.

[0345] In some embodiments, an LNP comprises a GalNAC-conjugated lipid. In some embodiments, a GalNAC-conjugated lipid is a GalNAc-PEG lipid.- 69 - 5099429. vl0399.2077001

[0346] In some embodiments, an LNP comprises a cationic (e.g., ionizable cationic) lipid, a non-cationic lipid, and a conjugated lipid.

[0347] In some embodiments, molar concentration of a cationic lipid is from about 20% to about 80% of the total lipid molar concentration, wherein the total lipid molar concentration is the sum of the cationic lipid, the non-cationic lipid, and the lipid conjugate molar concentrations. For example, molar concentration of a cationic lipid is about: 30%-70%, 40%-60%, 40%-50%, 45%-55%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the total lipid molar concentration.

[0348] In some embodiments, molar concentration of non-cationic lipids is from about 20% to about 80%, e.g., about: 30%-70%, 40%-70%, 40%-60%, 45%-50%, 20%, 25%, 30%, 35%, 40%, 45%, 48.5%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the total lipid molar concentration.

[0349] In some embodiments, molar concentration of a conjugated lipid is between about 0% to about 2%, e.g., about: 0.5%-2%, 0.5%-l%, 0.5%-1.5%, l%-2%, 1%-1.5%, 1%-1.2%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2.0%. In some embodiments, molar concentration of a conjugated lipid is more than 2%.

[0350] In some embodiments, a LNP comprises (e.g., encapsulates) a nucleic acid encoding a protein provided herein, and optionally, a gRNA, and comprises a molar ratio of cationic lipid to the nucleic acid, or, where the LNP also comprises a gRNA, a molar ratio of cationic lipid to the sum of nucleic acid and gRNA, of from about 1 to about 20, e.g., about: 1-18, 2-18, 2-16, 3- 16, 3-14, 4-14, 4-12, 5-12, 5-10, 6-10, 6-8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0351] For additional information on suitable LNPs, LNP components, methods of formulating payloads, including, for example, proteins and / or nucleic acids, into LNPs, as well as methods of contacting cells or tissues in vitro, ex vivo, or in vivo, with payloads formulated into LNPs, see Technov el al., Lipid Nanoparticle s^-From Liposomes to mRNA Vaccine Delivery, aLandscape of Research Diversity and Advancement, ACS Nano. 15(11): 16982-7015 (2021); Finn etal.,A Single Administration of CRISPR / Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing, Cell Rep. 22(9):2227-35 (2018); Gillmore et al. , CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis, N Engl J Med. 385(6):493 -502 (2021); Yan et al. , Harnessing lipid nanoparticles for efficient CRISPR delivery, Biomater Sci. 9(18):6001-l 1 (2021); Kazemian etal., Lipid-Nanoparticle-Based Delivery of CRISPR / Cas9- 70 - 5099429. vl0399.2077001Genome-Editing Components, Mol Pharm. 19(6): 1669-86 (2022); Mohammadian et al., Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing, Heliyon 10(2):e24606 (2024); Raguram et al., Therapeutic in vivo delivery of gene editing agents, Cell 185(15):2806-27 (2022); Ma et al., Intracellular Delivery of mRNA for Cell-Selective CRISPR / Cas9 Genome Editing using Lipid Nanoparticles, Chembiochem. 24(9):e202200801 (2023); Kowalski etal., Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery, Mol Ther.27(4):710-28 (2019); Madigan et al., Drug delivery systems for CRISPR-based genome editors, Nat Rev Drug Discov. 22(11):875-94 (2023); Aziz et al., Lipid-based nanocarrier mediated CRLSPR / Cas9 delivery for cancer therapy, J Biomater Sci Polym Ed. 34(3):398-418 (2023); Leung et al, Lipid nanoparticles for short interfering RNA delivery, Adv Genet. 88:71-110 (2014); Mok et al., Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties, Biochim Biophys Acta. 1419(2): 137-50 (1999); Eldrige et al., Lipid Nanoparticles: Production, Characterization, and Stability, Springer 2014, ISBN: 3319107100; Prakash et al., Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids, Adv Drug Deliv Rev. 184:114197 (2022); PCT application publications W02020206231, W02015095340, WO2017173054, WO2020219876, WO2015035136, WO 2010144740, WO2015199952, WO2017075531, and W02018081480; U.S. application publications US20040142025, US20070042031, US2020 / 0385721; and US Patents US7,745,651, US7,799,565, US7,901,708, US8,058,069, US8, 158,601, US8,492,359, US8,642,076, US8, 822,668, US9,005,654, US9,006,417, US9, 139,554, US9,364,435, US9,404,127, US9,415,109, US9,518,272, US9,593,077, US9,682,139, US9, 878,042, US9,999,673, US10,723,692, US10,941,395, and US11,141,378; the contents of each of which are incorporated herein by reference.

[0352] The skilled artisan will be able to select components of LNP, as well as their molar ratios, of components to each other and to respective payload, and suitable methods for preparation of such LNPs, based on the present disclosure and the knowledge in the art without undue experimentation.Cells

[0353] Also provided herein, among other things, is a cell comprising any one or more of the polynucleotides, vectors, compositions (e.g., pharmaceutical compositions), or gene delivery systems disclosed herein, or any combination of the foregoing.

[0354] In some embodiments, a cell is in vitro or ex vivo. In some embodiments, a cell is in vivo.- 71 - 5099429. vl0399.2077001

[0355] A cell may reside in or obtained (e.g., isolated) from a biological entity, for example, a plant, animal, or microorganism. In some embodiments, a cell resides in a biological entity or a tissue. In some embodiments, a cell is obtained (e.g., isolated) from a biological entity in vivo. In some embodiments, a cell is cultured in vitro.

[0356] In some embodiments, a cell is an animal cell, a fungal cell (such as a yeast), or a plant cell. In some embodiments, a cell is a mammalian cell. In some embodiments, a mammal cell is selected from a dog cell, a cat cell, a mouse cell, a rat cell, a hamster cell, a guinea pig cell, a horse cell, a pig cell, a sheep cell, a cow cell, a chimpanzee cell, a macaque cell, a cynomolgus monkey cell, and a human cell. In some embodiments, a cell is derived from a primate e.g., a human or a non-human primate). In some embodiments, a cell is a human cell.

[0357] In some embodiments, a cell is an RPE cell, a photoreceptor cell, a retinal vascular endothelial cell, a retinal ganglion cell, a cell of optic nerve head e.g., a glial cell, a monocyte, a macrophage, or a microglia cell), a corneal epithelial cell, a limbal stem cell, a corneal keratocyte, an epithelial cell, or a stromal cell. In some embodiments, a cell is an RPE cell. In some embodiments, a cell is a photoreceptor cell. In some embodiments, a cell is a retinal vascular endothelial cell. In some embodiments, a cell is a retinal ganglion cell. In some embodiments, a cell is a cell of optic nerve head e.g., a glial cell, a monocyte, a macrophage, or a microglia cell). In some embodiments, a cell is a corneal epithelial cell. In some embodiments, a cell is a limbal stem cell. In some embodiments, a cell is a corneal keratocyte. In some embodiments, a cell is an epithelial cell. In some embodiments, a cell is a stromal cell.

[0358] In some embodiments, a cell is a bone cell, a brain cell, an eye cell, an epithelial cell, a heart cell, a liver cell, a lung cell, a mesenchymal cell, a muscle cell, or a nerve cell.

[0359] In some embodiments, a cell is a bone cell. In some embodiments, a bone cell is an osteoblast. In some embodiments, a bone cell is an osteocyte. In some embodiments, a bone cell is an osteoclast. In some embodiments, a bone cell is a bone lining cell.

[0360] In some embodiments, a cell is a brain cell. In some embodiments, a brain cell is a neuron. In some embodiments, a brain cell is a glia.

[0361] In some embodiments, a cell is an eye cell. In some embodiments, an eye cell is a photoreceptor cell. In some embodiments, a photoreceptor cell is a rod cell. In some embodiments, a photoreceptor cell is a cone cell. In some embodiments, an eye cell is a neuronal cell. In some embodiments, an eye cell is a glia. In some embodiments, an eye cell is a retinal pigment epithelium (RPE) cell.

[0362] In some embodiments, a cell is an epithelial cell.- 72 - 5099429. vl0399.2077001

[0363] In some embodiments, a cell is a neural stem cell.

[0364] In some embodiments, a cell is a heart cell.

[0365] In some embodiments, a cell is a liver cell.

[0366] In some embodiments, a cell is a lung cell.

[0367] In some embodiments, a cell is a mesenchymal cell. In some embodiments, a cell is a mesenchymal cell that degenerates in aging. Non-limiting examples of mesenchymal cells include mesenchymal stem cells (MSCs), chondrocytes, osteoblasts, fibroblasts, adipocytes, myocytes, pericytes, and tenocytes. In some embodiments, a mesenchymal cell is a skin fibroblast.

[0368] In some embodiments, a cell is a muscle cell.

[0369] In some embodiments, a cell is a nerve cell.

[0370] In some embodiments, a cell is an induced pluripotent stem cell (iPSC).Progeny Cells

[0371] Also provided herein, among other things, is a progeny cell derived from a cell comprising any one or more of polynucleotides, vectors, compositions (e.g., pharmaceutical compositions), or gene delivery systems disclosed herein, or any combination of the foregoing.

[0372] In some embodiments, a progeny cell is in vitro or ex vivo. In some embodiments, a progeny cell is in vivo.

[0373] A progeny cell may reside in or obtained (e.g., isolated) from a biological entity, for example, a plant, animal, or microorganism. In some embodiments, a progeny cell resides in a biological entity or a tissue. In some embodiments, a progeny cell is obtained (e.g., isolated) from a biological entity in vivo. In some embodiments, a progeny cell is cultured in vitro.

[0374] In some embodiments, a progeny cell is an animal cell, a fungal cell (such as a yeast), or a plant cell. In some embodiments, a progeny cell is a mammalian cell. In some embodiments, a mammal cell is selected from a dog cell, a cat cell, a mouse cell, a rat cell, a hamster cell, a guinea pig cell, a horse cell, a pig cell, a sheep cell, a cow cell, a chimpanzee cell, a macaque cell, a cynomolgus monkey cell, and a human cell. In some embodiments, a progeny cell is derived from a primate (e.g., a human or a non-human primate). In some embodiments, a progeny cell is a human cell.

[0375] In some embodiments, a progeny cell is a bone cell, a brain cell, an eye cell, an epithelial cell, a heart cell, a liver cell, a lung cell, a mesenchymal cell, a muscle cell, or a nerve cell.- 73 - 5099429. vl0399.2077001

[0376] In some embodiments, a progeny cell is a bone cell. In some embodiments, a bone cell is an osteoblast. In some embodiments, a bone cell is an osteocyte. In some embodiments, a bone cell is an osteoclast. In some embodiments, a bone cell is a bone lining cell.

[0377] In some embodiments, a progeny cell is a brain cell. In some embodiments, a brain cell is a neuron. In some embodiments, a brain cell is a glia.

[0378] In some embodiments, a progeny cell is an eye cell. In some embodiments, an eye cell is a photoreceptor cell. In some embodiments, a photoreceptor cell is a rod cell. In some embodiments, a photoreceptor cell is a cone cell. In some embodiments, an eye cell is a neuronal cell. In some embodiments, an eye cell is a glia. In some embodiments, an eye cell is a RPE cell.

[0379] In some embodiments, a progeny cell is an epithelial cell.

[0380] In some embodiments, a progeny cell is a neural stem cell.

[0381] In some embodiments, a progeny cell is a heart cell.

[0382] In some embodiments, a progeny cell is a liver cell.

[0383] In some embodiments, a progeny cell is a lung cell.

[0384] In some embodiments, a progeny cell is a mesenchymal cell. In some embodiments, a progeny cell is a mesenchymal cell that degenerates in aging. Non-limiting examples of mesenchymal cells include MSCs, chondrocytes, osteoblasts, fibroblasts, adipocytes, myocytes, pericytes, and tenocytes. In some embodiments, a mesenchymal cell is a skin fibroblast.

[0385] In some embodiments, a progeny cell is a muscle cell.

[0386] In some embodiments, a progeny cell is a nerve cell.

[0387] In some embodiments, a progeny cell is an iPSC.Methods of Increasing Expression and / or Activity of Target Proteins

[0388] Also provided herein, among other things, are methods that increases expression and / or activity of a target protein disclosed herein (NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, or FosB_2,), a homolog thereof, or a variant (e.g., a functional variants such as fragments) thereof.

[0389] As used herein, the term “increasing” or “increase” refers to modulation that results in a higher level of expression, activity, function or a combination thereof of a target protein, or a metric (e.g., oxidative stress, cell survival, oxygen consumption rate, mitochondrial surface area, RPE atrophy area, total retinal thickness, outer nuclear layer thickness, or visual acuity), relative to a reference (e.g., a level prior to or in an absence of modulation by an agent). In some embodiments, a method or an agent increases expression or activity of a target protein, or the metric, by at least about 5% relative to a reference, e.g., by at least about: 10%, 15%, 20%, 25%,- 74 - 5099429. vl0399.207700130%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100%, 2 fold, 5 fold, 10 fold, 20 fold, 50 fold, 100 fold, 200 fold, 1500 fold, 1,000 fold, 2,000 fold, 5,000 fold, or 10,000 fold, relative to the reference.

[0390] In some embodiments, level of expression, activity, function or a combination thereof of a target protein, or a metric, is measured at least about 1 day after an agent is contacted with (e.g., a cell) or administered (e.g., to a subject), e.g., at least about: 2 days, 3 days, 4 days, 5 days, 6 days, 8 days, 9 days, 10 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months or 6 months, after a treatment regimen has begun.

[0391] Assays to determine target protein expression and / or activity are known in the art. Non-limiting examples include cell-based transcription assays, in vitro transcription assays, enzyme-linked immunosorbent assays (ELIS As), western blots, quantification of RNA (e.g., using reverse transcription polymerase chain reaction), and assays measuring oxidative stress, cell survival, oxygen consumption rate, mitochondrial surface area, RPE atrophy area, total retinal thickness, outer nuclear layer thickness, or visual acuity.

[0392] A wide range of processes, directly or indirectly, can be used to increase expression and / or activity of a target protein. Non-limiting examples include increasing copy number of a gene encoding a target protein, increasing transcriptional initiation, increasing elongation, reducing transcriptional termination, increasing RNA processing, increasing RNA stability (e.g., mRNA stability), reducing RNA degradation, increasing translation initiation, increasing protein stability, reducing protein degradation (e.g., reducing protease cleavage), modulating post-translational modification, agonizing a known function / activity of a target protein, and modulating (e.g., increasing) binding between a target protein and a binding partner.

[0393] In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is activated using a CRISPR-activating system, transcription activator-like effector nucleases (TALEN), or a zinc-finger nuclease (ZFN) system.

[0394] In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is activated using a CRISPR-activating system. In some embodiments, a CRISPR-activating system comprises an enzymatically dead Cas9 nuclease (or nuclease-deficient Cas9 (dCas9)) fused to a transcription activation domain (e.g., VP64-p65-Rta). In some embodiments, a guide RNA targeting a promoter or an enhancer region of a target gene is used.

[0395] For additional information on CRISPR-activating system. See, e.g., Gilbert etal., CRISP R-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes, Cell 154,5099429. vl0399.2077001442-51 (2013); Cheng et al., Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system, Cell Res. 23: 1163-71 (2013); Gilbert et al., Genome-Scale CRISP R-Mediated Control of Gene Repression and Activation, Cell 159: 647-61 (2014); Tanenbaum et al., A protein-tagging system for signal amplification in gene expression and fluorescence imaging, Cell 159: 635-46 (2014); Konermann etal., Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature 517: 583-88 (2015); Chavez et al., Highly efficient Cas9-mediated transcriptional programming, Nat. Methods. 12: 326-28 (2015); Zalatan et al., Engineering complex synthetic transcriptional programs with CRISPRRNA scaffolds, Cell 160: 339-50 (2015); Chavez etal., Comparison of Cas9 activators in multiple species, Nat Methods. 7: 563-67 (2016); Liao et al., In Vivo Target Gene Activation via CRISPR / Cas9-Mediated Trans-epigenetic Modulation, Cell 171(7): 1495-507 (2017); and Liu et al., CRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables Reprogramming to Pluripotency, Cell Stem Cell 22(2):252-61 (2018), the entire contents of which are incorporated herein by reference.

[0396] In some embodiments, a polynucleotide (e.g., an mRNA) is introduced into a target cell or into a target tissue by contacting the target cell or target tissue with a lipid nanoparticle (LNP) comprising (e.g., encapsulating) the polynucleotide .

[0397] In some embodiments, a CRISPR-activating system or a portion thereof is introduced into a target cell or into a target tissue by contacting the target cell or target tissue with a LNP comprising (e.g., encapsulating) a dCas9 DNA-binding domain, a guide RNA (e.g., an sgRNA), and / or a nucleic acid molecule encoding a guide RNA.

[0398] In some embodiments, expression of a target protein is activated by a small molecule. In some embodiments, a small molecule binds to a target protein. In some embodiments, a small molecule binds to a protein capable of modulating expression or activity of a target protein.

[0399] In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is increased transiently, for example, lasting for: less than 6 months, less than 5 months, less than 4 months, less than 3 months, less than 2 months, less than 1 month, less than 4 weeks, less than 3 weeks, less than 2 weeks, less than 7 days, less than 6 days, less than 5 days, less than 4 days, less than 3 days, less than 2 days, or less than 1 day.

[0400] In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is increased for: more than 1 day, for example, more than 2 days, more than 3 days, more than 4 days, more than 5 days, more than 6 days, more than 7 days, more than 2 weeks, more than 3 weeks, more than 4 weeks, more than 1 month, more than 2 months,- 76 - 5099429. vl0399.2077001more than 3 months, more than 4 months, more than 5 months, or more than 6 months. In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is increased for more than 6 days.

[0401] In some embodiments, an increase in expression and / or activity of a target protein, a homolog thereof, or a variant thereof lasts for about: 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day.

[0402] In some embodiments, a polynucleotide disclosed herein (e.g., an mRNA encoding a target protein, a homolog thereof, or a variant thereof) is administered only once. In some embodiments, a polynucleotide (e.g., an mRNA encoding a target protein, a homolog thereof, or a variant thereof) is administered approximately once a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months, once every 9 months, or once a year.

[0403] In some embodiments, expression and / or activity of a target protein, a homolog thereof, or a variant thereof is inducible.

[0404] A non-limiting example of an inducing agent is a reverse tetracycline transactivator (rtTA) or a functional variant thereof. In some embodiments, a rtTA binds to a TRE promoter (e.g., a TRE3G, a TRE2 promoter, or a P tight promoter) in the presence of tetracycline or a derivative thereof (e.g., doxycycline). In some embodiments, a rtTA comprises a mutant tetracycline repressor DNA binding protein (TetR) and a transactivation domain. For additional information on rtTA, see, e.g., Gossen etal., Transcriptional activation by tetracyclines in mammalian cells, Science 268(5218): 1766-69 (1995), and PCT Application Publication Nos. W02020069339, the entire contents of which are incorporated herein by reference.Methods of Treatment

[0405] Also provided herein, among other things, is a method of treating a disease or condition in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0406] In some embodiments, a disease or condition is an age-related disease or condition.

[0407] In some embodiments, a disease or condition is an oxidative stress-related disease or condition.

[0408] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target- 77 - 5099429. vl0399.2077001protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0409] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0410] Also provided herein, among other things, is a method of reducing cellular and / or mitochondria ROS of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject. In some embodiments, a method increases mitochondria mass and / or preserves mitochondria oxygen consumption rate (OCR). In some embodiments, a method increases mitochondria mass. In some embodiments, a method preserves mitochondria OCR.

[0411] In some embodiments, at least one target protein comprises NKX2-5, NKX2-1, or LTBR. In some embodiments, at least one target protein comprises NKX2-5.

[0412] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to at least one sequence set forth in SEQ ID NOs: 1-5. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to at least one sequence set forth in SEQ ID NOs:l-5. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to a sequence set forth in SEQ ID NOs: 1-5.

[0413] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:1. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO:1. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to SEQ ID NO:1.

[0414] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:2. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99%- 78 - 5099429. vl0399.2077001or 98-99% sequence identity to SEQ ID NO:2. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to SEQ ID NO:2.

[0415] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:3. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO:3. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to SEQ ID NO:3.

[0416] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:4. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO:4. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to SEQ ID NO:4.

[0417] In some embodiments, at least one target protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 5. In some embodiments, at least one target protein comprises an amino acid sequence having about: 80-99.9%, 80-99.8%, 85-99.8%, 85-99.6%, 88-99.6%, 88-99.5%, 90-99.5%, 90-99.4%, 92-99.4%, 92-99.2%, 95-99.2%, 95-99% or 98-99% sequence identity to SEQ ID NO: 5. In some embodiments, at least one target protein comprises an amino acid sequence having 100% sequence identity to SEQ ID NO:5.

[0418] In some embodiments, a method or an agent increases a DNA-binding independent activity of NKX2-5.

[0419] In some embodiments, a method or an agent increases expression and / or activity of at least two target proteins. In some embodiments, at least two target proteins comprise NKX2-5 and C2CD2L.

[0420] In some embodiments, a method comprises administering to a subject an agent that increases expression and / or activity of at least one target protein. In some embodiments, a method increases expression of at least one target protein in a subject. In some embodiments, a method increases activity of at least one target protein in a subject. In some embodiments, a method increases expression and activity of at least one target protein in the subject.

[0421] In some embodiments, an agent comprises a polynucleotide, vector, composition (e.g., a pharmaceutical composition), gene delivery system, cell, progeny cell, polypeptide, or small molecule. In some embodiments, an agent comprises a polynucleotide. In some- 79 - 5099429. vl0399.2077001embodiments, an agent comprises a vector. In some embodiments, an agent comprises a composition (e.g., a pharmaceutical composition). In some embodiments, an agent comprises a gene delivery system. In some embodiments, an agent comprises a cell. In some embodiments, an agent comprises a progeny cell.

[0422] In some embodiments, an agent is a polynucleotide, vector, composition (e.g., a pharmaceutical composition), gene delivery system, cell, progeny cell, polypeptide, or small molecule. In some embodiments, an agent is a polynucleotide. In some embodiments, an agent is a vector. In some embodiments, an agent is a composition (e.g., a pharmaceutical composition). In some embodiments, an agent is a gene delivery system. In some embodiments, an agent is a cell. In some embodiments, an agent is a progeny cell.

[0423] In some embodiments, expression and / or activity of at least one target gene is inducible or suppressible.

[0424] In some embodiments, expression and / or activity of at least one target gene is conditionally inducible by a small molecule, a light-switchable system, a ligand-switchable system, or a combination thereof.

[0425] In some embodiments, expression and / or activity of at least one target gene is conditionally inducible by:a) a small molecule comprising tetracycline (TET), doxycycline (DOX), caffeine, 4- hydroxytamoxifen, estrogen, ecdysone, abscisic acid, mifepristone, xylose, FKBP12-rapamycin, or an HCV NS3 / 4A protease inhibitor;b) a light-switchable system comprising:i. Phytochrome B (PhyB) and phytochrome interaction factor 6 (PIF6); or ii. GIGANTEA and a light oxygen voltage (LOV) domain of Flavin-Binding Kelch Repeat F-Box 1 (FKF1);c) a ligand-switchable system comprising a synthetic Notch receptor (synNotch), a modular extracellular sensor, and a synthetic intramembrane proteolysis receptor (SNIPR), orany combination of the foregoing.

[0426] In some embodiments, expression and / or activity of at least one target gene is conditionally inducible by a small molecule. Non-limiting examples of small molecules include tetracycline (TET), doxycycline (DOX), caffeine, 4-hydroxytamoxifen, estrogen, ecdysone, abscisic acid, mifepristone, xylose, FKBP12-rapamycin, and HCV NS3 / 4A protease inhibitors.- 80 - 5099429. vl0399.2077001

[0427] In some embodiments, expression and / or activity of at least one target gene is conditionally inducible by a light-switchable system. In some embodiments, a light-switchable system comprises Phytochrome B (PhyB) and phytochrome interaction factor 6 (PIF6). In some embodiments, a light-switchable system comprises GIGANTEA and a light oxygen voltage (LOV) domain of Flavin-Binding Kelch Repeat F-Box 1 (FKF1).

[0428] In some embodiments, expression and / or activity of at least one target gene is conditionally inducible by a ligand-switchable system. In some embodiments, a ligand-switchable system comprises a synthetic Notch receptor (synNotch), a modular extracellular sensor, and / or a synthetic intramembrane proteolysis receptor (SNIPR).

[0429] A subject to be treated according to a method may be one who has been diagnosed with a disease or condition, one at risk (e.g., high risk) of developing a disease or condition, or suspected of being at risk (e.g, high risk) for a disease or condition. Diagnosis may be performed by any method or technique known in the art. One skilled in the art will understand that a subject to be treated according to the present disclosure may have been subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition.

[0430] In some embodiments, a subject has been diagnosed with a disease or condition.

[0431] In some embodiments, a subject is at risk of developing a disease or condition.

[0432] In some embodiments, a subject is undergoing a concurrent therapy.

[0433] In some embodiments, a subject is a mammalian subject. In some embodiments, a mammalian subject is a dog, cat, mouse, rat, hamster, guinea pig, horse, rabbit, pig, sheep, cow, a non-human primate (e.g, a chimpanzee, macaque, or cynomolgus monkey), or a human. In some embodiments, a subject is a non-human primate. In some embodiments, a subject is a human.

[0434] In some embodiments, a subject (e.g., a human) is a female. In some embodiments, a subject (e.g., a human) is a male.

[0435] In some embodiments, a human subject is 40 years or older, e.g., 45 years or older, 50 years or older, 55 years or older, 60 years or older, 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, or 90 years or older. In some embodiments, a human subject is 45 years or older. In some embodiments, a human subject is 65 years or older.

[0436] In some embodiments, a human subject is between the ages of 40-100 years, for example, between the ages of 40-95 years, 45-95 years, 45-90 years, 50-90 years, 50-85 years, 55-85 years, 55-80 years, 60-80 years, 60-75 years, 65-75 years, or 65-70 years.- 81 - 5099429. vl0399.2077001

[0437] In some embodiments, a human subject is between the ages of 60-100 years, for example, between the ages of 60-95 years, 55-95 years, 55-90 years, 60-90 years, 60-85 years, 65-85 years, 65-80 years, 70-80 years, or 70-75 years.

[0438] In some embodiments, a human subject is 18 years or older. In some embodiments, a human subject is between the ages of 18-95 years, for example, 18-85 years, 18-75 years, 18-65 years, 18-55 years, 55-95 years, 55-85 years, 55-75 years, 55-65 years, 65-95 years, 65-85 years, 65-75 years, 75-95 years or 75-85 years. In some embodiments, a human subject is between the ages of 2-12 years, for example, 2-10 years, 2-8 years, 2-6 years, 2-5 years, 2-4 years, 4-12 years, 4-10 years, 4-8 years, 4-6 years, 4-5 years, 5-12 years, 5-10 years, 5-8 years, 5-6 years, 6-12 years, 6-10 years, 6-8 years, 8-12 years, or 8-10 years. In some embodiments, a human subject is between the ages of 6 months to 17 years, for example, 6 months to 16 years, 6 months to 14 years, 6 months to 12 years, 6 months to 10 years, 6 months to 8 years, 6 months to 6 years, 6 months to 4 years, 6 months to 2 years, 1-17 years, 1-16 years, 1-14 years, 1-12 years, 1-10 years, 1-8 years, 1-6 years, 1-4 years, 1-2 years, 2-17 years, 2-16 years, 2-14 years, 2-12 years, 2-10 years, 2-8 years, 2-6 years, 2-4 years, 4-17 years, 4-16 years, 4-14 years, 4-12 years, 4-10 years, 4-8 years, 4-6 years, 6-17 years, 6-16 years, 6-14 years, 6-12 years, 6-10 years, 6-8 years, 8-17 years, 8-16 years, 8-14 years, 8-12 years, 8-10 years, 10-17 years, 10-16 years, 10-14 years, 10-12 years, 12-17 years, 12-16 years, 12-14 years, 14-17 years, or 14-16 years.

[0439] In some embodiments, a human subject is >6 months, for example, >7 months, >8 months, >9 months, >10 months, >11 months, >1 year, >2 years, >3 years, >4 years, >5 years, >6 years, >7 years, >8 years, >9 years, >10 years, >11 years, >12 years, >13 years, >14 years, >15 years, >16 years, >17 years, or >18 years. In some embodiments, a human subject is >2 years. In some embodiments, a human subject is >12 years. In some embodiments, a human (e.g., a healthy human donor) is >18 years.

[0440] In some embodiments, a method comprises administering to a subject a cell disclosed herein. In some embodiments, a cell is an allogeneic cell. In some embodiments, a cell is an autologous cell.

[0441] In some embodiments, a method comprises administering to a subject a progeny cell disclosed herein. In some embodiments, a progeny cell is an allogeneic cell. In some embodiments, a progeny cell is an autologous cell.

[0442] In some embodiments, a method disclosed herein rejuvenate a cell by at least 1 year, for example, by at least: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 28, 30, 32, 35, 38, or 40 years. In some embodiments, a method rejuvenate a cell by about 1-40- 82 - 5099429. vl0399.2077001years, for example, about: 2-40, 3-40, 3-38, 4-38, 4-35, 5-35, 5-32, 6-32, 6-30, 7-30, 7-28, 8-28, 8-25, 9-25, 9-22, 10-22, 10-20, 11-20, 11-19, 12-19, 12-18, 13-18, 13-17, 14-17, 14-16, or 15-16 years.

[0443] In some embodiments, a method disclosed herein decreases transcriptomic age by at least 1 year, for example, by at least: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 25, 28, 30, 32, 35, 38, or 40 years. In some embodiments, a method decreases transcriptomic age by about 1-40 years, for example, about: 2-40, 3-40, 3-38, 4-38, 4-35, 5-35, 5-32, 6-32, 6-30, 7-30, 7-28, 8-28, 8-25, 9-25, 9-22, 10-22, 10-20, 11-20, 11-19, 12-19, 12-18, 13-18, 13-17, 14-17, 14-16, or 15-16 years.

[0444] In some embodiments, a method disclosed herein enhances respiration and / or mitochondria translation. In some embodiments, a method enhances respiration. In some embodiments, a method enhances mitochondria translation. In some embodiments, a method enhances respiration and mitochondria translation.Age-Related Diseases or Conditions

[0445] Also provided herein, among other things, is a method of treating an age-related disease or condition in a subject in need thereof, comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, orI184P)).

[0446] Also provided herein, among other things, is a method of treating an age-related disease or condition in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0447] In some embodiments, a subject is suspected of having, or at risk for developing an age-related disease or condition.

[0448] In some embodiments, a subject is diagnosed with an age-related disease or condition.

[0449] In some embodiments, incidence of an age-related disease or condition increases with age. In some embodiments, prevalence of an age-related disease or condition increases with age.

[0450] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target- 83 - 5099429. vl0399.2077001protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB_l, and FosB_2 in the subject, wherein the subject is suspected of having, or at risk for developing an age-related disease or condition.

[0451] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB_l, and FosB_2 in the subject, wherein the subject is diagnosed with an age-related disease or condition.

[0452] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, orI184P)).

[0453] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject, wherein the subject is suspected of having, or at risk for developing an age-related disease or condition.

[0454] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject, wherein the subject is diagnosed with an age-related disease or condition.

[0455] In some embodiments, an age-related disease comprises an age-related retinal disease or an age-related ocular surface disease. In some embodiments, an age-related disease comprises an age-related retinal disease. Non-limiting examples of age-related retinal diseases include AMD (dry and wet), diabetic retinopathy, and glaucoma. In some embodiments, an age-related disease comprises an age-related ocular surface disease. Non-limiting examples of age-related ocular surface diseases include dry eye, Fuchs’ dystrophy, corneal wound healing and scarring / fibrosis (e.g., in diabetic patients), ocular surface burns (alkali, thermal, chemical), and corneal inflammatory diseases (autoimmune, e.g., Steven Johnson’s syndrome).5099429. vl0399.2077001

[0456] In some embodiments, an age-related disease comprises AMD (e.g., dry AMD), diabetic retinopathy, glaucoma, dry eye, Fuchs’ dystrophy, corneal wound healing and scarring / fibrosis (e.g., in a diabetic patient), ocular surface bum (alkali, thermal, or chemical), or a corneal inflammatory disease (autoimmune, e.g., Steven Johnson’s syndrome). In some embodiments, an age-related disease comprises AMD. In some embodiments, an age-related disease comprises dry AMD. In some embodiments, dry AMD is early dry AMD. In some embodiments, dry AMD is intermediate dry AMD. In some embodiments, dry AMD is advanced dry AMD. In some embodiments, an age-related disease comprises wet AMD. In some embodiments, an age-related disease comprises diabetic retinopathy. In some embodiments, an age-related disease comprises glaucoma. In some embodiments, an age-related disease comprises dry eye. In some embodiments, an age-related disease comprises Fuchs’ dystrophy. In some embodiments, an age-related disease comprises corneal wound healing, scarring or fibrosis (e.g., in a diabetic patient). In some embodiments, an age-related disease comprises ocular surface bum. In some embodiments, an age-related disease comprises an alkali ocular surface burn. In some embodiments, an age-related disease comprises a thermal ocular surface bum. In some embodiments, an age-related disease comprises a chemical ocular surface bum. In some embodiments, an age-related disease comprises a comeal inflammatory disease (autoimmune, e.g., Steven Johnson’s syndrome). In some embodiments, an age-related disease comprises Steven Johnson’s syndrome.

[0457] In some embodiments, an age-related disease (e.g., that would be an appropriate indication for treatment with a protein of interest mentioned in this Application (e.g., NKX2-5 or a variant thereof, such as NKX2-5AHD) is an age-related disease of the retina and / or ocular surface. In addition, during development of an age-related disease of the retina and / or ocular surface, there is increased oxidative stress within one or more specific cellular targets in the retina and / or cornea. Non-limiting examples of cellular targets (where oxidative stress occur) are listed below for each indication.- 85 - 5099429. vl0399.2077001

[0458] Age-Related Retinal DiseasesAMD (dry and wet) RPE cellsdiabetic retinopathy photoreceptor cells and retinal vascular endothelial cellsglaucoma retinal ganglion cells; cells of optic nerve head (glial cells, monocytes / macrophages, and microglia cells) Age-Related Ocular Surface DiseasesDry eye comeal epithelial cells and / or limbal stem cells Fuchs’ dystrophy comeal endothelial cellsComeal wound healing and scarring / fibrosis comeal keratocytesComeal wound healing and scarring / fibrosis comeal keratocytesin diabetic patientsOcular surface bums (alkali, thermal, epithelial and stromal cellschemical)Comeal inflammatory diseases (autoimmune, comeal keratocytese.g., Steven Johnson’s Syndrome)

[0459] Below is a non-limiting list of cellular targets to rejuvenate cells in the retina or cornea that coincide with age-related loss of function, age-related diseases, or age-related susceptibility to oxidative stress. Non-limiting examples of promotors and AAV serotypes useful for selectively (e.g., specifically) expressing a target gene in a cellular target are also included.Rejuvenation in the Retinaretinal ganglion cells Synapsin promotor AAV2 photoreceptor cells Rhodopsin promotor AAV2 / 5, AAV2 / 8 retinal pigment epithelial cells Bestrophin-1 (Bestl) promotor AAV2Muller glial cells RLBP1 promotor AAV variant ShHIOY (retinaldehyde -binding protein)astrocytes GFAP promotor AAV5amacrine cells HKamac promotor (GNAT2 promotor AAV8+ IRBP enhancer)glial cells, monocytes; microglia mixture of CD68 + GFAP promoters AAV variant ALAVPFR cells of the optic nerve headRejuvenation in the Cornea Ocular Surfacecomeal epithelial cells Krt 12 promoter AAV8limbal stem cells ABCB5 promoter AAV6comeal stromal keratocytes Keratocan promoter AAV8 / 9comeal endothelial cells POU6F2 promoter AAV2 / 5- 86 - 5099429. vl0399.2077001

[0460] In some embodiments, an age-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof.

[0461] In some embodiments, an age-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof.

[0462] In some embodiments, an age-related disease or condition comprises:a) age-related macular degeneration (AMD);b) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;c) osteoarthritis, intervertebral disc degeneration, or both;d) osteoporosis, osteonecrosis, or both;e) fibrosis, systemic sclerosis, skin aging, or a combination thereof;f) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof; g) sarcopenia, muscle degeneration, or both;h) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; ori) tendinopathy, rotator cuff injury, or both.

[0463] In some embodiments, an age-related disease or condition comprises AMD. In some embodiments, AMD is dry AMD.

[0464] In some embodiments, an age-related disease or condition comprises osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof. In some embodiments, an age-related disease or condition comprises osteoporosis. In some embodiments, an age-related disease or condition comprises osteoarthritis. In some embodiments, an age-related disease or condition comprises sarcopenia. In some embodiments, an age-related disease or condition comprises impaired wound healing.

[0465] In some embodiments, an age-related disease or condition comprises osteoarthritis, intervertebral disc degeneration, or both. In some embodiments, an age-related disease or condition comprises osteoarthritis. In some embodiments, an age-related disease or condition- 87 - 5099429. vl0399.2077001comprises intervertebral disc degeneration. In some embodiments, an age-related disease or condition comprises osteoarthritis and intervertebral disc degeneration.

[0466] In some embodiments, an age-related disease or condition comprises osteoporosis, osteonecrosis, or both. In some embodiments, an age-related disease or condition comprises osteoporosis. In some embodiments, an age-related disease or condition comprises osteonecrosis. In some embodiments, an age-related disease or condition comprises osteoporosis and osteonecrosis.

[0467] In some embodiments, an age-related disease or condition comprises fibrosis, systemic sclerosis, skin aging, or a combination thereof. In some embodiments, an age-related disease or condition comprises fibrosis. In some embodiments, an age-related disease or condition comprises systemic sclerosis. In some embodiments, an age-related disease or condition comprises skin aging. In some embodiments, an age-related disease or condition comprises fibrosis, systemic sclerosis, and skin aging.

[0468] In some embodiments, an age-related disease or condition comprises type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof. In some embodiments, an age-related disease or condition comprises type 2 diabetes. In some embodiments, an age-related disease or condition comprises lipodystrophy. In some embodiments, an age-related disease or condition comprises metabolic syndrome. In some embodiments, an age-related disease or condition comprises type 2 diabetes, lipodystrophy, and metabolic syndrome.

[0469] In some embodiments, an age-related disease or condition comprises sarcopenia, muscle degeneration, or both. In some embodiments, an age-related disease or condition comprises sarcopenia. In some embodiments, an age-related disease or condition comprises muscle degeneration. In some embodiments, an age-related disease or condition comprises sarcopenia and muscle degeneration.

[0470] In some embodiments, an age-related disease or condition comprises microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof. In some embodiments, an age-related disease or condition comprises microvascular dysfunction. In some embodiments, an age-related disease or condition comprises neurodegenerative diseases. In some embodiments, an age-related disease or condition comprises diabetic retinopathy. In some embodiments, an age-related disease or condition comprises microvascular dysfunction, neurodegenerative diseases, and diabetic retinopathy.

[0471] In some embodiments, an age-related disease or condition comprises tendinopathy, rotator cuff injury, or both. In some embodiments, an age-related disease or condition comprises- 88 - 5099429. vl0399.2077001tendinopathy. In some embodiments, an age-related disease or condition comprises rotator cuff injury. In some embodiments, an age-related disease or condition comprises tendinopathy and rotator cuff injury.

[0472] In some embodiments, an age-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof. In some embodiments, an age-related disease or condition comprises pulmonary fibrosis. In some embodiments, an age-related disease or condition comprises cardiac fibrosis. In some embodiments, an age-related disease or condition comprises kidney fibrosis. In some embodiments, an age-related disease or condition comprises liver fibrosis.Oxidative Stress-Related Diseases or Conditions

[0473] Also provided herein, among other things, is a method of treating an oxidative stress-related disease or condition in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting ofNKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2. In some embodiments, a protein comprises NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P)).

[0474] Also provided herein, among other things, is a method of treating an oxidative stress-related disease or condition in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.

[0475] In some embodiments, a subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition.

[0476] In some embodiments, a subject is diagnosed with an oxidative stress-related disease or condition.

[0477] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB_l, and FosB_2 in the subject, wherein the subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition.

[0478] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2,- 89 - 5099429. vl0399.2077001MED1, C2CD2L, NKX2-1, SEMA4G, FosB_l, and FosB_2 in the subject, wherein the subject is diagnosed with an oxidative stress-related disease or condition.

[0479] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject, wherein the subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition.

[0480] Also provided herein, among other things, is a method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject, wherein the subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition.

[0481] In some embodiments, an oxidative stress-related disease or condition comprises AMD (e.g., dry AMD), diabetic retinopathy, glaucoma, dry eye, Fuchs’ dystrophy, corneal wound healing and scarring / fibrosis (e.g., in a diabetic patient), ocular surface burn (alkali, thermal, or chemical), or a corneal inflammatory disease (autoimmune, e.g, Steven Johnson’s syndrome). In some embodiments, an oxidative stress-related disease or condition comprises AMD. In some embodiments, an oxidative stress-related disease or condition comprises dry AMD. In some embodiments, an oxidative stress-related disease or condition comprises wet AMD. In some embodiments, an oxidative stress-related disease or condition comprises diabetic retinopathy. In some embodiments, an oxidative stress-related disease or condition comprises glaucoma. In some embodiments, an oxidative stress-related disease or condition comprises dry eye. In some embodiments, an oxidative stress-related disease or condition comprises Fuchs’ dystrophy. In some embodiments, an oxidative stress-related disease or condition comprises corneal wound healing, scarring or fibrosis (e.g, in a diabetic patient). In some embodiments, an oxidative stress-related disease or condition comprises ocular surface bum. In some embodiments, an oxidative stress-related disease or condition comprises an alkali ocular surface bum. In some embodiments, an oxidative stress-related disease or condition comprises a thermal ocular surface burn. In some embodiments, an oxidative stress-related disease or condition comprises a chemical ocular surface burn. In some embodiments, an oxidative stress-related disease or condition comprises a corneal inflammatory disease (autoimmune, e.g, Steven- 90 - 5099429. vl0399.2077001Johnson’s syndrome). In some embodiments, an oxidative stress-related disease or condition comprises Steven Johnson’s syndrome.

[0482] In some embodiments, an oxidative stress-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof.

[0483] In some embodiments, an oxidative stress-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof.

[0484] In some embodiments, an oxidative stress-related disease or condition comprises: a) age-related macular degeneration (AMD);b) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;c) osteoarthritis, intervertebral disc degeneration, or both;d) osteoporosis, osteonecrosis, or both;e) fibrosis, systemic sclerosis, skin aging, or a combination thereof;f) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof; g) sarcopenia, muscle degeneration, or both;h) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; ori) tendinopathy, rotator cuff injury, or both.

[0485] In some embodiments, an oxidative stress-related disease or condition comprises AMD. In some embodiments, AMD is dry AMD.

[0486] In some embodiments, an oxidative stress-related disease or condition comprises osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof. In some embodiments, an oxidative stress-related disease or condition comprises osteoporosis. In some embodiments, an oxidative stress-related disease or condition comprises osteoarthritis. In some embodiments, an oxidative stress-related disease or condition comprises sarcopenia. In some embodiments, an oxidative stress-related disease or condition comprises impaired wound healing.- 91 - 5099429. vl0399.2077001

[0487] In some embodiments, an oxidative stress-related disease or condition comprises osteoarthritis, intervertebral disc degeneration, or both. In some embodiments, an oxidative stress-related disease or condition comprises osteoarthritis. In some embodiments, an oxidative stress-related disease or condition comprises intervertebral disc degeneration. In some embodiments, an oxidative stress-related disease or condition comprises osteoarthritis and intervertebral disc degeneration.

[0488] In some embodiments, an oxidative stress-related disease or condition comprises osteoporosis, osteonecrosis, or both. In some embodiments, an oxidative stress-related disease or condition comprises osteoporosis. In some embodiments, an oxidative stress-related disease or condition comprises osteonecrosis. In some embodiments, an oxidative stress-related disease or condition comprises osteoporosis and osteonecrosis.

[0489] In some embodiments, an oxidative stress-related disease or condition comprises fibrosis, systemic sclerosis, skin aging, or a combination thereof. In some embodiments, an oxidative stress-related disease or condition comprises fibrosis. In some embodiments, an oxidative stress-related disease or condition comprises systemic sclerosis. In some embodiments, an oxidative stress-related disease or condition comprises skin aging. In some embodiments, an oxidative stress-related disease or condition comprises fibrosis, systemic sclerosis, and skin aging.

[0490] In some embodiments, an oxidative stress-related disease or condition comprises type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof. In some embodiments, an oxidative stress-related disease or condition comprises type 2 diabetes. In some embodiments, an oxidative stress-related disease or condition comprises lipodystrophy. In some embodiments, an oxidative stress-related disease or condition comprises metabolic syndrome. In some embodiments, an oxidative stress-related disease or condition comprises type 2 diabetes, lipodystrophy, and metabolic syndrome.

[0491] In some embodiments, an oxidative stress-related disease or condition comprises sarcopenia, muscle degeneration, or both. In some embodiments, an oxidative stress-related disease or condition comprises sarcopenia. In some embodiments, an oxidative stress-related disease or condition comprises muscle degeneration. In some embodiments, an oxidative stress-related disease or condition comprises sarcopenia and muscle degeneration.

[0492] In some embodiments, an oxidative stress-related disease or condition comprises microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof. In some embodiments, an oxidative stress-related disease or condition comprises- 92 - 5099429. vl0399.2077001microvascular dysfunction. In some embodiments, an oxidative stress-related disease or condition comprises neurodegenerative diseases. In some embodiments, an oxidative stress-related disease or condition comprises diabetic retinopathy. In some embodiments, an oxidative stress-related disease or condition comprises microvascular dysfunction, neurodegenerative diseases, and diabetic retinopathy.

[0493] In some embodiments, an oxidative stress-related disease or condition comprises tendinopathy, rotator cuff injury, or both. In some embodiments, an oxidative stress-related disease or condition comprises tendinopathy. In some embodiments, an oxidative stress-related disease or condition comprises rotator cuff injury. In some embodiments, an oxidative stress-related disease or condition comprises tendinopathy and rotator cuff injury.

[0494] In some embodiments, an oxidative stress-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof. In some embodiments, an oxidative stress-related disease or condition comprises pulmonary fibrosis. In some embodiments, an oxidative stress-related disease or condition comprises cardiac fibrosis. In some embodiments, an oxidative stress-related disease or condition comprises kidney fibrosis. In some embodiments, an oxidative stress-related disease or condition comprises liver fibrosis.Methods of Treatment Targeting NKX2-5

[0495] Also provided herein, among other things, is a method of rejuvenating a cell in a subject in need thereof, comprising increasing expression of NKX2-5 or a variant thereof (e.g., AHD, I184M, or I184P) in the cell.

[0496] In some embodiments, a cell is an RPE cell, a photoreceptor cell, a retinal vascular endothelial cell, a retinal ganglion cell, a cell of optic nerve head (e.g, a glial cell, a monocyte, a macrophage, or a microglia cell), a corneal epithelial cell, a limbal stem cell, a corneal keratocyte, an epithelial cell, or a stromal cell. In some embodiments, a cell is an RPE cell. In some embodiments, a cell is a photoreceptor cell. In some embodiments, a cell is a retinal vascular endothelial cell. In some embodiments, a cell is a retinal ganglion cell. In some embodiments, a cell is a cell of optic nerve head (e.g, a glial cell, a monocyte, a macrophage, or a microglia cell). In some embodiments, a cell is a corneal epithelial cell. In some embodiments, a cell is a limbal stem cell. In some embodiments, a cell is a corneal keratocyte. In some embodiments, a cell is an epithelial cell. In some embodiments, a cell is a stromal cell.- 93 - 5099429. vl0399.2077001

[0497] Also provided herein, among other things, is a method of rejuvenating a RPE cell in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the RPE cell.

[0498] Also provided herein, among other things, is a method of treating damage to RPE cells in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the RPE cells.

[0499] Also provided herein, among other things, is a method of treating AMD in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the subject.

[0500] In some embodiments, a subject is suspected of having, or at risk for developing AMD.

[0501] In some embodiments, a subject is diagnosed with AMD.

[0502] In some embodiments, AMD is dry AMD.

[0503] In some embodiments, a method comprises administering to the subject an agent that increases the expression and / or the activity of NKX2-5.

[0504] In some embodiments, a method increases the expression of NKX2-5 in the subject.

[0505] In some embodiments, a method increases the activity of NKX2-5 in the subject.

[0506] In some embodiments, a method increases a DNA-binding independent activity of NKX2-5.

[0507] In some embodiments, an agent comprises a polynucleotide, a vector, a composition (e.g., a pharmaceutical composition), a gene delivery system, a cell, a polypeptide, or a small molecule.

[0508] In some embodiments, a method comprises administering to an eye of a subject an AAV vector comprising a polynucleotide encoding NKX2-5.

[0509] In some embodiments, a method reduces damaged RPE area (e.g., RPE atrophy area) by at least 5%, for example, reduces damaged RPE area (e.g., RPE atrophy area) by at least: 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.

[0510] In some embodiments, a method reduces age-related macular degeneration by at least 5%, for example, reduces age-related macular degeneration by at least: 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.- 94 - 5099429. vl0399.2077001

[0511] In some embodiments, a method reduces atrophic macular degeneration by at least 5%, for example, reduces atrophic macular degeneration by at least: 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.

[0512] In some embodiments, a method increases total retinal thickness by at least 1%, for example, increases total retinal thickness by at least: 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.

[0513] In some embodiments, a method increases outer nuclear layer thickness by at least 1%, for example, increases outer nuclear layer thickness by at least: 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.

[0514] In some embodiments, a method increases total pigmented RPE area by at least 1%, for example, increases total pigmented RPE area by at least: 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55% or 60%.

[0515] In some embodiments, a method improves visual acuity by at least 1%, for example, increases improves visual acuity by at least: 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, or 600%. In some embodiments, visual acuity is measured using an optical mark recognition (OMR) test. In some embodiments, a method improves visual acuity by at least two lines of vision (e.g., 2-5 lines of vision) as measured using an ETDRS (Early Treatment Diabetic Retinopathy Study) chart.

[0516] In some embodiments, a method slows disease progression and / or improves macular function, e.g., in a patient suffering from age-related macular degeneration. In some embodiments, a method produces one or more structural and / or functional improvements. Nonlimiting examples of functional improvements include increased visual acuity, increased retinal- 95 - 5099429. vl0399.2077001sensitivity (e.g., as measured via microperimetry), increased contrast sensitivity, improved retinal function in the macula (e.g., as measured via electroretinography (ERG), e.g., multifocal ERG (mfERG)). Non-limiting examples of structural improvements include morphological changes such as reduced subretinal and / or intraretinal fluid, reduced RPE atrophy, and increased photoreceptor layer integrity, which may be measured using OCT.Administration

[0517] In some embodiments, a method comprises administering a polynucleotide comprising a nucleic acid sequence encoding a protein or variant thereof (e.g., NKX2-5 or a variant thereof (e.g., AHD, I184M, I184P, AI184)) to a subject.

[0518] In some embodiments, a polynucleotide comprises a nucleic acid sequence operably linked to a promoter.

[0519] In some embodiments, a method comprises administering a vector (e.g., an AAV vector) comprising a polynucleotide (e.g., comprising a nucleic acid sequence encoding a NKX2-5 variant (e.g., AHD, I184M, or I184P)) to a subject.

[0520] In some embodiments, a polynucleotide or vector is locally administered to an organ or tissue in need of such treating or rejuvenation.

[0521] Non-limiting examples of routes of administration (e.g., locally administered to retina AAV-NKX2-5, NKX2-5AHD, or other AAV or viral vectors) include intravitreal injection, subretinal injection, supra-choroidal injection, and intra-retinal injection.

[0522] Non-limiting examples of routes of administration (e.g., locally administered to cornea AAV-NKX2-5, NKX2-5AHD, or other AAV or viral vectors) include intrastromal injection, subconjunctival injection, lacrimal gland injection, and anterior chamber injection.CERTAIN EMBODIMENTS1. A polynucleotide, comprising:a) a nucleic acid sequence encoding at least one target protein selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2- like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, FosB_2, homologs, and variants thereof; and- 96 - 5099429. vl0399.2077001b) a promoter operably linked to the nucleic acid sequence, optionally, the promoter is mesenchymal cell-specific.2. The polynucleotide of Embodiment 1, wherein the at least one target protein comprises NKX2-5, NKX2-1, or LTBR.3. The polynucleotide of Embodiment 1 or Error! Reference source not found., wherein the at least one target protein comprises NKX2-5.4. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or a combination thereof.5. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO: 1.6. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:2.7. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:3.8. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the nucleic acid sequence encodes at least two target proteins selected from the group consisting ofNKX2-5, LTBR, C4BPA, Cllorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2, homologs, and variants thereof.9. The polynucleotide of Embodiment Error! Reference source not found., wherein the at least two target proteins comprise NKX2-5 and C2CD2L.10. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the nucleic acid sequence encodes an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 or a fragment thereof, SEQ ID NO:2 or a fragment thereof, SEQ ID NO:3 or a fragment thereof, SEQ ID NO:4 or a fragment thereof, SEQ ID NO: 5 or a fragment thereof, or a combination thereof.11. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the nucleic acid sequence encodes a protein having 100% sequence identity to- 97 - 5099429. vl0399.2077001SEQ ID NO: 1 or a fragment thereof, SEQ ID NO:2 or a fragment thereof, SEQ ID NO:3 or a fragment thereof, SEQ ID NO:4 or a fragment thereof, SEQ ID NO:5 or a fragment thereof, or a combination thereof.12. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the nucleic acid sequence encodes aNKX2-5 comprising at least one amino acid substitution, deletion, and / or addition in the homeodomain.13. The polynucleotide of Embodiment Error! Reference source not found., wherein the at least one amino acid substitution, deletion, and / or addition reduces DNA-binding and / or transcription regulation mediated by the homeodomain of NKX2-5.14. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter.15. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the promoter is a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, or a human Synapsin 1 (hSyn) promoter.16. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the promoter comprises an inducer-responsive element, optionally, wherein the inducer-responsive element comprises a Tet response element (TRE).17. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the polynucleotide is a deoxyribonucleic acid (DNA).18. The polynucleotide of Embodiment Error! Reference source not found., wherein the DNA is a plasmid DNA.19. The polynucleotide of any one of Embodiments 1-Error! Reference source not found., wherein the polynucleotide is a ribonucleic acid (RNA).20. The polynucleotide of Embodiment Error! Reference source not found., wherein the RNA is an mRNA.- 98 - 5099429. vl0399.207700121. The polynucleotide of any one of Embodiments 1 -Error! Reference source not found., wherein the polynucleotide is encapsulated in at least one nanoparticle.22. A vector, comprising the polynucleotide of any one of Embodiments 1 -Error! Reference source not found..23. A vector compri sing :a) a nucleic acid sequence encoding NKX2-5 or a variant thereof; andb) a promoter selected from a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, and a human Synapsin 1 (hSyn) promoter, wherein the promoter is operably linked to the nucleic acid sequence.24. The vector of Embodiment Error! Reference source not found, or Error! Reference source not found., wherein the vector is a virus vector.25. The vector of Embodiment Error! Reference source not found, or Error! Reference source not found., wherein the vector is an AAV vector.26. The vector of Embodiment Error! Reference source not found., wherein the AAV vector is an AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, or AAV10 vector, or a variant thereof.27. The vector of Embodiment Error! Reference source not found, or Error! Reference source not found., wherein the AAV vector is an AAV2 or AAV9 vector, or a variant thereof.28. A composition, comprising the polynucleotide of any one of Embodiments 1-Error! Reference source not found., or the vector of any one of Embodiments Error! Reference source not found.-Error! Reference source not found..29. A composition, comprising:a) a first polynucleotide comprising a first a nucleic acid sequence and a first promoter operably linked to the first nucleic acid sequence, andb) a second polynucleotide comprising a second a nucleic acid sequence and a second promoter operably linked to the second nucleic acid sequence, wherein:- 99 - 5099429. vl0399.2077001the first polynucleotide is the polynucleotide of any one of Embodiments 1 -Error! Reference source not found, and Error! Reference source not found.-Error! Reference source not found.,the second polynucleotide is the polynucleotide of any one of Embodiments 1 -Error! Reference source not found, and Error! Reference source not found.-Error! Reference source not found., andthe first nucleic acid sequence and the second nucleic acid sequence encode different target proteins.30. The composition of Embodiment Error! Reference source not found, or Error! Reference source not found., wherein:a) the first nucleic acid sequence encodes NKX2-5 or a variant thereof, and b) the second nucleic acid sequence encodes C2CD2L or a variant thereof.31. A pharmaceutical composition, comprising the composition of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., and a pharmaceutically acceptable carrier.32. A gene delivery system, comprising the polynucleotide of any one of Embodiments 1- Error! Reference source not found., the vector of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., the composition of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., or the pharmaceutical composition of Embodiment Error! Reference source not found..33. A kit comprising a container and optionally an instruction for use, wherein the container comprises the polynucleotide of any one of Embodiments 1 -Error! Reference source not found., the vector of any one of Embodiments Error! Reference source not found.- Error! Reference source not found., the composition of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., the pharmaceutical composition of Embodiment Error! Reference source not found., or the gene delivery system of Embodiment Error! Reference source not found..34. A cell, comprising the polynucleotide of any one of Embodiments 1 -Error! Reference source not found., the vector of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., the composition of Embodiment Error!- 100 - 5099429. vl0399.2077001Reference source not found.-Error! Reference source not found., the pharmaceutical composition of Embodiment Error! Reference source not found., or the gene delivery system of Embodiment Error! Reference source not found..35. The cell of Embodiment Error! Reference source not found., wherein the cell is a bone cell, a brain cell, an eye cell, an epithelial cell, a heart cell, a liver cell, a lung cell, a mesenchymal cell, a muscle cell, or a nerve cell, optionally, the cell is a retinal pigment epithelium (RPE) cell.36. The cell of Embodiment Error! Reference source not found., wherein the cell is an induced pluripotent stem cell (iPSC).37. The cell of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the cell is in vitro or ex vivo.38. The cell of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the cell is in vivo.39. A progeny cell derived from the cell of any one of Embodiments Error! Reference source not found.-Error! Reference source not found..40. A method of treating an age-related disease or condition in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.41. The method of Embodiment 9, wherein the subject is suspected of having, or at risk for developing an age-related disease or condition.42. The method of Embodiment 9, wherein the subject is diagnosed with an age-related disease or condition.43. The method of any one of Embodiments 9-Error! Reference source not found., wherein the age-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof.- 101 - 5099429. vl0399.207700144. The method of any one of Embodiments 9-Error! Reference source not found., wherein the age-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof.45. The method of any one of Embodiments 9-Error! Reference source not found., wherein the age-related disease or condition comprises:a) an age-related macular degeneration (AMD);b) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;c) osteoarthritis, intervertebral disc degeneration, or both;d) osteoporosis, osteonecrosis, or both;e) fibrosis, systemic sclerosis, skin aging, or a combination thereof;f) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof; g) sarcopenia, muscle degeneration, or both;h) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; ori) tendinopathy, rotator cuff injury, or both.46. The method of any one of Embodiments 9-Error! Reference source not found., wherein the age-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof.47. The method of any one of Embodiments 9-Error! Reference source not found., wherein the age-related disease or condition comprises an AMD.48. The method of Embodiment Error! Reference source not found., wherein the AMD is dry AMD.49. A method of rejuvenating a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.- 102 - 5099429. vl0399.207700150. A method of treating an oxidative stress-related disease or condition in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, MOCS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.51. The method of Embodiment 13, wherein the subject is suspected of having, or at risk for developing an oxidative stress-related disease or condition.52. The method of Embodiment 13, wherein the subject is diagnosed with an oxidative stress-related disease or condition.53. The method of any one of Embodiments 13-14. b), wherein the oxidative stress-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof.54. The method of any one of Embodiments 13-Error! Reference source not found., wherein the oxidative stress-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof.55. The method of any one of Embodiments 13-Error! Reference source not found., wherein the oxidative stress-related disease or condition comprises:a) an AMD;b) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;c) osteoarthritis, intervertebral disc degeneration, or both;d) osteoporosis, osteonecrosis, or both;e) fibrosis, systemic sclerosis, skin aging, or a combination thereof;f) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof; g) sarcopenia, muscle degeneration, or both;h) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; or- 103 - 5099429. vl0399.2077001i) tendinopathy, rotator cuff injury, or both.56. The method of any one of Embodiments 13-Error! Reference source not found., wherein the oxidative stress-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof.57. The method of any one of Embodiments 13-Error! Reference source not found., wherein the oxidative stress-related disease or condition comprises an AMD.58. The method of Embodiment Error! Reference source not found., wherein the AMD is dry AMD.59. A method of enhancing oxidative resistance of a cell in a subject in need thereof, comprising increasing expression and / or activity of at least one target protein selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2 in the subject.60. The method of any one of Embodiments 9-16, wherein the at least one target protein comprises NKX2-5, NKX2-1, or LTBR.61. The method of any one of Embodiments 9-17, wherein the at least one target protein comprises NKX2-5.62. The method of any one of Embodiments 9-Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO: 3, or a combination thereof.63. The method of any one of Embodiments 9-Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO: 1.64. The method of any one of Embodiments 9-Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:2.65. The method of any one of Embodiments 9-Error! Reference source not found., wherein the at least one target protein comprises SEQ ID NO:3.66. The method of any one of Embodiments 9-Error! Reference source not found., wherein the method increases a DNA-binding independent activity of NKX2-5.- 104 - 5099429. vl0399.207700167. The method of any one of Embodiments 9-Error! Reference source notfound., comprising increasing the expression and / or the activity of at least two target proteins.68. The method of Embodiment Error! Reference source not found., wherein the at least two target proteins comprise NKX2-5 and C2CD2L.69. The method of any one of Embodiments 9-Error! Reference source not found., wherein the method comprises administering to the subject an agent that increases the expression and / or the activity of the at least one target protein.70. The method of any one of Embodiments 9-Error! Reference source not found., wherein the method increases the expression of the at least one target protein in the subject.71. The method of any one of Embodiments 9-Error! Reference source not found., wherein the method increases the activity of the at least one target protein in the subject.72. The method of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the agent comprises a polynucleotide, a vector, a composition, a pharmaceutical composition, a gene delivery system, a cell, a polypeptide, or a small molecule.73. The method of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the agent comprises:a) the polynucleotide of any one of Embodiments 1 -Error! Reference source not found.,b) the vector of any one of Embodiments Error! Reference source not found.- Error! Reference source not found.,c) the composition of any one of Embodiments Error! Reference source not found.-Error! Reference source not found.,d) the pharmaceutical composition of Embodiment Error! Reference source not found.,e) the gene delivery system of Embodiment Error! Reference source not found., f) the cell of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., or- 105 - 5099429. vl0399.2077001g) the progeny cell of Embodiment Error! Reference source not found..74. The method of any one of Embodiments 9-Error! Reference source not found., wherein the expression and / or the activity of the at least one target gene is inducible or suppressible.75. The method of any one of Embodiments 9-Error! Reference source not found., wherein the expression and / or the activity of the at least one target gene is conditionally inducible by a small molecule, a light-switchable system, a ligand-switchable system, or a combination thereof.76. The method of Embodiment Error! Reference source not found., wherein:a) the small molecule comprises tetracycline (TET), doxycycline (DOX), caffeine, 4-hydroxytamoxifen, estrogen, ecdysone, abscisic acid, mifepristone, xylose, FKBP12-rapamycin, or an HCV NS3 / 4A protease inhibitor;b) the light-switchable system comprises:i) Phytochrome B (PhyB) and phytochrome interaction factor 6 (PIF6); or ii) GIGANTEA and a light oxygen voltage (LOV) domain of Flavin-Binding Kelch Repeat F-Box 1 (FKF1);c) a ligand-switchable system comprises a synthetic Notch receptor (synNotch), a modular extracellular sensor, or a synthetic intramembrane proteolysis receptor (SNIPR), ord) any combination of the foregoing.77. A method of rejuvenating a retinal pigment epithelium (RPE) cell in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the RPE cell.78. A method of treating damage to RPE cells in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the RPE cells.79. The method of Embodiment 22 or 23, wherein the subject is suspected of having, or at risk for developing AMD.80. The method of Embodiment 22 or 23, wherein the subject is diagnosed with AMD.81. A method of treating AMD in a subject in need thereof, comprising increasing expression and / or activity of NKX2-5 in the subject.- 106 - 5099429. vl0399.207700182. The method of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the AMD is dry AMD.83. The method of any one of Embodiments 22-Error! Reference source not found., wherein the method comprises administering to the subject an agent that increases the expression and / or the activity of NKX2-5.84. The method of any one of Embodiments 22-Error! Reference source not found., wherein the method increases the expression of NKX2-5 in the subject.85. The method of any one of Embodiments 22-Error! Reference source not found., wherein the method increases the activity of NKX2-5 in the subject.86. The method of any one of Embodiments 22-Error! Reference source not found., wherein the method increases a DNA-binding independent activity of NKX2-5.87. The method of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., wherein the agent comprises a polynucleotide, a vector, a composition, a pharmaceutical composition, a gene delivery system, a cell, a polypeptide, or a small molecule.88. The method of any one of Embodiments 22-Error! Reference source not found., wherein the agent is:a) the polynucleotide of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., orb) the vector of any one of Embodiments Error! Reference source not found.- Error! Reference source not found., the composition of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., the pharmaceutical composition of Embodiment Error! Reference source not found., the gene delivery system of Embodiment Error! Reference source not found., the cell of any one of Embodiments Error! Reference source not found.-Error! Reference source not found., or the progeny cell of Embodiment Error! Reference source not found., wherein the at least one target protein is NKX2-5.- 107 - 5099429. vl0399.207700189. The method of any one of Embodiments 22-Error! Reference source not found., wherein the method comprises administering to an eye of the subject an adeno-associated virus (AAV) vector comprising a polynucleotide encoding NKX2-5.90. The method of any one of Embodiments 9-Error! Reference source not found., wherein the subject is a mammal.91. The method of Embodiment Error! Reference source not found., wherein the mammal is a human.92. The method of Embodiment Error! Reference source not found., wherein the mammal is a mouse, rat, rabbit, pig, or a non-human primate.EXEMPLIFICATION

[0523] Oxidative stress plays a pivotal role in the development of age-related macular degeneration (AMD). Lacking highly effective therapies, AMD is a major cause of blindness that impacts 200 million people worldwide {4, 5). Degeneration of retinal pigment epithelium (RPE) cells, which can be triggered by oxidative stress, is fundamental to the pathogenesis of AMD (6, 7). The RPE’s critical location, between the highly oxygenated choroidal blood supply and the photo-oxidatively stressed retina, places it in a highly vulnerable position (S). Given these intense demands, additional oxidative stress from lifestyle and / or mitochondria dysfunction during aging can overwhelm the RPE’s natural defense mechanisms (FIGs. 1A-1E).

[0524] Oxidative stress damages RPE via accumulation of excess reactive oxygen species (ROS), molecules with oxidizing properties that increase during aging and / or chemical injury (FIGs. 1A-1E). Their causal role is supported by Age-Related Eye Disease Study 2 (AREDS2) (9). This multicenter randomized placebo-controlled trial of oral micronutrient supplementation, showed that oral antioxidants slow AMD disease progression. However, the detailed molecular pathways for sensing, processing, and adapting to ROS are not fully understood {10, 77).Moreover, whether there are potent oxidative protecting genes for RPE cells is underexplored.

[0525] The development of genome-wide interrogations of gene function has dramatically expanded the ability to conduct systematic forward genetic screens for desired phenotypes in mammalian systems. These technologies include turning down (CRISPRi) (72), epigenetic silencing (CRISPRoff) {13, 14), and overexpressing (CRISPRa) individual or combinations of genes (75).- 108 - 5099429. vl0399.2077001

[0526] Overexpression screens with open reading frames (ORFs) and transcription factors (TFs) are more technically demanding and therefore less commonly used (16, 17). However, they offer key advantages over CRISPR knockout screens, including single-step infection and the ability to directly identify candidate genes for gene therapy (18). Unlike knockout screens, overexpression screens can also reveal novel gene functions by expressing genes ectopically. Previously, epigenetic reprogramming factors have been used to rejuvenate retinal ganglion cells (19-21) and other tissues (22, 23). Examples 1-6 describe a genome-wide overexpression screen (FIGs. 2A-2E), identification of genes that enhance antioxidative function in RPE cells (19, 24), and novel antioxidative mechanisms and genetic interventions. The effectiveness and mechanisms of the identified genes, including those of NKX2-5 (25, 26), were explored using cell culture and animal models.Example 1. A Genome-Wide Screen Identifying Novel Rejuvenation Factors.

[0527] A lentiviral library of 12,000 unique open reading frames (ORFs) from the human genome, each with unique set of barcodes (16), were introduced into 160 million arising retinal pigment epithelia (ARPE)-19 cells, ensuring most cells had only one ORF integration. ARPE-19 cells were chosen due to efficiencies of growth in tissue culture and lentiviral infection, enabling high coverage (2,000 cells per ORF) for each experimental arm (FIG. 2A). An optimal ARPE-19 maturation protocol, which included nicotinamide (2), was used, allowing one week of maturation before inducing damage.

[0528] Sodium Iodate (NalOs) is a potent prooxidant. In vivo, NalOs causes mitochondrial damage and ferroptosis selective for RPE (27). NalOs is widely used to trigger RPE oxidative damage similar to oxidative damage in aging RPE (FIGs. 1D-1E). In vitro, NalCh treatment of RPE has been reported to induce necroptosis (28). Here, following maturation, ARPE-19 cells that survived NalCh treatment were able to reattach to a culture plate. The ORF barcodes in reattached ARPE-19 cells were compared to those in unchallenged or floating dead cells (FIG. 2A)

[0529] Twenty unique ORFs strongly enriched in live cells (FIGs. 2B-2D) were identified. Each ORF was subcloned into a doxycycline (DOX)-inducible lentiviral vector. The oxidative protective effects were validated for ten ORFs: NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (M0CS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), and two isoforms of FB J murine osteosarcoma viral- 109 - 5099429. vl0399.2077001oncogene homolog B (FosB (FIGs. 2E-2F). These candidate genes have distinct expression levels in RPE aging and diseases in Spectacle, an ocular scRNA-seq database (FIG. 3A). For example, FosB expression is higher in infant RPEs and is significantly upregulated in neovascular age-related macular degeneration (nAMD) (FIG. 3A). These ORFs are expressed at varying levels across different tissues (FIG. 3B), and understanding their functional mechanisms is essential for determining if their overexpression could benefit RPE in aging and / or diseases.

[0530] Example 1 is the first genome-wide overexpression screen for identifying genes that enhance oxidative resistance in RPE cells. This screen was designed based on the discovery that oxidative damaged necrotic cells remain attached to the plate but lose their ability to reattach. This is the first time that a genome-wide screen, which allows an unbiased evaluation of all genetic modifications for producing a desired phenotype, was applied to a retinal cell type.Example 1 also marks the first application of a new Death-seq methodology (29), which compares live versus dead cells to achieve a significantly improved signal-to-noise ratio in cell death screens, to an overexpression screen.Example 2. Classifying the Candidate Genes.

[0531] To assess the similarities and functional differences among the ten validated oxidative-protective ORFs, RNA-seq and transcriptomic profiling were conducted after four days of individual ORF expression. Nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor a (TNFa) treatment were included as controls for comparison. By calculating the correlation of pathway enrichment profiles, these ten ORFs were classified into at least two distinct classes based on their transcriptome signatures (FIG. 3C).

[0532] The first class is exemplified by LTBR, a receptor in the TNF superfamily (FIG. 4A).Overexpression of LTBR induced a transcriptomic signature and epithelial-to-mesenchymal transition (EMT)-like morphology similar to that triggered by TNFa. It upregulated v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) and Re!B. activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB)-AnN&n. EMT, a phenomenon frequently observed in AMD patients (30, 31) (FIG. 4B). Surprisingly, it was found that all ligands in the TNF superfamily provided oxidative protection (FIG. 4C). Mechanistically, it was observed that superoxide dismutase 2 (SOD2), a downstream antioxidative gene responsive to NF-KB signaling, was strongly upregulated by overexpression of both LTBR and TNFa. CRISPR-Cas9 knock out of RelA, RelB, and SOD2 showed that the oxidative protection conferred by TNFa was abolished by these treatments (FIG. 4D). In contrast, knockout of olfactory receptor family 1 subfamily F member 1 (OR1F1), a control gene not expressed in RPE cells, had no effect. These- 110 - 5099429. vl0399.2077001findings highlight the essential role of the NF-KB / S0D2 axis in mediating oxidative protection in RPE cells (FIG. 4E) and suggest that anti-TNFa therapy may need to be combined with antioxidant supplements treatment to prevent RPE cell death resulting from loss of NF-KB / S0D2 protection. Other members of this class include FosB l and FosB_2.

[0533] Interestingly, the second class is exemplified by a homeobox transcription factor, NKX2-5 (FIG. 3C), typically expressed in the heart and spleen, and completely silenced in other tissues (FIG. 5A). Its transcriptomic signature groups with Nrf2. When using a novel transcriptomic aging clock (32) that was able to detect age acceleration in AMD patients’ RPE tissues and aged mice’s RPE cells (FIGs. 3D-3E), NKX2-5, FosB, SEMA4G, and NKX2-1 overexpression are predicted to rejuvenate ARPE-19 by over 17 years (FIG. 3F). Unlike FosB, an oncogene which rejuvenates ARPE-19 partially through cell cycle, or TNFa that drives EMT, NKX2-5 does not activate cell cycle or EMT, but rejuvenates potentially through enhancing respiration and mitochondria translation (FIG. 3G). Importantly, RPE cells overexpressing NKX2-5 also displayed resistance to complement damage, another stressor associated with AMD (FIG. 10B). Other members of this class include C4BPA, MOCS2, and Cl lorfl.Example 3. Evaluation ofNKX2-5.

[0534] NKX2-5 is the most potent oxidative protector identified from this screen (FIGs. 2D-2E), and its effects were both fast-acting and long-lasting (FIGs. 5B-5D). Importantly, NKX2-5 continued to confer protection six days after its expression was shut down (FIG. 5C), indicating a lasting memory effect. This finding suggests the potential for utilizing transient NKX2-5 expression, delivered via mRNA packaged in lipid nanoparticles (LNPs), to achieve therapeutic benefits.

[0535] Although NKX2-5 interacts with GATA4, TBX5, and Myh6 to initiate cardiogenesis during development, these genes were not expressed in RPE cells even upon NKX2-5 overexpression (FIG. 5E), which may explain why RPE cells expressing NKX2-5 did not undergo obvious morphological changes (FIG. 5D).

[0536] Importantly, NKX2-5 not only rejuvenated cells at the transcriptomic level; when epigenetic age was assessed using a DNA methylation clock, cells expressing NKX2-5 showed a significantly reduced DNA methylation age compared to the controls (FIG. 5F).

[0537] Loss of function mutations in NKX2-5 have been linked to various congenital heart diseases and conduction defects in both mouse models and humans. Transgenic mice engineered to express NKX2-5 with congenital heart disease-associated point mutations (25) developed right ventricular dysfunction, suggesting that NKX2-5 influences cardiomyocyte metabolism (33). It- Ill - 5099429. vl0399.2077001is also noteworthy that NKX2-5 expression declines during cardiac aging in both mice and monkeys, suggesting that its reduction may contribute to age-related cardiac dysfunction(3- / ). In view of the findings disclosed herein, NKX2-5 overexpression could have therapeutic potential for mitigating heart function decline and cardiovascular disease in aging.

[0538] While NKX2-5 is expressed in adult cardiomyocytes, its secondary function in adult cells was unknown (35). Therefore, overexpressing NKX2-5 in RPE provided a unique opportunity to explore the previously unknown anti oxidative function of NKX2-5 in a clean biological background. Importantly, a traditional CRISPR knockout screen would not have identified NKX2-5, since its expression is silenced in RPE cells during development.

[0539] As shown in FIG. 6A, when cells were exposed to NalCh, NKX2-5 could not protect cells without a functional mitochondrial electron transport chain, a condition cells usually tolerate when unchallenged by NalCh (36). The data suggests that NKX2-5 provides protection through mitochondria and prevents mitochondrial dysfunction.

[0540] Cellular ROS (CellRos Green or DCFH-DA)(37), mitochondria ROS (MitoSox Green), and mitochondria surface area (MitoTracker) were observed by staining in the presence or absence NalOs treatment (FIG. 6B). There was a lower ROS level in NKX2-5 expressing cells and more mitochondria mass post oxidative damage (FIG. 6B). The mitochondria oxygen consumption rate (OCR) (38) wa also preserved in NKX2-5 expressing cells post damage (FIGs. 6C-6D). Therefore, under oxidative stress, NKX2-5 preserves the mitochondrial electron transport chain which is crucial for cell survival (FIGs. 6A-6D).

[0541] NKX2-5 homeodomain (HD) is responsible for DNA binding ability and activation of target genes (39) (FIG. 7A). A heterozygous mutation 1184 (I184M or I184P), a well-conserved amino acid located within the NKX2-5 homeodomain (HD), had been reported to reduce its DNA binding ability and impair activation of certain target genes (39) (FIG. 7A). Therefore, NKX2-5 carrying a HD deletion (AHD) or mutation in HD (I184M or I184P) should reduce DNA binding ability. To determine if the homeodomain of NKX2-5 is required for the oxidative protection, functional mutants of NKX2-5 (I184M, I184P, and AHD) were synthesized, together with WT NKX2-5 (FIG. 7A-7C), and DOX-inducible stable RPE lines were generated.

[0542] Surprisingly, all of the homeodomain mutants tested, I184M, I184P, and AHD mutants of NKX2-5, exhibited significant oxidative protection effect against N al O3 (FIGs. 7C-7E). While WT NKX2-5 is localized in the nucleus, I184M, I184P, and AHD NKX2-5 showed reduced nuclear localization, but still entered nucleus (FIG. 7D). The data suggest that one or more less-characterized domains, other than the HD domain, of NKX2-5 play a critical role in- 112 - 5099429. vl0399.2077001this function. This hypothesis is supported by the AlphaFold structure prediction (FIG. 7B). These data uncover NKX2-5’s novel anti oxidative and rejuvenative properties, and are useful for improving specificity and reducing toxicity for therapeutic development.

[0543] The transcriptomic changes induced by NKX2-5 and NKX2-5 AHD, identified in FIG. 7F, shared differentially expressed genes. These include two mitochondria genes MAOA and SLC25A36, and SLC16A4 that influences redox balance (FIG. 7F).

[0544] Two NKX2-5 mutants with an impaired YRD domain, AYRD (YRD domain deletion) and YRD-Y-A (tyrosine-to-alanine substitutions within the YRD (SEQ ID NO: 7)), were generated. Both mutants localized to the nucleus (FIG. 7G). However, neither conferred protection against NalOs-induced oxidative stress (FIG. 7H). These results support the dispensability of the HD domain and highlight the essential role of the YRD domain in protection against NalOs-induced oxidative stress.

[0545] Next, an AAV vector encoding NKX2-5 AHD was generated and packaged using the AAV2 for infecting RPE in two groups of mice. A first group (n=4) included 15-mo-old, aged mice with AAV2-GFP subretinal injection, and a second group (n=6) included 15-mo-old mice with AAV2-NKX2-5 AHD subretinal injection. Baseline OMR testing was performed at Day -7 before injection. At Day 0, the AAV was administered to drive either GFP (control) or NKX2-5 HD expression. Post- AAV OMR testing was conducted at regular intervals to assess functional vision (FIG. 71). Aged mice injected with AAV2-NKX2-5 AHD showed improved vision beginning at 4 weeks after injection, and further improved by 8 weeks post injection (FIG. 7 J).These results indicate that the HD domain of NKX2-5 is not required for the in vivo functional improvement.Example 4. In Vivo Over expression of NKX2-5 Protects RPE In Dry AMD Mouse Models

[0546] In 1926, intravenous injection of septojod in patients with puerperal septicaemia was found to cause fundus pigmentary changes and blindness. In 1941, it was found that, the NalCh content of septojod has specific oxidative toxic effect on the RPE (40). Since then, NalCh injection into C57BL / 6J mice has been developed as a model for dry AMD. Here, AAV-NKX2-5, AAV-GFP, or AAV-LTBR was injected subretinally in P0 mouse pups. At D10 post injection, DOX water was administrated to induce NKX2-5. Four days later, 30 mg / kg of NalOs was injected intravenously to cause RPE dysfunction and formation of necrotic lesions (47) within seven days. The posterior cups were collected on day seven and stained for F-actin to quantify the regions of atrophic RPE cells (42). In the NalOs-induced RPE injury model, sub-retinal injection of AAV-NKX2-5 in 2-month-old mice was found to reduce RPE atrophy and RPE- 113 - 5099429. vl0399.2077001degeneration compared to the AAV-GFP injected and to two other candidates, LTBR and NKX2-1, injected eyes (FIGs. 8A-8F).Example 5. AAV-NKX2-5 Improves Visual Acuity in Aged Mice.

[0547] ROS accumulation in the eye during aging is a natural trigger for RPE degeneration, therefore aging is a major risk factor for AMD (FIGs. 1A-1E). Given that during aging of the RPE, there is substantial mitochondrial deoxyribonucleic acid (mtDNA) damage that leads to mitochondria dysfunction and accumulation of ROS (43), effects of NKX2-5 expression in the RPE of young (3 month old) or aged (15 month old) mice were also examined.

[0548] Two groups of aged mice were evaluated: (i) 15-month old mice with AAV2-GFP subretinal injection (n=7, 4M3F), and (ii) 15-month old mice with AAV2-NKX2-5 subretinal injection (n=5, 2M3F) (FIG. 9A). Baseline optical mark recognition (OMR) tests were performed at Day -7 before injection. At Day 0, AAV was administered to drive either GFP (control) or NKX2-5 expression. Post-AAV OMR testing was conducted at regular intervals (Days 14, 28, 42, and 56) to assess functional vision (FIG. 9B). The data indicate that overexpressing NKX2-5 in the retina of aged mice results in remarkable vision acuity improvement within four weeks, reaching the visual acuity of young mice by eight weeks (FIGs.9C-9D)

[0549] OCT is a non-invasive imaging method that provides a cross-sectional view of the retina, and has been frequently used for examining toxic effects associated with retinal gene therapies (44). When AAV-NKX2-5 was expressed in retinas of 23-month-old aged mice for 5 weeks, no toxicity was observed with six weeks of NKX2-5 expression (FIG. 9E). The mice were then euthanized, and the posterior eye cups were examined for retinal histology (FIG. 9F).In the NKX2-5 -treated regions of aged RPE, melanin pigmentation was restored to youthful levels compared to the untreated areas (FIG. 9F). Ultrastructural analysis revealed that classic aging features, including disoriented photoreceptor outer segments (OS), loss of melanin granules in the RPE, lipofuscin accumulation, basal deposits in Bruch’s membrane, and its thickening (45), were all markedly improved in the NKX2-5-treated areas, closely resembling a youthful retina (FIGs. 9G-9H).Example 6. Evaluation of the Other Candidate Genes.

[0550] Besides NKX2-5, nine other genes were found to provide strong NalOs protection to RPE cells. Given that ROS can originate from different sources and various biochemical- 114 - 5099429. vl0399.2077001pathways, the ORFs were hypothesized to offer unique and robust protection against different ROS depending on their mechanisms of action.

[0551] Considering that NalCh is an AMD-related stressor that primarily induces cytosolic and mitochondrial ROS production (46), the candidates were tested against other AMD-associated stressors that interact with other cell components (e.g. lysosome and endoplasmic reticulum). These include oxidized-LDL (ox-LDL), cigarette smoking extract (CSE) (47), tert-Butyl hydroperoxide (tBH) (48), and complement (49, 50) (FIGs. 10A-10C).

[0552] A combination of candidate genes (such as NKX2-5 plus C2CD2L) may confer more comprehensive oxidative protection in RPE cells (FIG. 10D), for example, via synergistic effects. Combinations of candidate genes will be tested in an AMD mouse model (aged mice carrying the human CFH risk allele on a HFC enriched diet, CFH-H / H-WC (3)) and human iPSC-RPE carrying CFH risk alleles (FIG. 10E).

[0553] The differential survival rates (FIG. 10D) show that: (1) NKX2-5 protection was the most robust and specific to mitochondrial ROS introduced by NalOs; (2) C2CD2L, a lipid transporter, (57) was protective to ox-LDL; (3) FosB 2, another transcription factor, was protective against CSE and tBH (FIG. 10D); and (4) the well-known antioxidant gene, Nrf2 (52) failed to provide protection under these acute conditions. These data provide further support that a combination of two or more of the ORFs, such as NKX2-5 plus C2CD2L, can confer broader protection for AMD.Example 7. Long-term safety ofNKX2-5AHD

[0554] To evaluate whether removal of the NKX2-5 homeodomain would improve longterm retinal safety profile of NKX2-5 overexpression, longitudinal OCT analysis was performed. AAV-GFP, AAV-NKX2-5, or AAV-NKX2-5AHD was injected subretinally into 3-month-old mice, and retinal thickness was determined every 4 weeks for up to 32 weeks (FIG. 11 A). At the AAV injection site, full-length NKX2-5 caused a progressive reduction in total retinal thickness, whereas NKX2-5AHD largely preserved retinal thickness over the same time course and remained comparable to GFP-treated controls and intact retina (FIG. 1 IB). These data suggest that deletion of the homeodomain substantially reduces long-term structural toxicity associated with full-length NKX2-5 expression.

[0555] To explore potential molecular basis underlying the improved safety, co-IP-mass spectrometry was performed to identify NKX2-5 or NKX2-5 AHD interacting proteins.CARDIO, a positive regular of inflammation pathway NF-KB, emerged as a strong binding partner of full-length NKX2-5 but not NKX2-5AHD. The data suggest that CARDIO interacts- 115 - 5099429. vl0399.2077001with NKX2-5 through, or in a manner dependent on, the homeodomain (FIG. 11C). This finding provides a potential mechanism underlying uncoupling of NKX2-5-associated rejuvenating activity from deleterious protein interactions when homeodomain function is reduced or eliminated.Example 8. Functional benefits ofNKX2-5AHD in aged mice

[0556] Next, whether the NKX2-5AHD construct retained functional benefits in aged mice was tested. AAV-GFP or AAV-NKX2-5AHD was injected subretinally into fifteen-month-old mice, and visual acuity was monitored by optomotor response over 10 weeks after AAV injection (FIG. 12A). AAV-NKX2-5AHD significantly improved visual acuity compared to AAV-GFP controls; the effect became more pronounced over time, reaching the levels of 3-month-old baseline reference (FIG. 12B). In a subgroup of mice, visual acuity was monitored for 25 weeks after AAV injection. NKX2-5AHD mediated sustained, long term visual improvement, whereas visual acuity of GFP-injected aged mice remained near baseline level of aged mice (FIGs. 12C and 12D). These data indicate that NKX2-5AHD can produce durable visual functional improvement in aged mice.

[0557] Consistent with the OMR results, ERG recordings at 10 weeks post- AAV injection showed thatNKX2-5AHD improved retinal electrophysiological responses in aged mice.Compared to old GFP-treated controls, NKX2-5AHD increased scotopic a-wave and b-wave amplitudes across stimulus intensities (FIGs. 12E and 12F), indicating improved photoreceptor and downstream retinal responses. NKX2-5AHD also improved the scotopic c-wave response (FIG. 12G), suggesting enhanced RPE-associated retinal function. Together, these functional assays support that NKX2-5AHD preserves the beneficial activity of NKX2-5 while mitigating structural toxicity.Example 9. Transcriptomic rejuvenation by NKX2-5AHD

[0558] Next, whether NKX2-5 AHD also induces molecular rejuvenation in aged RPE was examined. According to a multi-tissue transcriptomic clock, NKX2-5AHD-treated old RPE showed a significant reduction in predicted transcriptomic age compared to GFP-treated controls (FIG. 12H). Module-specific clock analysis further revealed thatNKX2-5AHD shifted multiple aging-associated pathways toward a rejuvenated state, including modules related to inflammation, cholesterol metabolism, mitochondrial function, and DNA repair, while a smaller set of modules showed pro-aging shifts (FIG. 121). Thus, NKX2-5AHD not only improves aged visual function but also partially reverses aging-associated transcriptional programs in RPE.- 116 - 5099429. vl0399.2077001

[0559] In sum, a genome-wide screen was used herein as an unbiased approach for identifying genetic modifications capable of producing desired phenotypes and uncovering novel rejuvenation factors. A critical risk factor of aging was targeted. Oxidative stress, also a causal driver of dry AMD, is a condition affecting 200 million people worldwide and currently lacking effective treatments. An oxidative survival screen pipeline was developed, and the first genomewide overexpression screen was performed in RPE cells. Ten genes, conferring oxidative protection and rejuvenating RPE cells (measured by a transcriptomic aging clock), were identified.

[0560] The candidate genes were classified into at least two unique functional groups based on distinct transcriptomic signatures. The first class is exemplified by LTBR, a receptor in the TNF superfamily. LTBR activates the NF-KB / SOD2 axis but also induces EMT, a natural response observed in AMD disease progression. The second class is characterized by NKX2-5, a cardiac transcription factor potentially contributing to the remarkable longevity of cardiomyocytes. NKX2-5 rejuvenates human RPE cells by 17 years and provides robust protection to mitochondria under oxidative stress, an underexplored secondary function post heart development. In an acute RPE degeneration mouse model, AAV-delivered NKX2-5 preserved RPE morphology and function and restored vision in aged mice. By uncovering the pathophysiology of EMT-related disease procession in AMD and previously unrecognized antioxidative and rejuvenating genes, these findings are essential for developing novel methods and therapeutics targeting oxidative stress related diseases and aging.REFERENCES1. A. P. Voigt et a!.. Spectacle: An interactive resource for ocular single-cell RNA sequencing data analysis. Exp Eye Res 200, 108204 (2020).2. R. A. Hazim, S. Volland, A. Yen, B. L. Burgess, D. S. Williams, Rapid differentiation of the human RPE cell line, ARPE-19, induced by nicotinamide. Exp Eye Res 179, 18-24 (20...

Claims

0399.2077001CLAIMSWhat is claimed is:

1. A polynucleotide, comprising:a) a nucleic acid sequence encoding a protein or a variant thereof, wherein the protein is selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, and FosB_2, homologs; andb) a promoter operably linked to the nucleic acid sequence, wherein the promoter is an eye cell-specific, epithelial cell-specific, or nerve cell-specific promoter.

2. The polynucleotide of claim 1, wherein the nucleic acid sequence encodes a NKX2-5 variant comprising a mutation within the homeodomain, optionally wherein the mutation comprises a substitution of at least one amino acid, a deletion of at least one amino acid, or both.

3. The polynucleotide of claim 2, wherein the mutation comprises:a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12); orb) a deletion of 2 to 60 amino acids (e.g., a deletion of at least 10, 20, 30, 40, or 50 amino acids) within the homeodomain.

4. The polynucleotide of claim 2 or 3, wherein the NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NOs:l-14, optionally wherein the NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8.

5. The polynucleotide of any one of claims 2-4, wherein the NKX2-5 variant comprises an amino acid sequence set forth in:a) SEQ ID NO:2 and SEQ IDNO:6;b) SEQ ID NO:2 and SEQ IDNO:3;- 121 - 5099429. vl0399.2077001c) SEQ ID N0:8;d) SEQ ID NO: 9;e) SEQ ID NO: 10;a) SEQ ID NO: 11;b) SEQ ID NO: 13; orf) SEQ ID NO: 14,optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

6. The polynucleotide of any one of claims 1-5, wherein:a) the promoter is a Bestrophin-1 (Bestl) promoter, a RedO promoter, a rhodopsin (Rho) promoter, a human rhodopsin kinase (hRK) promoter, a cone arrestin (CAR) promoter, or a human Synapsin 1 (hSyn) promoter;b) the promoter comprises an inducer-responsive element, optionally, wherein the inducer-responsive element comprises a Tet response element (TRE), or both a) and b).

7. A composition comprising a polynucleotide, wherein:the polynucleotide comprises a nucleic acid sequence encoding a protein or a variant thereof, wherein the protein is selected from the group consisting of NK2 homeobox 5 (NKX2-5), lymphotoxin beta receptor (LTBR), complement component 4 binding protein alpha (C4BPA), Chromosome 11 open reading frame one (Cl lorfl), molybdenum cofactor synthesis 2 (MOCS2), mediator complex subunit 1 (MED1), C2 domain-containing protein 2-like (C2CD2L), NK2 homeobox 1 (NKX2-1), semaphorin 4G (SEMA4G), FBJ murine osteosarcoma viral oncogene homolog B (FosB)_l, and FosB_2, homologs, and wherein:a) the polynucleotide is a messenger ribonucleic acid (mRNA) encapsulated in lipid nanoparticles (LNPs); orb) the polynucleotide is an adeno-associated virus (AAV) vector, optionally wherein the AAV vector is an AAV2 or AAV9 vector, or a variant thereof, optionally wherein the composition further comprises a pharmaceutically acceptable carrier.

8. A cell comprising the polynucleotide of any one of claims 1-6 or the composition of claim 7, wherein:- 122 - 5099429. vl0399.2077001a) the cell is an eye cell, an epithelial cell, a bone cell, a brain cell, a liver cell, a lung cell, a mesenchymal cell, a muscle cell, or a nerve cell, optionally wherein the cell is a retinal pigment epithelium (RPE) cell; orb) the cell is an induced pluripotent stem cell (iPSC).

9. A method of treating an age-related disease or condition in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, andFosB_2.

10. The method of claim 9, wherein:a) the subject is suspected of having, or at risk for developing an age-related disease or condition; orb) the subject is diagnosed with an age-related disease or condition.

11. The method of claim 9 or 10, wherein:a) the age-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof;b) the age-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof;c) the age-related disease or condition comprises:i) an age-related macular degeneration (AMD);ii) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;iii) osteoarthritis, intervertebral disc degeneration, or both;iv) osteoporosis, osteonecrosis, or both;v) fibrosis, systemic sclerosis, skin aging, or a combination thereof;vi) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof;- 123 - 5099429. vl0399.2077001vii) sarcopenia, muscle degeneration, or both;viii) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; orix) tendinopathy, rotator cuff injury, or both;d) the age-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof;e) the age-related disease or condition comprises an AMD, optionally wherein the AMD is dry AMD,or any combination of the foregoing.

12. A method of rejuvenating a cell in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2.

13. A method of treating an oxidative stress-related disease or condition in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cl lorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, and FosB_2.

14. The method of claim 13, wherein:a) the subject is suspected of having, or at risk for developing an oxidative stress- related disease or condition; orb) the subject is diagnosed with an oxidative stress-related disease or condition.

15. The method of claim 13 or 14, wherein:a) the oxidative stress-related disease or condition affects blood vessel, breast, bone, brain, cloaca, ear, eye, fin, hair, heart, intestine, kidney, liver, lung, mouth, muscle, nerve tissue, nose, oesophagus, ovary, pancreas, penis, prostate, skin, stomach, testis, udder, or a combination thereof;b) the oxidative stress-related disease or condition comprises an autoimmune disease, a cancer, a cardiovascular disease, an eye disease, a genetic disease, a hematological disease, an inflammatory disease, infectious disease, a mitochondrial disease, an ocular disease, a liver disease, a lung disease, a musculoskeletal disease, a neurological disorder, a painful condition, a- 124 - 5099429. vl0399.2077001proliferative disease, a psychiatric disorder, a spleen disease, or a combination thereof;c) the oxidative stress-related disease or condition comprises:i) an AMD;ii) osteoporosis, osteoarthritis, sarcopenia, impaired wound healing, or a combination thereof;iii) osteoarthritis, intervertebral disc degeneration, or both;iv) osteoporosis, osteonecrosis, or both;v) fibrosis, systemic sclerosis, skin aging, or a combination thereof; vi) type 2 diabetes, lipodystrophy, metabolic syndrome, or a combination thereof;vii) sarcopenia, muscle degeneration, or both;viii) microvascular dysfunction, neurodegenerative diseases, diabetic retinopathy, or a combination thereof; orix) tendinopathy, rotator cuff injury, or both;d) the oxidative stress-related disease or condition comprises pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis, or a combination thereof;e) the oxidative stress-related disease or condition comprises an AMD, optionally wherein the AMD is dry AMD,or any combination of the foregoing.

16. A method of enhancing oxidative resistance of a cell in a subject in need thereof, the method comprising increasing expression of a protein or a variant thereof in the subject, wherein the protein is selected from the group consisting of NKX2-5, LTBR, C4BPA, Cllorfl, M0CS2, MED1, C2CD2L, NKX2-1, SEMA4G, FosB l, andFosB_2.

17. The method of any one of claims 9-16, wherein the protein comprises a NKX2-5 variant comprising a mutation within the homeodomain, optionally wherein the mutation comprises a substitution of at least one amino acid or a deletion of at least one amino acid.

18. The method of claim 17, wherein the mutation within the homeodomain comprises: a) a substitution or a deletion of an isoleucine (I) corresponding to 1184 of SEQ ID NO:1 (e.g., 1183 of SEQ ID NO: 12); or- 125 - 5099429. vl0399.2077001b) a deletion of 2 to 60 amino acids (e.g., a deletion of at least 10, 20, 30, 40, or 50 amino acids) within the homeodomain.

19. The method of claim 17 or 18, wherein the NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NOs: 1-14, optionally wherein the NKX2-5 variant has at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO:8.

20. The method of any one of claims 17-19, wherein the NKX2-5 variant comprises an amino acid sequence set forth in:a) SEQ ID NO:2 and SEQ IDNO:6;b) SEQ ID NO:2 and SEQ IDNO:3;c) SEQ ID NO:8;d) SEQ ID NO: 9;e) SEQ ID NO: 10;f) SEQ ID NO: 11;g) SEQ ID NO: 13; orh) SEQ ID NO: 14;optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

21. The method of any one of claims 9-20, wherein the method comprises increasing expression of C2CD2L.

22. A method of rejuvenating a retinal pigment epithelium (RPE) cell in a subject in need thereof, comprising increasing expression of a NKX2-5 variant in the RPE cell, wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO: 14, optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.

23. A method of treating damage to RPE cells in a subject in need thereof, comprising increasing expression of a NKX2-5 variant in the RPE cell, wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO: 14, optionally wherein the NKX2-5 variant comprises an amino acid sequence set forth in SEQ ID NO:8.- 126 - 5099429. vl0399.207700124. The method of claim 23, wherein:a) the subject is suspected of having, or at risk for developing AMD; or b) the subject is diagnosed with AMD,optionally wherein the AMD is dry AMD.

25. The method of any one of claims 9-24, wherein the subject is a human.

26. The method of any one of claims 9-25, wherein the method comprises administering a polynucleotide comprising a nucleic acid sequence encoding the protein or variant thereof to the subject.

27. The method of claim 26, wherein the polynucleotide comprises a nucleic acid sequence operably linked to a promoter.

28. The method of claim 26 or claim 27, wherein the method comprises administering a vector comprising the polynucleotide to the subject.

29. The method of any one of claims 26-28, wherein the polynucleotide or vector is locally administered to an organ or tissue in need of such treating or rejuvenation.- 127 - 5099429. vl